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SUMMARY 
Background. Chronic obstructive pulmonary disease (COPD) constitutes one of the 
principal demands on healthcare in primary care. Acute exacerbations of COPD are 
typical events that characterize the course of the disease. Antimicrobial therapy 
remains a controversial issue, mainly in acute exacerbations of mild-to-moderate 
COPD. Even though most of the patients attended in the community correspond to 
mild and moderate COPD, antibiotics are highly prescribed for exacerbations in Spain. 
Aims. The main objective was to evaluate the effectiveness of antibiotic therapy 
compared with placebo at day 9-11 in acute exacerbations of mild-to-moderate COPD. 
The secondary objectives were to evaluate the rate of clinical success of antibiotic 
therapy compared with placebo at day 20 and assess the symptom-free interval, i.e. 
days till next exacerbation in both groups. 
Design. Multicentre, parallel, double-blinded placebo-controlled randomized clinical 
trial carried out from January 2006 to June 2011. 
Study setting: Twenty-three primary care centres in Catalonia.  
Subjects. Patients aged 40 or older, smokers or ex-smokers of ten packs-year or more, 
with spirometrically-based diagnosis of mild-to-moderate COPD (forced expiratory 
volume in one second (FEV1) > 50% expected and FEV1/forced vital capacity ratio < 
0.7% expected) from a lung function test performed within 24 months prior to 
inclusion, and the presence of an acute exacerbation defined as the presence of at 
least one of the following signs and symptoms: increase of dyspnoea, increase in 
sputum volume and/or increase of sputum purulence. Patients with bronchial asthma, 
hypersensitivity to β-lactams, bronchiectasis of origin other than COPD, active 
neoplasm, tracheotomy, presence of radiological signs of pneumonia or hospital 
admission criteria, and those who refused to participate in the study were all excluded. 
Measurements and interventions. The patients were randomised into two treatment 
groups: amoxicillin and clavulanic acid (500/125 mg three times daily for 8 days) or 
placebo three times daily for 8 days). The use of antithermics or analgesics was 
allowed as were short-acting and long-acting β-adrenergics, anticholinergics, 
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theophyllines, inhaled or oral corticosteroids and any medication that the patient may 
been have taken for chronic disease and which had been initiated three months prior 
to inclusion in the study, except for antibiotics. Cure was defined as the disappearance 
of the acute signs and symptoms related to the infection, improvement, as the non-
complete resolution of the symptoms and failure was defined as with an insufficient 
reduction in the signs and symptoms of infection. Clinical success was considered 
when either cure or improvement was observed.  
Results. A total of 353 subjects were included in the study. Forty-three patients were 
excluded as they did not fulfil the inclusion criteria. Three hundred ten (158 patients in 
the amoxicillin and clavulanic acid arm and 152 patients in the placebo arm) fulfilled all 
the criteria for efficacy analysis. The mean age was 68.1 years (SD: 10.4 years) and the 
mean FEV1 was 65% (SD: 11.9%). No differences were found between the two groups 
regarding the different basal variables analysed. A total of 117 patients assigned to the 
intervention group (74.1%) and 91 to control group (59.9%) were considered cured at 
days 9-11 (p<0.05). In the multivariate regression analysis failure was associated with 
C-reactive protein (CRP) concentrations ≥ 40 mg/l (OR: 7.9; 95% CI: 3.9 –16.3), placebo 
treatment (OR: 2.9; 95% CI: 1.4 – 6) and presence of coronary heart disease (OR: 2.6; 
95%CI: 1 – 6.7). Among patients treated with placebo clinical predictors for failure 
were CRP ≥ 40 mg/l (OR of cure: 0.1; 95% CI: 0 – 0.2) and purulent sputum (OR: 0.2; 
95% CI: 0 – 0.7). The predictive value of Anthonisen criteria for clinical outcome in 
those patients was 0.708 (95% CI: 0.616 – 0.801) and rose to 0.842 (95% CI: 0.76 – 
0.924; p<0.001) when CRP ≥ 40 mg/l was added. Regardless of the number the 
Anthonisen criteria, the presence of both CRP low levels and uncoloured sputum was 
associated with a clinical success of 90% among patients not treated with antibiotics. 
Conclusions. Treatment of acute exacerbations of mild-to-moderate COPD with 
amoxicillin and clavulanic acid is more effective than placebo. Nonetheless, this thesis 
indicates when antibiotic therapy may be safely withheld in acute exacerbations of 
mild-to-moderate COPD.  
Key words. Acute exacerbations. Mild-to-moderate COPD. Antibiotic. Effectiveness. 
Randomised clinical trial. 
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RESUM 
Fonament. La malaltia pulmonar obstructiva crònica (MPOC) representa un dels 
principals motius de salut en atenció primària. Les exacerbacions són events típics que 
caracteritzen el curs de l’MPOC. El tractament antimicrobià és un tema controvertit, 
principalment en les exacerbacions de l’MPOC lleu-moderada. Encara que la majoria 
dels pacients atesos a la comunitat presenten MPOC lleu i moderada, la prescripció 
antibiòtica en les exacerbacions és molt elevada a Espanya. 
Objectius. L’objectiu principal fou avaluar l’efectivitat de l’antibioteràpia en 
comparació amb el placebo en el dia 9-11 en les exacerbacions de l’MPOC lleu a 
moderada. Els objectius secundaris foren avaluar la taxa d’èxit clínic de la teràpia 
antibiòtica en comparació amb el placebo en el dia 20 i avaluar l’interval lliure de 
símptomes; és a dir, nombre de dies fins a la següent exacerbació, en ambdós grups. 
Disseny. Assaig clínic aleatori, controlat amb placebo, doble cec, paral·lel i multicèntric, 
dut a terme des de gener de 2006 fins a juny de 2011. 
Emplaçament. Vint-i-tres centres de salut de Catalunya.  
Subjectes. Pacients de 40 o més anys, fumadors o exfumadors de deu paquets-any o 
més, amb diagnòstic espiromètric d’MPOC lleu-moderada (volum espiratori forçat en 
un segon (FEV1) > 50% esperat i raó FEV1/capacitat vital forçada < 0,7% esperat) basat 
en una espirometría feta en els 24 mesos previs a la inclusió i presència d’exacerbació 
definida com la presència d'almenys un dels següents signes i símptomes: augment de 
la dispnea, augment del volum d'expectoració i/o augment de la purulència de l'esput. 
Es van excloure als pacients amb asma bronquial, hipersensibilitat als β-lactàmics, 
bronquièctasis d'origen diferent d’MPOC, neoplàsia, traqueotomia, presència de signes 
radiològics de pneumònia o criteris d'hospitalització i aquells que van declinar 
participar.  
Mesuraments i intervencions. Els pacients s’aleatoritzaren en dos grups: amoxicil·lina i 
àcid clavulànic (500/125 mg/8 hores, 8 dies) o placebo (cada 8 hores, 8 dies). Es va 
permetre ús d’antitèrmics, analgèsics, β-adrenèrgics d'acció llarga i curta, 
anticolinèrgics, teofil·lines, corticoides inhalats o orals i qualsevol altra medicació que 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
iv | P a g e  
 
el pacient estigués prenent per a una malaltia crònica i s'hagués iniciat tres mesos 
abans de la inclusió en l'estudi, menys antibiòtics. Es va definir guariment quan va 
haver-hi desaparició dels signes aguts i els símptomes relacionats amb la infecció, 
millora com a falta de resolució completa dels símptomes i fracàs com a reducció 
insuficient dels signes i símptomes de la infecció. Es va considerar èxit clínic quan es va 
observar guariment o millora. 
Resultats. S’inclogueren en l’estudi un total de 353 subjectes, dels quals 43 es van 
excloure per no complir els criteris d’inclusió. Un total de 310 (158 pacients en el grup 
assignat a amoxicil·lina i àcid clavulànic i 152 pacients a placebo) resultaren ser 
avaluables en l’anàlisi d’eficàcia. L’edat mitjana fou de 68,1 anys (DE: 10,4 anys) i el 
FEV1 mig va ser del 65% (DE: 11,9%). No s’observaren diferències entre els dos grups 
quant a les distintes variables basals analitzades. Es guariren en el dia 9-11 un total de 
117 pacients en el grup d’intervenció (74,1%) i 91 del grupo control (59,9%; p<0.05). En 
l'anàlisi de regressió logística multivariant es va observar una associació entre el fracàs 
clínic amb les concentracions de proteïna C reactiva (PCR) ≥ 40 mg/l (OR: 7,9; IC 95%: 
3,9 –16,3), estar assignat al grup placebo (OR: 2,9; IC 95%: 1,4 – 6) i presència de 
cardiopatia isquémica (OR: 2,6; IC 95%: 1 – 6,7). Els predictors clínics de fracàs entre 
els pacients no tractats amb antibiòtics van ser la PCR ≥ 40 mg/l (OR de guariment: 0,1; 
IC 95%: 0 – 0,2) i la purulència de l’esput (OR: 0,2; IC 95%: 0 – 0,7). El valor dels criteris 
d’Anthonisen per predir resultat clínic en aquests pacients, amb l’àrea sota la corba 
ROC, fou de 0,708 (IC 95%: 0,616  –  0,801) i va pujar a 0,842 (IC 95%: 0,76 – 0,924; 
p<0,001) quan es va afegir la PCR ≥ 40 mg/l. Amb independència del nombre de criteris 
d’Anthonisen, la presència de valors baixos de PCR i esput no purulent s’associaren 
amb un percentatge d’èxit del 90% entre els pacients no tractats amb antibiòtics. 
Conclusions. El tractament de les exacerbacions de l’MPOC lleu-moderada amb 
amoxicil·lina i àcid clavulànic és més efectiu que el placebo. No obstant això, aquesta 
tesi aclareix quan una exacerbació d’MPOC lleu-moderada pot ser tractada sense 
necessitat de donar antibiòtics. 
Paraules clau. Exacerbació aguda. MPOC lleu-moderada. Antibiòtic. Efectivitat. Assaig 
clínic aleatori. 
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RESUMEN 
Fundamento. La enfermedad pulmonar obstructiva crónica (EPOC) constituye uno de 
los principales motivos de salud en atención primaria. Las exacerbaciones son eventos 
típicos que caracterizan el curso de la EPOC. El tratamiento antimicrobiano es un tema 
controvertido, principalmente en las exacerbaciones de la EPOC leve-moderada. 
Aunque la mayoría de los pacientes atendidos en la comunidad presentan EPOC leve-
moderada, la prescripción antibiótica en las exacerbaciones es muy elevada en España. 
Objetivos. El objetivo principal fue evaluar la efectividad de la antibioterapia en 
comparación con el placebo en el día 9-11 en las exacerbaciones de la EPOC leve a 
moderada. Los objetivos secundarios fueron evaluar la tasa de éxito clínico de la 
terapia antibiótica en comparación con el placebo en el día 20 y evaluar el intervalo 
libre de síntomas, es decir, días hasta la próxima exacerbación, en ambos grupos. 
Diseño. Ensayo clínico aleatorio, controlado con placebo, doble ciego, paralelo y 
multicéntrico, realizado desde enero de 2006 a junio de 2011. 
Emplazamiento. Veintitrés centros de salud de Cataluña.  
Sujetos. Pacientes de 40 o más años, fumadores o exfumadores de diez paquetes-año 
o más, con diagnóstico de EPOC leve-moderada (volumen espiratorio forzado en un 
segundo (FEV1) > 50% esperado y razón FEV1/capacidad vital forzada < 0,7% esperado) 
basado en espirometría realizada en los 24 meses previos a la inclusión y presencia de 
exacerbación definida como la presencia de al menos uno de los siguientes signos y 
síntomas: aumento de disnea, aumento del volumen de expectoración y/o aumento de 
la purulencia del esputo. Se excluyeron a los pacientes con asma bronquial, 
hipersensibilidad a los β-lactámicos, bronquiectasias de origen distinto de EPOC, 
neoplasia, traqueotomía, presencia de signos radiológicos de neumonía o criterios de 
hospitalización y aquellos que declinaron participar. 
Medidas e intervenciones. Se aleatorizaron a los pacientes en dos grupos: amoxicilina y 
ácido clavulánico (500/125 mg/8 horas, 8 días) o placebo (cada 8 horas, 8 días). Se 
permitió uso de antitérmicos, analgésicos, β-adrenérgicos de acción larga y corta, 
anticolinérgicos, teofilinas, corticoides inhalados u orales y cualquier otra medicación 
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que el paciente estuviera tomando para una enfermedad crónica y se hubiera iniciado 
tres meses antes de la inclusión en el estudio, menos antibióticos. Se definió curación 
cuando hubo desaparición de los signos agudos y los síntomas relacionados con la 
infección, mejoría como falta de resolución completa de los síntomas y fracaso como 
reducción insuficiente de los signos y síntomas de la infección. Se consideró éxito 
clínico cuando se observó curación o mejoría. 
Resultados. Se incluyeron en el estudio un total de 353 sujetos, de los cuales 43 se 
excluyeron por no cumplir los criterios de inclusión. Un total de 310 (158 pacientes en 
el grupo asignado a antibiótico y 152 pacientes a placebo) resultaron ser evaluables en 
el análisis de eficacia. La edad media fue de 68,1 años (DE: 10,4 años) y el FEV1 medio 
fue 65% (DE: 11,9%). No se observaron diferencias entre los dos grupos en cuanto a las 
distintas variables basales analizadas. Se curaron en el día 9-11 un total de 117 
pacientes en el grupo de intervención (74,1%) y 91 del grupo control (59,9%; p<0.05). 
En el análisis de regresión logística multivariante se observó una asociación entre el 
fracaso clínico con las concentraciones de proteína C reactiva (PCR) ≥ 40 mg/l (OR: 7,9; 
IC 95%: 3,9 –16,3), tomar placebo (OR: 2,9; IC95%: 1,4 – 6) y presencia de cardiopatía 
isquémica (OR: 2,6; IC95%: 1 – 6,7). Los predictores clínicos de fracaso entre los 
tratados con placebo fueron PCR ≥ 40 mg/l (OR de curación: 0,1; IC 95%: 0 – 0,2) y 
esputo purulento (OR: 0,2; IC 95%: 0 – 0,7). El valor de los criterios de Anthonisen para 
predecir resultado clínico en estos pacientes, con el área bajo la curva ROC, fue de 
0,708 (IC 95%: 0,616  –  0,801) y ascendió a 0,842 (IC 95%: 0,76 – 0,924; p<0,001) 
cuando se añadió la PCR ≥ 40 mg/l. Con independencia del número de criterios de 
Anthonisen, la presencia de valores bajos de PCR y esputo no purulento se asociaron 
con un porcentaje de éxito del 90% entre los pacientes no tratados con antibióticos. 
Conclusiones. El tratamiento de las exacerbaciones de la EPOC leve-moderada con 
amoxicilina y ácido clavulánico es más efectivo que el placebo. Sin embargo, esta tesis 
clarifica cuando una exacerbación de EPOC leve-moderada puede ser tratada sin 
necesidad de dar antibióticos. 
Palabras clave. Exacerbación aguda. EPOC leve-moderada. Antibiótico. Efectividad. 
Ensayo clínico aleatorio. 
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ABBREVIATIONS 
AUC   Area under the curve 
CI  Confidence interval 
COPD  Chronic obstructive pulmonary disease 
CRP  C-reactive protein 
FEV1  Forced expiratory volume in one second 
FVC  Forced vital capacity 
GOLD  Global Initiative for Chronic Obstructive Lung Disease 
GP  General practitioner 
HRQL  Health-related quality of life 
IQR  Interquartiile range 
ITT  Intention to treat 
l/min  Litres/minute 
mg/l  Milligrams/litre 
NS  Non-significant 
OR  Odds ratio 
PCR  Polymerase chain reaction 
PP  Per protocol 
ROC  Receiver operating characteristic 
SD  Standard deviation 
SGRQ  St George’s respiratory questionnaire 
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Definitions 
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease 
with some significant extrapulmonary effects that may contribute to the severity in 
individual patients. The main component affects the lungs and is characterized by 
airflow limitation that is not fully reversible. The airflow limitation is usually 
progressive and associated with an abnormal inflammatory response of the lung to 
noxious particles or gases (Global Initiative for Chronic Obstructive Lung Disease, 
2010). This definition does not use the terms chronic bronchitis and emphysema and 
definitely excludes asthma which is a reversible airflow limitation. Symptoms of COPD 
mainly include cough, sputum production and dyspnoea. Chronic bronchitis, defined as 
the presence of cough and sputum production for at least 3 months in each 2 
consecutive years, is not necessarily associated with airflow limitation. Worldwide, the 
most commonly encountered risk factor for COPD is cigarette smoking. It means 
therefore that a diagnosis of COPD should be considered in any patient who has 
dyspnoea, chronic cough or sputum production and a history of exposure to risk 
factors for the disease, especially cigarette smoking (Global Initiative for Chronic 
Obstructive Lung Disease, 2010). Other aetiologies different from smoking are actually 
uncommon in our country. 
The diagnosis of COPD should be based on a spirometric study, with the measurement 
of the forced vital capacity (FVC), defined as the maximum volume of air that can be 
exhaled during a forced manoeuvre, and the forced expiratory volume in one second 
(FEV1), which can be defined as the volume expired in the first second of maximal 
expiration after a maximal inspiration. In other words, this is a measure of how quickly 
the lungs can be emptied. With the former two measurements, the rate FEV1/FVC can 
be calculated, expressing the FEV1 as a percentage of the FVC, giving a clinical useful 
index of airflow limitation. The ratio FEV1/FVC is between 70% and 80% in normal 
adults; a value less than 70% indicates airflow limitation and the possibility of COPD. 
Postbronchodilator FEV1 is recommended for the diagnosis and assessment of severity 
of COPD (Global Initiative for Chronic Obstructive Lung Disease, 2010). Patients with 
COPD typically show a decrease in both FEV1 and FEV1/FVC. FEV1 is influenced by the 
age, sex, height and ethnicity, and is best considered as a percentage of the predicted 
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normal value. The degree of spirometric abnormality generally reflects the severity of 
COPD. According the update guidelines of Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), stage I or mild COPD is defined as a mild airflow limitation 
(FEV1/FVC < 70% and FEV1 ≥ 80% predicted) and sometimes, but not always, chronic 
cough and sputum production. Not all the guidelines define this stage similarly and it 
depends on which classification system is used (Celli BR et al, 2004a; Global Initiative 
for Chronic Obstructive Lung Disease, 2010; Institute for Clinical Systems Improvement, 
2009). However, mild COPD is consistently defined as a FEV1 ≥ 80% (Celli BR et al, 
2004a; Global Initiative for Chronic Obstructive Lung Disease, 2010; Institute for Clinical 
Systems Improvement, 2009). At this stage most individuals may not be aware that his 
or her lung function is abnormal.  
Stage II or moderate COPD is defined as the worsening airflow limitation (FEV1/FVC < 
70% and a FEV1 ranged from 50% to 80%), with shortness of breath typically 
developing on exertion. This is the stage at which patients typically seek medical 
attention because of chronic respiratory symptoms or an exacerbation of their disease. 
There are two other stages: stage III or severe COPD with further worsening of airflow 
limitation (FEV1/FVC < 70% and FEV1 between 30% and 50%), and stage IV or very 
severe COPD, with severe airflow limitation FEV1/FVC < 70% and FEV1< 30% predicted, 
but these stages are not being treated in this thesis. A fifth category, stage 0 or at-risk, 
appeared in the 2001 report but it is no longer included as a stage of COPD, as there is 
incomplete evidence that the individuals who meet the definition of at-risk (chronic 
cough and sputum production, and normal spirometry) necessarily progress on to 
stage I or mild COPD (Global Initiative for Chronic Obstructive Lung Disease, 2010). 
Nevertheless, the importance of the public health message that chronic cough and 
sputum are not normal is unchanged and their presence should trigger a search for 
underlying causes. The goals of COPD management include the relief of symptoms, the 
prevention of disease progression, the improvement of the exercise tolerance, the 
improvement of health status, the prevention and treatment of complications, the 
prevention and treatment of exacerbations, the reduction of mortality and the 
prevention or minimization of side effects from treatment. Table 1 describes the 
updated definitions of non-severe COPD in the most important classifications in the 
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world. The GOLD classification will be used hereafter in this thesis, since it is widely use 
(Global Initiative for Chronic Obstructive Lung Disease, 2010). 
 
TABLE 1. Definitions of mild to moderate COPD in current classification systems 
 Mild Moderate 
GOLD Stage I: 
• FEV1/FVC < 0.70 
• FEV1 ≥ 80% predicted 
Stage II: 
• FEV1/FVC < 0.70 
• 50% ≤ FEV1 < 80% predicted  
ATS/ERS  • FEV1/FVC ≤ 0.70 
• FEV1 ≥ 80% predicted 
• FEV1/FVC ≤ 0.70 
• FEV1 50–80% predicted 
ICSI • FEV1 ≥ 80% predicted 
• No abnormal signs 
• Cough (± sputum) 
• Little or no dyspnoea 
• FEV1 50–79% predicted 
• Breathlessness (± wheeze on 
moderate exertion) 
• Cough (± sputum) 
• Variable abnormal signs 
(general reduction in breath sounds, 
presence of wheezes) 
• Hypoxaemia may be present 
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global 
Initiative for Chronic Obstructive Lung Disease; ATS/ERS: American Thoracic 
Society/European Respiratory Society; ICSI: Institute for Clinical Systems Improvement 
 
According to GOLD guidelines, an exacerbation of COPD is defined as an event in the 
natural course of the disease characterized by a change in the patient’s baseline 
dyspnoea, cough, and/or sputum production that is beyond normal day-to-day 
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variations, is acute in onset, and may warrant a change in regular medication in a 
patient with underlying COPD (Global Initiative for Chronic Obstructive Lung Disease, 
2010). These episodes may be accompanied with systemic symptoms such as fatigue, 
sleep disturbances and low-grade fever (Anzueto A et al, 2007). 
 
Impact of exacerbations on COPD  
COPD affects a large number of patients and is associated with significant morbidity, 
disability and mortality (Global Initiative for Chronic Obstructive Lung Disease, 2010; 
Mannino DM et al, 2002; Rabe KF et al, 2007). In fact, COPD is one of the main causes 
of morbidity and mortality in developed countries (Anzueto A et al, 2008). The 
prevalence of spirometrically-confirmed COPD in England was estimated at 1.4%, 
compared with 3.6% for coronary heart disease, 1.5% for stroke, 3.3% for diabetes, 
0.5% for cancer, and 5.8% for asthma (Health and Social Care Information Centre, 
2005). The BOLD study, in which nearly ten thousand individuals from twelve countries 
completed postbronchodilator spirometry testing plus questionnaires on respiratory 
symptoms, health status, and exposure to COPD risk factors revealed that the 
prevalence of GOLD stage II or higher COPD was 10.1% overall, 11.8% in men and 8.5% 
in women (Buist AS et al, 2007). The overall pooled estimate of the adjusted OR for 
COPD was 1.94 per 10-year age increment (Buist AS et al, 2007). The prevalence of 
non-severe COPD among patients with COPD is high and varies significantly between 
countries (Buist AS et al, 2007). In the BOLD study, the prevalence of GOLD stage I 
COPD ranged from 1% in the Philippines to 16% in Austria, while that of GOLD stage II 
COPD ranged from 5% in Germany to 12% in South Africa (Buist AS et al, 2007). 
Miravitlles et al has recently reported a prevalence of 56% of mild COPD and 38% of 
moderate COPD (Miravitlles M et al, 2009). 
Exacerbations of COPD are of major global importance. Yet controversies remain over 
the definition of exacerbations, how they should be monitored and their underlying 
mechanisms. Exacerbations of COPD are now recognised as important events in the 
natural course of COPD and this fact is underlined in major international guidelines 
(Global Initiative for Chronic Obstructive Lung Disease, 2010; Celli BR et al 2004a). 
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Exacerbations are an important outcome, not only because they pose a considerable 
economic burden but more importantly because repeated exacerbations of COPD lead 
to deteriorating health-related quality of life (HRQL) (Seemungal TA et al, 1988; 
Donaldson GC et al, 2002) and, when associated with ventilatory failure, to premature 
death (Connors AF Jr et al, 1996).  
Although poorly characterized in the past, recent investigations have clarified the 
significance, aetiology, and pathogenesis of exacerbations (Sethi S et al, 2008a). In a 
landmark longitudinal study in the 1960s, no relationship was found between loss of 
lung function and frequency of COPD exacerbation (Fletcher F et al, 1977). Recent 
studies dispute the earlier result (Donaldson GC et al, 2002; Kanner R et al, 2001). 
Exacerbations are the leading cause of death in advanced COPD, are associated with a 
more rapid decline in the HRQL of patients with COPD, and as a result of 
hospitalization, account for 40% – 50% of the costs of care of COPD (Andersson F et al, 
2002; Calverley PM et al, 2007; Spencer S et al, 2001). Exacerbations of COPD are 
estimated to result in approximately 110,000 deaths in United States and more than 
500,000 hospitalisations per year, with over $18 billion spent in direct costs annually 
(National Institutes of Health. National Heart, Lung, and Blood Institute, 2002: 
Mannino DM et al, 2002). In addition to the financial burden required to care for these 
patients, other costs, such as days missed from work and severe limitations in HRQL, 
are important features of this condition (Miravitlles M et al, 2002a; Miravitlles M et al, 
2004a).  
Exacerbations are a significant component of the clinical course in COPD (Halpern MT 
et al, 2003). Furthermore, as COPD progresses, exacerbations become more frequent 
(Burge PS et al, 2000; Donaldson GC et al, 2002; Global Initiative for Chronic 
Obstructive Lung Disease, 2010; Gompertz S et al, 2001a; Greenberg SB et al, 2000; 
Miravitlles M et al, 1999a; Miravitlles M et al, 2000; Paggiaro PL et al, 1998). 
Donaldson et al (Donaldson GC et al, 2002) reported that patients with severe COPD 
(GOLD stage III) had an annual exacerbation frequency of 3.4 events per year 
compared with 2.7 per year for those with moderate COPD (GOLD stage II; p< 0.05). 
Paggiaro et al (Paggiaro PL et al, 1998) reported, in patients with forced expiratory 
volume (FEV1) > 60% predicted, 1.6 exacerbations per year compared with 1.9 
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exacerbations in patients with FEV1 59%–40% predicted, and 2.3 exacerbations in 
patients with FEV1 < 40% predicted (Donaldson GC et al, 2002; Paggiaro PL et al, 1998). 
Other studies showed that patients who suffer a high number of exacerbations will 
continue to have frequent episodes (Gompertz S et al, 2001a). Recent large 
prospective clinical studies have shown that COPD patients in GOLD category II (FEV1 
50–80% predicted) also have a significant number of exacerbations that can be 
reduced with pharmacotherapy (Decramer M et al, 2009; Jenkins CR et al, 2009). Thus, 
patients with more severe COPD are going to have frequent exacerbations, but it is 
also important to point out that patients with more moderate disease also develop a 
significant number of these events.  
 
Impact of exacerbations on systemic inflammation and comorbidities 
COPD is a condition that becomes clinically apparent in mid-to-late life. Comorbidity is 
relatively common in patients with COPD and this raises the issue as to whether such a 
comorbidity is age-related, related to a common factor, such as smoking and 
cardiovascular disease, due to the effect of drugs like corticosteroids and the 
development of diabetes, or a reflection of the increase in systemic inflammatory 
cytokine concentrations, which are a feature of COPD with systemic involvement. Data 
are emerging that the same inflammatory mediators are central to the pathogenesis of 
other diseases and, to illustrate this, focus was directed towards type 2 diabetes and 
cardiovascular diseases. Coexistent cardiac disease has been shown to be a risk factor 
for increased hospital admission (Adams SG et al, 2000; Dewan NA et al, 2000) and 
mortality in patients with COPD exacerbation (Antonelli Incalzi R et al, 1997; Murata 
GH et al, 1992). Recent studies have shown that there is a 3.1 and 2.6 incidence ratio 
of myocardial infarction or first stroke during the first 3 days after a systemic 
respiratory infection, suggesting a close association (Smeeth L et al, 2004). 
Furthermore, ischaemic heart disease and/or congestive heart failure were reported to 
increase the rate of treatment failure, thus contributing to the worsening of the 
patients' condition (Adams SG et al, 2000; Dewan NA et al, 2000). However, in a 
hospital-based study, very severe COPD patients (FEV1 < 35% predicted and use of 
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supplemental oxygen therapy) no association between cardiac comorbidity and 
outcome was found (Antonelli Incalzi R et al, 1997). The results suggest that cardiac 
comorbidity is a risk factor of poor outcome, particularly in moderate–severe COPD 
patients; however, when lung disease is severe, impairment in pulmonary function 
prevails over cardiac disease. Additionally, older patients who also have more severe 
comorbid conditions appear to be at risk for severe life-threatening exacerbations that 
may result in hospital admission and even death (Antonelli Incalzi R et al, 1997, 
Miravitlles M et al, 2000; Vilkman S et al, 1997).  
Several studies have shown that COPD patients have higher levels of some 
inflammatory markers in blood, mainly CRP (Pinto-Plata VM et al, 2006), fibrinogen 
(Dahl M et al, 2001) and inflammatory cytokines (Piehl-Aulin K et al, 2009). A study 
indicated that the concentrations of interleukin 6 and CRP in plasma were significantly 
related to an increased risk of coronary heart disease in males and females (Pai JK et 
al, 2004). Cardiac troponin-1 is often raised during acute exacerbations that require 
hospitalisation but are without other evidence of an acute coronary syndrome, 
indicating that an acute exacerbation has detrimental effects on cardiac muscle 
(Harvey MG et al, 2004). Elevation of the CRP is as well an independent predictor of 
myocardial infarction. Eagan et al (Eagan TM et al, 2010) assessed the systemic levels 
of six inflammatory mediators in a large cohort of COPD patients and controls. These 
investigators confirmed that certain circulating inflammatory mediators are affected in 
COPD. COPD confounded variables, such as sex, age, smoking status, disease severity, 
comorbid conditions, etc., were controlled. These investigators demonstrated that 
COPD patients were more likely to have significantly decreased blood levels of 
osteoprotegrin and higher levels of CRP. They were also able to identify that soluble 
tumour necrosis factor receptor-1 and osteoprotegrin changes were related to disease 
severity, based on GOLD stage and frequency of exacerbations. Furthermore, recent 
reports have shown that using anti-inflammatory medications, such as statins, 
significantly impact the rate of lung function decline, and their use prior to 
exacerbations is associated with significant decreases in mortality (Mortensen EM et 
al, 2009). Therefore, exacerbations are likely to be present in patients with comorbid 
conditions and result in a significant inflammatory burden.  
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The interaction between comorbidities and COPD is only just beginning to be explored 
but it is clear that survival in COPD is better predicted by variables other than simply 
the degree of airflow limitation (Celli BR et al, 2004b). How these factors relate to the 
development and perpetuation of exacerbations remains to be elucidated but they are 
likely to be very important in patients with COPD.  
 
Impact of exacerbations on lung function 
Some investigators believe that more frequent exacerbations are associated with more 
rapid decline of FEV1 (Anzueto A et al, 2009a). Donaldson et al (Donaldson GC et al, 
2002) reported a mean of 2.9 exacerbations per year in COPD patients with moderate 
to very severe disease (mean FEV1 38% predicted). The mean rate of decline in FEV1 in 
the total cohort was 36 ml per year but was greater in patients with more 
exacerbations (40.1 ml per year versus 32.1 ml per year, respectively). Frequent 
exacerbations (more than two per year) have been associated with increased 
dyspnoea and reduced exercise capacity (Donaldson GC et al, 2002; Jenkins CR et al, 
2009), greater decline in health status (Spencer S et al, 2001; Spencer S et al, 2003) and 
increased likelihood of becoming housebound (Donaldson GC et al, 2002; Donaldson 
GC et al, 2005). More recently, Celli et al (Celli BR et al, 2008) reported the impact of 
frequent exacerbations on the decline in FEV1 in data from the TORCH study, in which 
patients experiencing greater frequency of exacerbations during the 3-yr study period 
had a faster decline in FEV1.  
It seems logical that repeated episodes of COPD exacerbations may potentially impair 
lung tissues and lead to an accelerated rate of decline in pulmonary function. This 
concept is supported by a number of experimental observations. First, exacerbations 
are associated with transient decreases in pulmonary function that, in some cases, 
take weeks to return to baseline levels (Connors AF Jr. et al, 1996; Seemungal TA et al, 
2000a). Second, patients suffering from recurrent exacerbations have been shown to 
have increased concentrations of inflammatory markers in sputum, even in stable 
phase, which suggests persistent inflammation and potential lung damage (Crooks SW 
et al, 2000). Third, neutrophils are attracted into the airway lumen during 
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exacerbations (Ras G et al, 1990). In fact, increased levels of neutrophils in sputum 
correlated with rapid decline in FEV1 in a 15-yr follow-up study (Stanescu D et al, 
1996). There are recent reports that have identified a significantly increased number of 
eosinophils in patients with COPD exacerbation (Papi A et al, 2006; Zhu J et al, 2001). 
The significance of these findings is not fully understood. Fourth, in cross-sectional 
studies, higher bacterial load in respiratory secretions have been associated with 
increased inflammation and decreased lung function (Sethi S et al, 2000). Fifth, the 
urinary excretion of desmosine and isodesmosine, products of degradation of lung 
elastine, are significantly increased during exacerbations of COPD compared with 
stable phase (Viglio S et al, 2000), coinciding with an increase in free elastase during 
exacerbations (Crooks SW et al, 2000; Gompertz S et al, 2001b); furthermore, higher 
urinary concentrations of desmosine have been associated with faster decline in FEV1 
in COPD (Gottlieb DJ et al, 1996). Finally, a correlation has been found between the 
number of previous exacerbations and the extent of emphysematous changes seen by 
computed tomography scan (Kosmas EN et al, 1997).  
 
Impact of exacerbations on health-related quality of life 
Although it is recognised that exacerbations are associated with considerable 
symptomatic and physiological deterioration, the burden imposed on patients may be 
underestimated. Interestingly, patients are not familiar with the term exacerbation as 
used by healthcare professionals and, if given a choice, they may use their own words 
to describe the worsening of symptoms. The terminology used by patients is extremely 
varied but consistent for each patient. The way in which patients perceive 
exacerbations and how exacerbations affect patients have been greatly helped by the 
systematic scoring of health status questionnaires. The application of such tools to 
study exacerbations has provided major new insights, although it still remains a 
hypothesis-generating exercise. Exacerbations have been shown to dramatically impair 
the feeling of wellbeing in COPD patients. Differences in scores in HRQL questionnaires 
between the stable phase and the exacerbation are very important in magnitude. A 
group of patients with COPD exacerbation showed a moderate-to-large improvement 
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in all four domains of the Chronic Respiratory Disease Questionnaire after 10 days of 
treatment (Aaron SD et al, 2002). This improvement was not observed in patients who 
relapsed after treatment of exacerbation.  
A study by Connors JR et al (Connors AF Jr. et al, 1996) reported the quality of life 
outcomes in patients hospitalised with acute exacerbations of COPD. At 6 months, 54% 
of patients required assistance with at least one activity of daily living and 49% 
considered their health status to be fair or poor. No analysis was conducted on the 
relationship between readmissions and perceived quality of life. The recovery of HRQL 
parameters after an acute COPD exacerbation may be determined by several factors. 
Spencer et al (Spencer S et al, 2001) in exacerbated patients who did not relapse 
during follow-up experienced an improvement in the St George's Respiratory 
Questionnaire (SGRQ) of 11.8 units at 1 month and 17 units after 5 months of the 
onset of the exacerbation. These results indicate that the recovery of health status 
after an exacerbation may take longer than previously expected. In contrast, median 
recovery time for lung function after an exacerbation is 6 days and for symptoms is 7 
days (Spencer S et al, 2001). However, this recovery may be influenced by the severity 
of the exacerbation. The more severe the exacerbation, the longer it takes to recover. 
Seemungal et al (Seemungal TA et al, 2000a) showed that only 75% of patients return 
to their baseline peak flow values 35 days after the episode. The SGRQ and Medical 
Research Council questionnaire were completed by patients at the end of the study. 
Exacerbations were more frequent in patients with frequent previous exacerbations 
with an odds ratio (OR) of 5.5. Using the median number of exacerbations, patients 
were classified as infrequent exacerbators (0–2) or frequent exacerbators (3–8). SGRQ 
total score was significantly worse in frequent exacerbators, with a mean difference of 
14.8. 
In multiple regression analyses, exacerbation frequency was strongly correlated with 
SGRQ total score and component scores. Miravitlles et al (Miravitlles M et al, 2004a) 
confirmed the impact of exacerbations on health status. Thus, these studies showed 
that patients who suffered more exacerbations had significantly worse SGRQ scores 
compared with infrequent exacerbators, and HRQL-related questionnaires offer 
complementary information to lung function and respiratory symptoms to monitor the 
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course of recovery of an exacerbation. The slow recovery of HRQL after an 
exacerbation suggests that these patients will not return to their baseline condition 
and will experience further deterioration of their HRQL over time. Furthermore, a 
patient's therapy during the exacerbation may influence outcome. Andersson et al 
(Andersson I et al, 2002) showed that patients who received long-term oxygen therapy 
had an improvement of the SGRQ scores by a mean of 14 units after 3 months; in 
contrast, those who did not receive oxygen showed a change of 9 units.  
Unreported exacerbations are common and their long-term impact on HRQL has been 
identified. Previous studies have shown that at least half of all COPD exacerbations 
identified by symptom worsening were not medically reported and therefore left 
untreated. Seemungal et al (Seemungal TA et al, 1998) demonstrated that unreported 
exacerbations had similar characteristics to the reported ones. These exacerbations 
are associated with worsening symptoms when they remain untreated. The short- and 
long-term impacts of unreported exacerbations on HRLQ were recently reported by Xu 
et al (Xu W et al, 2010). In a multicentre prospective cohort of 491 COPD patients, 
these investigators demonstrated that more than one unreported exacerbation was 
associated with significant worsening of the SGRQ score, and HRQL at 1 year after 
adjusting for known confounders. These data suggest that unreported exacerbations 
may have important long-term impact on patients, and there is an urgent need to 
develop tools that emphasise early recognition of exacerbations.  
Symptomatic GOLD stage I COPD patients have shown to increase respiratory care 
utilisation, including inhaler use, emergency room visits, hospitalisation due to 
respiratory problems and ambulatory visits, and lower HRQL than asymptomatic GOLD 
stage I patients. These latter are similar to individuals with normal lung function 
(Bridevaux PO et al, 2008). Even symptomatic mild COPD patients with relatively 
preserved FEV1, FVC and resting inspiratory capacity have extensive small airway 
dysfunction that results in troublesome exertional symptoms (Ofir D et al, 2008). 
Furthermore, GOLD stages I and II patients also have an approximately 3-fold 
increased risk of depressive symptoms than healthy individuals (Omachi TA et al, 
2009). 
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Impact of exacerbations on exercise performance 
COPD exacerbations not only impair both the short- and long-term quality of life, but 
also produce significant reduction in physical activity (García-Aymerich J et al, 2006). In 
order to understand how exacerbations actual impaired patients, Haughney et al 
(Haughney J et al, 2005) reported a study that used actual patients' relative value 
judgment with discrete choice modelling techniques. These investigators 
demonstrated that exacerbations significant impact daily activities and level of medical 
care. For patients, the main impact of exacerbation on daily life is being housebound, 
more so than the actual symptoms. Other studies have also shown that exacerbations 
will not only impact physical activity but also physiological wellbeing (Kessler R et al, 
2006). These and future studies are needed to develop strategies in the prevention 
and management of COPD.  
Loss of skeletal muscle has long been established as a feature of stable COPD. COPD 
patients have decreased quadriceps strength and fat-free mass (Hopkinson NS et al, 
2007). These effects are worse after acute exacerbations. These effects may be more 
pronounced if we take into consideration that these patients received high doses of 
corticosteroids during an exacerbation. Further data related to the impact of 
exacerbation on exercise activity is the work by Donaldson et al (Donaldson GC et al, 
2005). In a longitudinal study, these investigators quantified time spent outdoors, and 
found that frequent exacerbators had spent less time. These investigators identified 
decreased activity a few days prior to exacerbations, which remained decreased for up 
to 5 weeks. More recent studies have utilised ambulatory activity monitoring. Pitta et 
al (Pitta F et al, 2006) confirmed prior reports, and also described decreased activity 
level in patients that have exacerbations compared with those who did not. 
Furthermore, a decreased activity level 1 month after an exacerbation was associated 
with increased risk for hospitalisation. Thus, the investigators concluded that 
exacerbations decreased the overall exercise tolerance. More recently, the effect of 
exacerbations on the Body mass, Obstruction, Dyspnoea and Exercise capacity (BODE) 
index were reported (Cote C et al, 2007). The BODE index significantly decreases with 
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an exacerbation and these effects remain over time. Most of the effect is due to 
significantly decreased exercise tolerance, manifested as decreased distance in 6-
minute walk test. Thus, exacerbations also impact upon exercise tolerance.  
 
Economic impact of exacerbations 
Some studies have determined that hospitalisation costs represent 40–57% of total 
direct costs generated by patients with COPD, and this percentage may be as high as 
63% in severe patients (Hilleman DE et al, 2000). Since acute exacerbations are the 
main cause of hospitalisation among COPD patients, it is evident that the economic 
burden of acute exacerbations is considerable. Observational studies performed in 
primary care centres observed that 16–22% of patients having exacerbations were 
admitted during 1 year (Pena VS et al, 2000). The costs of exacerbations that require 
hospitalisation increase dramatically compared with those that can be treated in an 
ambulatory setting. An analysis derived from a clinical trial in patients with COPD 
demonstrated that the 15% of exacerbations requiring hospital admission generated 
90% of the costs associated with exacerbations (Miravitlles M et al, 2002). In a recent 
study in primary care in Spain, the mean total cost of an acute exacerbation of COPD 
was estimated to be US$159, with the main part being due to hospitalisations, which 
represented 58% of the total cost, followed by the drug costs amounting to 32% of the 
total (Miravitlles M et al, 2005). Failure implies a cost that is three times higher than 
the cost of management of the exacerbation, particularly due to the high cost of 
hospitalisation. If the percentage of relapses could be reduced, especially in severe 
cases, or if switching a patient from parenteral to oral therapy could reduce the length 
of hospital stay, valuable resources could be saved. The costs of managing acute 
exacerbations of chronic bronchitis are high, particularly because of the high costs 
associated with relapse (Feenstra TL et al, 2001; Jacobson L et al, 2000). Strategies to 
improve the outcome of ambulatory treatment of exacerbations should be very cost-
effective, especially in more severe patients who are at increased risk of being 
admitted to hospital as a consequence of therapeutic failure.  
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The direct health costs of COPD are substantial, even in non-severe COPD. A Spanish 1-
year follow-up study estimated that mild COPD incurred a cost of $1,484 per patient 
(versus $2,911 for severe COPD), with hospitalisations accounting for 41.2%, drug 
acquisition accounting for 42.5% and clinic visits and laboratory/diagnostic accounting 
for 16.2% of the costs (Miravitlles M et al, 2003a; Miravitlles M et al, 2003b). In an 
Italian study, the mean annual direct healthcare cost per patient was approximately 
€755 for GOLD stage 0, €1,000 for GOLD stage I and €2,000 for GOLD stage III COPD 
(Dal Negro RW et al, 2008).  
 
Impact of exacerbations on mortality  
Clinical studies have reported a high mortality rate in patients admitted to the hospital 
with an acute exacerbation of COPD (Almagro P et al, 2002; Connors AF Jr et al, 1996; 
Fuso L et al, 1995; Groenewegen KH et al, 2003; Soler-Cataluña JJ et al, 2005). Soler-
Cataluña et al (Soler-Cataluña JJ et al, 2005) were the first to report that severe 
exacerbations of COPD have an independent negative prognostic impact, with 
mortality increasing with the frequency of severe exacerbations and those requiring 
hospitalisation. Patients with frequent exacerbations had the highest mortality rate 
with a risk of death 4.3 times greater than for patients requiring no hospital 
management. Thus, exacerbation itself may be a significant factor associated with 
increased mortality in COPD, but the severity of the underlying disease may influence 
patient's outcome. No studies on non-severe COPD have been carried out so far. 
 
Impact of treatment on reduction of exacerbations among patients with non-severe 
COPD 
The two most important preventive measures of COPD exacerbation are active 
immunisations, including influenza and pneumococcal vaccinations, and chronic 
maintenance pharmacotherapy (Global Initiative for Chronic Obstructive Lung Disease, 
2010; Rabe KF et al, 2007).  
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The 2010 updated GOLD report states that, alongside active reduction of risk factors 
and influenza vaccination, patients with GOLD stage I mild COPD should receive 
symptomatic treatment with short-acting bronchodilators, while those in stage II 
should also have regular treatment with one or more long-acting bronchodilators, plus 
rehabilitation (Global Initiative for Chronic Obstructive Lung Disease, 2010). 
Furthermore, the GOLD report emphasises that the underrecognition and 
underdiagnosis of COPD can lead to significant underreporting and, crucially, that early 
diagnosis and implementation of treatment, including smoking cessation, can prevent 
or delay the course of airflow obstruction or reduce its expression. The American 
College of Physicians concludes that there is evidence to support inhaled treatment in 
symptomatic patients with an FEV1 < 60% predicted and perform a spirometry in 
symptomatic adults with an FEV1 > 60% predicted for determining when to initiate 
therapy (Qaseem A et al, 2007). This has recently been challenged by the findings in 
TORCH and UPLIFT (Decramer M et al, 2009; Jenkins CR et al, 2009). 
The principle that patients with non-severe COPD could benefit significantly from 
intervention was established in 1994 by the Lung Health Study (Anthonisen NR et al, 
1994) in which 5,887 patients with moderate airway obstruction (FEV1 50% –90% 
predicted and FEV1/FVC ≤ 70%) who were otherwise healthy were randomised to an 
intensive, long-term smoking cessation program or usual care for 5 years. Sustained 
smoking cessation was associated with significantly lower declines in FEV1 than 
continued smoking, at 31 ml/year and 62 ml/year respectively, and a significant 
difference in change in FEV1 % predicted compared with intermittent smoking, at 
1.98% and - 0.74% respectively (Scanlon PD et al, 2000).  
Recent clinical studies have demonstrated that chronic maintenance therapy in 
patients with COPD can significantly decrease the frequency of exacerbations. These 
studies show that long-active bronchodilators, including long-acting β-agonists (Mahler 
DA et al, 1999); and long-acting anticholinergics, such as tiotropium, reduce the mean 
rate of COPD exacerbation (Decramer M et al, 2009; Dusser D et al, 2006; Niewoehner 
DE et al, 2005; Tashkin DP et al, 2008). These effects have also been reported with 
combination therapy of inhaled corticosteroids and long-acting β-adrenergics (Anzueto 
A et al, 2009b; Calverley PM et al, 2007; Ferguson GT et al, 2008; Hanania NA et al, 
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2003). Furthermore, these studies have demonstrated that the reduction in 
exacerbations results in a significant decrease in hospitalisations and healthcare 
utilisation (Anzueto A et al, 2009b; Calverley PM et al, 2007; Dusser D et al, 2006; 
Ferguson GT et al, 2008; Hanania NA et al, 2003; Niewoehner DE et al, 2005; Tashkin 
DP et al, 2008). However, these studies have been carried with patients with also 
severe and very severe COPD. Among patients with non-severe COPD only some 
studies analysing tiotropium and inhaled corticosteroids have shown some positive 
results but clinically not relevant. 
TORCH study, which compared salmeterol plus fluticasone versus single substances 
and placebo, included 2,156 patients with GOLD stage II disease, who had a mean 
baseline FEV1 of 58.8% predicted (Jenkins CR et al, 2009). Post-hoc analysis showed 
that, compared with placebo, salmeterol plus fluticasone was associated with an 
increase in FEV1 of 101 ml and a decrease in the decline of FEV1 of 16 ml/year. This 
compared with an increase in FEV1 of 46 ml and a decrease in the decline of FEV1 of 14 
ml/year with fluticasone alone, and with an increase in FEV1 of 67 ml and a decrease in 
the decline of FEV1 of 20 ml/year with salmeterol alone. Furthermore, combination 
therapy significantly reduced the number of exacerbations per patient per year 
compared with placebo.  
In UPLIFT study, which compared tiotropium bromide versus placebo, 2,739 (46%) 
patients were in GOLD stage II (Decramer M et al, 2009; Tashkin DP et al, 2008). Post 
hoc analysis demonstrated that treatment with tiotropium in these patients 
significantly reduced rates of decline in post-bronchodilator FEV1 compared with 
placebo, with improvements in lung function sustained over 4 years. Tiotropium also, 
compared with placebo, significantly slightly reduced the number of exacerbations per 
patient per year and significantly increased the median time to the first exacerbation, 
at 23.1 months versus 17.5 months. Active treatment significantly improved SGRQ 
scores at all-time points during follow-up (Decramer M et al, 2009). Importantly, the 
benefits of tiotropium observed in the MISTRAL and UPLIFT studies occurred despite 
patients being allowed to receive other drugs, such as inhaled corticosteroids (61%–
74%, respectively) and/or long-acting β-adrenergics (32%–72%, respectively) (Dusser D 
et al, 2006; Tashkin DP et al, 2008). Crucially, a further post-hoc analysis of the UPLIFT 
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data in 810 treatment naïve patients, 60% of whom were in GOLD stage II, showed 
that tiotropium, compared with placebo, was associated with a significantly lower rate 
of post-bronchodilator decline in FEV1, a significantly higher morning pre-dose FEV1 at 
48 months and a significantly slower decline in SGRQ total score (Troosters T et al, 
2010). 
Early treatment may also have an impact on exercise capacity. A preliminary study by 
O’Donnell et al demonstrated that, in 16 patients with symptomatic GOLD stage I 
COPD, nebulised ipratropium bromide 500 µg significantly increased pulmonary 
function, as measured by FEV1, residual volume and specific airway resistance within 2 
hours. Furthermore, during constant-load exercise, active treatment was associated 
with a significant reduction in dyspnoea per minute ventilation and a significant 
increase in tidal volume (O’Donnell DE et al, 2009). Other chronic therapies, such as 
carbocisteine and N-acetylcysteine, showed a decrease in COPD exacerbations 
(Gramdjean EM et al, 2000; Poole B et al, 2010; Stey C et al, 2000; Zheng JP et al, 
2008), while other studies failed to show these effects (Decramer M et al, 2005). These 
findings could also be explained by the severity of patients enrolled in these studies 
and the use of concomitant medications.  
All these trials, overall, demonstrate that, in the early studies, inhaled corticosteroids 
did not benefit lung function and improvements with salmeterol/fluticasone in the 
TORCH study were restricted to patients with an FEV1 between 50% and 60%. All other 
interventions were associated with negative results, aside from intensive smoking 
intervention.  
 
Aetiology of COPD exacerbations 
Under normal conditions, the healthy human tracheobronchial tree and lung 
parenchyma have a remarkable ability to maintain sterility, in spite of repetitive 
exposure to microbial inocula from micro-aspiration and inhalation. In the setting of 
COPD, however, this innate lung defence appears to be disrupted as a result of 
exposure to smoke and other environmental irritants. The impairment in lung defence 
results in two distinct infection cycles in COPD that could contribute to progressive loss 
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of lung function (Sethi S, 2010). The acute cycle is well recognised. The lung in COPD 
becomes susceptible to repeated acute airway mucosal infections with viruses and 
bacterial pathogens, leading to episodes of increased inflammation and worsened 
symptoms, which are clinically diagnosed as exacerbations of COPD. The viral and 
bacterial pathogens associated with exacerbations share several common 
characteristics. All have tropism for the upper airway in the healthy human host. The 
primary mode of transmission is human to human. They usually asymptomatically 
colonize the upper airway, above the glottis, or cause mild infections. In the patient 
without COPD, the innate defence mechanisms keep the lower airway sterile in spite 
of repeated inhalation and micro-aspiration of bacteria and viruses (Sethi S et al, 
2008a). In the context of COPD, the innate lung defence system is damaged, with 
subsequent increased risk of microbial colonization that extends into the lower 
(subglottic) airway. Pathogen presence in the lower airway stimulates a host immune-
inflammatory response in an attempt to eradicate the pathogens. 
COPD is now recognized as an inflammatory disease of the airways and the 
parenchyma of the lung (Hogg JC et al, 2004). Exacerbations have been characterized 
as acute inflammatory events superimposed on this background of chronic 
inflammation (Sethi S et al, 2008a; Sethi S et al, 2008b). This excess inflammation 
increases airway obstruction by inducing bronchoconstriction, excess mucus 
production, and airway oedema, which translates to the cardinal clinical symptoms of 
dyspnoea, cough, and sputum production. Many patients with COPD have these 
symptoms when they are at their stable baseline status; in such patients, an increase in 
symptoms that are beyond their usual day to day variability defines an exacerbation, 
as before mentioned. The typical course of an exacerbation, with a sub-acute onset 
over days to a peak, followed by gradual resolution over days, is suggestive of an 
infectious process. With use of modern diagnostic techniques, it is clear that the 
majority of exacerbations are of infectious origin (Sethi S et al, 2008a). Viruses, 
bacteria and environmental agents account for the vast majority of episodes of 
exacerbation (Rohde GG, 2010). In a study of patients admitted to hospital with severe 
exacerbations, 78% of patients had evidence of viral or bacterial infection (Papi A et al, 
2006).  
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The less well-recognised infection cycle in COPD is the chronic cycle, whereby 
microbial colonisation results in chronic inflammation and lung destruction, 
conceptualised as the called ‘vicious circle hypothesis’ (Sethi S et al, 2001; Sethi S, 
2010). This hypothesis posits that once impaired innate lung defence due to tobacco 
smoking allows microbial pathogens to become established in the lower respiratory 
tract, the microbial pathogens further impair mucociliary clearance and lung defence 
due to increased mucus secretion, disrupted ciliary activity and airway epithelial injury 
(Sethi S et al, 2001). Thus, microbial colonisation of the lower airways in patients with 
COPD can perpetuate itself. There is evidence to suggest a defect in macrophage 
phagocytosis in COPD patients that may result in defective clearance of infectious 
agents from the lower respiratory tract (Hodge S et al, 2003). Furthermore, this chronic 
presence of bacteria in the lower airways is not innocuous; rather, it induces 
inflammation and can contribute to progressive airflow obstruction and lung damage 
characteristic of this disease (Sethi S, 2010). 
 
Role of viruses 
There is considerable evidence that upper respiratory tract viruses may precipitate 
exacerbations of COPD. Approximately 50% of exacerbations are associated with upper 
respiratory tract virus infections and infection with rhinovirus, respiratory syncytial 
virus and influenza has been associated with exacerbations (Papi A et al, 2006; 
Wedzicha JA et al, 2004). The presence of an upper respiratory tract infection leads to 
a more severe exacerbation and a longer symptom recovery time at exacerbation 
(Seemungal TA et al, 2000a). Increased symptoms induced by virus-associated 
exacerbations appear to last longer than bacterial exacerbations (Seemungal T et al, 
2001). More than 60% of exacerbations in COPD are associated with the symptoms of 
a common cold (Seemungal TA et al, 2000b).  
Several studies carried out during the 1950s–1970s report a viral aetiology of COPD 
exacerbations. These studies relied on viral culture and serologic findings (Murphy TF 
et al, 1992). With these techniques, the presence of at least one respiratory virus was 
associated with approximately 30% of exacerbations. In contrast, when the same 
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patients with COPD were studied in stable periods, viral isolation or serologic 
conversion was found in less than 1% of the cases. A major drawback in these older 
studies and several recent studies is the reliance on nasopharyngeal samples for viral 
culture. There may be discordance between the presence of virus in the 
nasopharyngeal samples and virus in the lower respiratory tract. The presence of virus 
and a specific 4-fold increase in antibody titre in convalescent serum samples is 
supportive evidence of infection. A positive serologic response could occur in a viral 
upper airway infection. Therefore, although earlier studies are supportive of a viral 
causation of exacerbations, it was presumed that the nasopharyngeal samples culture 
results are indicative of infection in the tracheobronchial tree and that an increase in 
antibody titre reflects lower, and not upper, airway infection.  
Introduction of polymerase chain reaction (PCR) methods in the 1990s ushered in a 
new wave of studies examining the viral causation of exacerbations of COPD (Cameron 
RJ et al, 2006; Falsey AR et al, 2006; Hutchinson AF et al, 2007; Rohde G et al, 2003; 
Seemungal TA et al, 2000b; Seemungal T et al, 2001). These studies report the 
presence of viral nucleic acid in 30% - 60% of exacerbations. At least one virus is 
detected by PCR in 64% of exacerbations of COPD patients and these patients have a 
higher exacerbation frequency than patients in whom viruses are not detected 
(Seemungal T et al, 2001). COPD patients with a history of frequent exacerbations may 
be more susceptible to respiratory viral infections, although the nature of this 
susceptibility has not yet been defined. It is possible that up-regulation of the 
intercellular adhesion molecule-1, which acts as a receptor for rhinoviruses, in airway 
epithelial cells is important (Patel IS et al, 2003). Rhinovirus can be recovered from the 
sputum more easily than from the upper airways, indicating that these viruses directly 
infect the lower respiratory tract (Rohde G et al, 2003; Seemungal T et al, 2000b). 
Beckham et al (Beckham JD et al, 2005) found viruses by culture in 23.4% of 194 upper 
airway samples obtained from two studies of adults with respiratory illness, including 
exacerbations of COPD. When these samples were subjected to reverse-transcriptase 
PCR viral nucleic acid detection, the viral yield increased to 41.8% (Beckham JD et al, 
2005). In some of the studies with the highest rates of detection, a higher rate of 
detection in subsequent stable state samples was also seen (Rohde G et al, 2003; 
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Seemungal T et al, 2001). The spectrum of viral pathogens detected by the molecular 
techniques was similar to that seen by culture in earlier studies, with the exception of 
newly discovered viruses, such as human metapneumovirus (Martinello RA et al, 
2006). The relative frequency of viruses also changed. Influenza was detected less 
often, and respiratory syncitial virus was detected more often (Falsey AR et al, 2005). 
This redistribution could also reflect the change in method of detection or changes in 
prevalence as a result of influenza vaccination. Of interest, detection of viral nucleic 
acid was higher using sputum as opposed to nasopharyngeal samples when both sites 
were simultaneously sampled (Seemungal TA et al, 2000b; McManus TE et al, 2008). 
Sputum samples are considered to be more representative of lower airway infection 
than are nasopharyngeal samples, provided the samples meets the quality criteria of > 
25 white blood cells and < 10 epithelial cells per low-power field.  
Molecular detection of virus in sputum is sensitive, specific, and less traumatic than 
that in nasopharyngeal swab specimens. The problem is the interpretation of the 
results. Investigators are not sure to conclude that the presence of viral nucleic acids, 
detected by PCR of sputum samples, implies and proves infection by the virus. The fact 
is that PCR can detect as few as 10–100 copies of a target respiratory virus. Whether 
such low viral titres are of pathological significance is unclear (Borg I et al, 2003). One 
limitation of PCR studies is the lack of immunological assays to determine the presence 
or absence of an antibody. Other markers of the host response might help. Papi et al 
(Papi A et al, 2006) report sputum eosinophilia only when viruses are detected by PCR 
in sputum during an exacerbation, suggesting therefore that different inflammatory 
mediators are involved. Viral infection is a very common cause of acute exacerbation 
and is also associated with severe exacerbations (Wedzicha JA, 2004). Accordingly, a 
viral cause was identified in 43% of 105 patients requiring mechanical ventilation for 
COPD (Cameron RJ et al, 2006). In other studies, increased levels of sputum interleukin 
6 were reported using molecular detection of virus (Hutchinson AF et al, 2007). 
Molecular detection of viral pathogens will likely become the diagnostic method of 
choice in exacerbations of COPD in the future because of its rapidity, convenience, and 
sensitivity, compared with culture. Development of new antiviral drugs will likely spur 
the use of molecular diagnosis in the clinical setting.  
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Role of bacteria 
Prior studies that attempted to determine the extent of bacterial causation of 
exacerbations in COPD were unsuccessful (Tager I et al, 1975). Bacteria colonize the 
tracheobronchial tree in stable COPD. Therefore, simply detecting bacteria in sputum 
samples from patients with COPD does not differentiate between colonization and 
infection, as was shown in early studies of the bacteriology of sputum in COPD (Gump 
DW et al, 1976; McHardy VU et al, 1980). Early studies based on culture of respiratory 
secretions and serological tests revealed that about one-third of exacerbations were 
related to bacterial infection. However, in the remaining cases, the aetiology appeared 
to be uncertain; specifically, the significance of bacterial isolation from sputum was 
unclear (Gump DW et al, 1976). A causal relationship between bacteria and 
exacerbation was largely discredited when longitudinal studies showed similar rates of 
isolation of Streptococcus pneumoniae and Haemophilus influenzae from sputum 
during both acute exacerbations and stable disease (Fagon JY et al, 1996; Gump DW et 
al, 1976; McHardy VU et al, 1980; Smith CB et al, 1976; Tager I et al, 1975). A 
significant limitation of these studies was their failure to differentiate among strains 
within a bacterial species (Sethi S et al, 2002), as the technology was not available at 
that time for such differentiation. Consequently, changes in strains within a species in 
the airways of individual patients over time were undetected.  
In recent years, new research techniques, including molecular typing, have led to 
renewed interest in the area of bacteria and COPD. Recent studies have used more 
sophisticated diagnostic tools and the application of molecular technologies to further 
explore a causal relationship between infection and exacerbation. Acquisition of new 
bacterial strains from the environment has been shown to be the major driver of 
exacerbations (Veeramachaneni SB et al, 2006). In this model, following acquisition of 
a new bacterial strain, the balance between the virulence of the pathogen and the host 
lung defence determines the degree of excess airway and systemic inflammation 
engendered by the bacterial pathogen. The degree of increased inflammation in turn 
determines the extent of symptoms, which, if they lead to the patient seeking 
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healthcare, are diagnosed as an acute exacerbation. The host mounts an adaptive 
immune response to the infecting bacterial strain, which, possibly augmented by the 
use of antibiotics, controls and eventually eliminates the infecting strain. However, 
because the immune response is strain-specific, antigenically unrelated strains from 
the same species and of course other bacterial species cause recurrent exacerbations. 
In a prospective cohort study it was found that the frequency of exacerbations 
increased more than two-fold at clinic visits at which a new strain with one of these 
four major pathogens was isolated from sputum (Sethi S et al, 2002). However, less 
than 15% of all exacerbations recorded by the authors could be attributed to the 
acquisition of new strains, thus indirectly supporting the view that the vast majority of 
COPD exacerbations might be caused by viral infections. Statistically significant 
increased risk of exacerbations was seen with H. influenzae, S. pneumoniae and 
Moraxella catarrhalis acquisition.  
There is a clear relationship between the acquisition of new strains and exacerbations 
of COPD (Sethi S et al, 2002). Furthermore, exacerbations with new strains are 
associated with mucosal and systemic immune response to the infecting strain and are 
strongly associated with a neutrophilic inflammatory profile in sputum (Hill AT et al, 
2000; Murphy TF et al, 2005; Murphy TF et al, 2008; Sethi S et al, 2004a; Sethi S et al, 
2008b). These studies clearly established non-typeable H. influenzae, S. pneumoniae, 
M. catarrhalis, and Pseudomonas aeruginosa as causative for a significant proportion 
of COPD exacerbations. All observations to date are based on the use of sputum 
cultures to identify the presence of bacterial infection. In addition, White et al (White 
AJ et al, 2003) have shown that clearance of bacteria following 10 days of treatment 
with antibiotics for purulent sputum exacerbations was associated with a reduction in 
neutrophilic inflammation, while bacterial persistence was associated with persistent 
elevation of airway inflammation.  
The contribution of bacterial load to the occurrence of exacerbations of COPD is, 
however, uncertain. Sethi et al observed that concentrations of Haemophilus 
parainfluenzae were significantly lower during exacerbations than during stable 
periods. Among new strains of M. catarrhalis and H. influenzae, however, increased 
concentrations of during exacerbation, as compared with during stable visits (Sethi S et 
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al, 2007). Although statistically significant, this small difference in bacterial load is 
unlikely to be biologically significant (Wilkinson TM, 2007). Bacterial load is also an 
important determinant of airway inflammation, with increasing concentrations 
associated with greater intensity of neutrophilic airway inflammation (Hill AT et al, 
2000; Sethi S et al, 2000).  
Microbial pathogen presence in the airways of patients with COPD has been regarded 
as ‘colonisation’, primarily because of the absence of acute symptoms of infection. 
However, the appropriate definition of colonisation is the presence of a pathogen that 
does not cause damaging effects to the host or elicit a host response. In contrast, 
several recent studies show that bacterial pathogens are associated with host 
inflammatory and immune responses in stable COPD (Bandi V et al, 2001; Banerjee D 
et al, 2004; Hogg JC et al, 2004; Laurenzi GA et al, 1961; Murphy TF et al, 2004; Sethi S 
et al, 2006; Soler N et al, 1999). These findings suggest that application of the term 
colonisation to the lower airway bacterial presence in COPD is a misnomer, because it 
is likely that it is a low-grade chronic infection, with significant pathophysiological 
consequences. Various microbial pathogens have been implicated in chronic infection 
in COPD. These include typical bacteria such as non-typeable H. influenzae and P. 
aeruginosa, atypical bacterium such as Chlamydophila pneumoniae, viruses such as 
adenovirus and possibly respiratory syncytial virus, and recently a fungus, 
Pneumocystis jiroveci (Table 2). 
The vicious circle hypothesis is a useful conceptual model showing how chronic 
infection can contribute to COPD progression (Banerjee D et al, 2004; Sethi S et al, 
2006; Soler N et al, 1999). Evidence supporting this hypothesis is accumulating, such as 
the demonstration of a microbial colonisation-associated lower airway neutrophilic 
inflammation. Additional support for this hypothesis comes from the demonstration of 
persistent inflammation in ex-smokers with COPD, pathological evidence of local 
adaptive immune responses in the small airways in COPD, and radiological evidence of 
bronchiectasis developing in advanced disease (Bandi V et al, 2001; Hogg JC et al, 
2004; Laurenzi GA et al, 1961; Murphy TF et al, 2004). Chronic microbial infection can 
contribute to inflammation in COPD as a direct inflammatory stimulus or indirectly by 
altering the host response to tobacco smoke. In order to further test the hypothesis 
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that bacterial colonisation is associated with airway inflammation in stable COPD, Sethi 
et al obtained bronchoalveolar lavage in three groups of subjects: 26 ex-smokers with 
stable COPD, 20 ex-smokers without COPD (ex-smokers), and 15 healthy non-smokers 
(Sethi S et al, 2006). Quantitative bacterial cultures, cell counts, chemokine, cytokine, 
proteinase/antiproteinase, and endotoxin levels in the bronchoalveolar lavage fluid 
were compared. Potentially pathogenic microorganisms were recovered in 34.6% of 
COPD, 0% of ex-smokers, and 6.7% of non-smokers. Colonised COPD subjects had 
significantly greater relative and absolute neutrophil counts, interleukin 8, active 
matrix metalloproteinase-9 and endotoxin levels in the bronchoalveolar lavage than 
the non-colonised COPD subjects. Several inflammatory constituents of 
bronchoalveolar lavage were also significantly elevated in colonised COPD subjects 
when compared with ex-smokers and non-smokers. These results further demonstrate 
that bacterial colonisation drives inflammation of the distal airways in patients with 
COPD (Sethi S et al, 2006). 
Although the rate of decline in lung function following smoking cessation returns to 
that of a non-smoker in patients with early COPD, this may not be the case with more 
advanced disease. Persistent airway inflammation in ex-smokers is observed in relation 
to microbial colonisation. Whether this microbial colonisation-induced inflammation 
contributes to COPD disease progression is not clear, though some suggestive evidence 
exists. In a small study of thirty patients with advanced COPD, Wilkinson et al 
(Wilkinson TM et al, 2003) observed that an increase in airway bacterial load over the 
1-year follow-up was related to a decline in FEV1. Additional larger studies are 
probably required to confirm and extend these observations. Table 2 shows the 
updated information about the role of the different bacterial agents both in 
exacerbations and during the stable COPD. 
 
Mixed bacterial-viral aetiology 
There is increasing recognition that many patients with exacerbations have 
concomitant viral and bacterial infection. Approximately 25% of patients admitted to 
hospital with an exacerbation of COPD had co-infection with bacteria and viruses, and 
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these patients had more severe exacerbations, as measured by length of 
hospitalisation (Papi A et al, 2006). In a recent survey, approximately 70% of 
exacerbations were associated with an increase in H. influenzae and those patients 
who had concomitant rhinovirus infection had a greater fall in FEV1 and rise in serum 
interleukin 6 and sputum interleukin 8 (Wilkinson TM et al, 2006). This suggests that 
patients co-infected with a virus and bacteria may have more severe exacerbations.  
 
Non-infectious aetiology 
However, many patients (up to 25% of the cases) suffer from exacerbations where no 
specific causes can be identified. Some episodes appear to be related to environmental 
or irritant exposures. Epidemiological studies have shown that hospital admissions 
with COPD exacerbations increase slightly with a rise in atmospheric levels of sulphur 
dioxide, ozone, nitrogen dioxide and particulates (Anderson HR et al, 1997). There is 
convincing evidence that exposure to particulates with a 50% cut-off aerodynamic 
diameter of 10 μm is associated with increased hospital admissions in COPD patients 
(Wordley J et al, 1997). Particulates induce oxidative stress and, in vitro, this leads to 
activation of different inflammatory markers, such as interleukin and histone 
acetylation (Gilmour PS et al, 2003). Gilmour et al suggested that there may be an 
interaction between virus infection and air pollution in triggering exacerbations 
(Gilmour PS et al, 2001).  
Low temperatures may also be associated with exacerbations of COPD. Reduced 
temperatures in the bedroom and outside air have been associated with falls in the 
lung function of COPD patients and an increased frequency of exacerbations 
(Donaldson GC et al, 1999). The mechanisms are not yet understood but may relate in 
part to increased susceptibility to upper respiratory tract virus infections in cold 
weather. In patients admitted to hospital with severe COPD exacerbations of unknown 
cause, 25% had pulmonary embolism confirmed by spiral computerised tomography 
(Tillie-Leblond I et al, 2006). Heart failure may also lead to a symptomatic exacerbation 
of COPD, although it may be difficult to differentiate the symptoms of increased heart 
failure from those of a COPD exacerbation (Rutten FH et al, 2006). 
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TABLE 2. Microbial pathogens in chronic obstructive pulmonary disease 
Microbe Role in exacerbations Role in stable disease 
Bacteria   
Haemophilus influenzae 20-30% of exacerbations Major pathogen 
Streptococcus pneumoniae 10-15% of exacerbations Minor role 
Moraxella catarrhalis 10-15% of exacerbations Minor role 
Pseudomonas aeruginosa 5-10% of exacerbations, 
prevalent in advanced 
disease 
Likely important in 
advanced disease 












Staphylococcus aureus Isolated infrequently, 
unlikely cause 
Unlikely 
Viruses   
Rhinovirus 20-25% of exacerbations Unlikely 
Parainfluenza 5-10% of exacerbations Unlikely 
Influenza 5-10% of exacerbations Unlikely 
Respiratory syncytial virus 5-10% of exacerbations Controversial 
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Coronavirus 5-10% of exacerbations Unlikely 
Adenovirus 3-5% of exacerbations Latent infection seen, 
pathogenic significance 
undefined 
Human metapneumovirus 3-5% of exacerbations Unlikely 
Atypical bacteria   
Chlamydophila 
pneumoniae 
3-5% of exacerbations Commonly detected, 
pathogenic significance 
undefined 
Mycoplasma pneumoniae 1-2% of exacerbations Unlikely 
Fungi   





Use of biomarkers in exacerbations of COPD 
A novel approach to estimate the presence of an infection and its treatment response 
is the use of biomarkers. A biomarker refers to the measurement of any molecule or 
material (cells and tissue) that reflects the disease process. In COPD, several types of 
biomarker have been measured that are related to disease pathophysiology and the 
inflammatory and destructive process in the lung, but there are few measurements 
during exacerbations (Barnes PJ et al, 2006). Biomarkers have been measured in blood, 
urine, sputum, bronchoalveolar lavage and exhaled breath. So far there is little 
information about whether biomarkers can predict exacerbations or distinguish 
between different causal mechanisms for exacerbations, thus providing a means of 
guiding the therapy.  
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A wide variety of surrogate markers of the inflammatory process have been measured 
in the stable state and during acute exacerbation (Aaron SD et al, 2001; Bhowmik A et 
al, 2000; Bozinovski S et al, 2008; Gompertz S et al, 2001b; Rahman I et al, 1996; 
Roland M et al, 2001; Sahin U et al, 2001). Various inflammatory biomarkers, including 
tumour necrosis factor α, interleukin 6 and C-reactive protein (CRP) are increased in 
the plasma of patients with stable COPD, but not all of them predict exacerbations. 
There is an increase in plasma concentrations of inflammatory markers during acute 
exacerbations and this may represent overspill from the lung (Calikoglu M et al, 2004; 
Wedzicha JA et al, 2000). A recent study measured 36 plasma biomarkers during acute 
exacerbations in 90 patients with COPD and compared concentrations with the 
baseline state (Hurst JR et al, 2006a). The most selective biomarker turned out to be 
CRP, although it was not specific for an exacerbation. The interrelationships between 
the various biomarkers suggested that there was an increase in monocyte and 
lymphocyte activation during an exacerbation. None of the biomarkers proved to be 
useful in predicting the clinical severity of an exacerbation. Plasma leptin 
concentrations are increased during an exacerbation and this may indicate negative 
energy balance during an acute exacerbation (Calikoglu M et al, 2004; Creutzberg EC et 
al, 2000). Systemic oxidative stress is also increased during exacerbations, with 
increased concentrations of markers of oxidative stress and reduced antioxidants 
(Rahman I et al, 1997).  
Several inflammatory markers are increased in induced sputum of COPD patients 
during acute exacerbations and fall during recovery. Increased sputum concentrations 
of tumour necrosis factor α, interleukins 6 and 8 and endothelin-1 have been reported 
(Aaron SD et al, 2001; Bhowmik A et al, 2000; Gompertz S et al, 2001b; Roland M et al, 
2001; Tsoumakidou M et al, 2005). The increased purulence and colour change of 
sputum during exacerbations reflects the increased numbers of neutrophils containing 
the green pigment myeloperoxidase (Stockley RA et al, 2001). The colour may be 
useful in guiding whether antibiotic therapy is likely to be effective (Hill AT et al, 2000).  
Brain natriuretic peptide levels independently predict the need for intensive care. 
Brain natriuretic peptide levels; however, failed to adequately predict short-term and 
long-term mortality rates in patients with acute exacerbations (Stolz D et al, 2008a). In 
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another study, midregional proatrial natriuretic peptide level has been shown to be 
higher on admission for exacerbation, compared with recovery and stable state. 
Midregional proatrial natriuretic peptide was also an independent predictor of 
mortality (Bernasconi M et al, 2011). The potent vasodilator peptide 
proadrenomedullin independently predicted 2-year survival in patients admitted for 
COPD exacerbation (Stolz D et al, 2008b). Serum angiopoietin-2 concentrations have 
been shown to be significantly higher in patients with acute exacerbations of COPD 
than in those with stable COPD or control subjects (Cho YJ et al, 2011). Copeptin is 
another marker of inflammation recently studied in patients with exacerbations of 
COPD. Copeptin is the C-terminal part of the vasopressin precursor and thus it reliably 
reflects levels of vasopressin. Copeptin is increased in patients with critical care illness 
and it correlates with the severity of the primary disease (Seligman R et al, 2008). 
Müller et al (Müller B et al, 2007) demonstrated that copeptin levels were elevated in 
patients hospitalized with a lower respiratory tract infection and it was a predictor of 
outcome. In a subgroup of patients with exacerbations of COPD and acute bronchitis 
due to lower respiratory tract infection, copeptin levels were elevated compared with 
controls; however, the severity of exacerbation did not significantly affect the levels. 
Authors also found that a copeptin threshold of 53 pmol/l had a sensitivity of 58% and 
specificity of 80% in predicting mortality. A recent study by Stolz et al found that 
copeptin levels correlated significantly with length of hospital stay and length of 
intensive care unit stay in patients admitted with exacerbations of COPD. A cut-off 
level of 40 pmol/l on hospital admission was associated with additional 5 days of 
hospitalization and has an odds ratio for long-term clinical failure of 3.1. The Kaplan–
Meier survival curve shows that in the patient with long-term clinical failure, copeptin 
level was significantly higher compared with those with long-term clinical success. 
Copeptin level on the hospital admission was the only factor significantly associated 
with hospital outcome and length of hospital stay independent of lung function 
impairment, hypoxemia, and comorbidities. Incorporating the simple information 
about history of hospitalization due to exacerbations of COPD within the previous year 
further enhances prognostic value of copeptin as a biomarker (Stolz D et al, 2007a). No 
studies, however, have been carried out with this biomarker in the outpatient setting. 
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The levels of exhaled nitric oxide measured at the mouth are usually normal in patients 
with COPD (Kharitonov SA et al, 2001) but when exhaled nitric oxide is partitioned by 
the multiple flow technique, peripheral nitric oxide (including small airways and lung 
parenchyma) is increased, whereas bronchial nitric oxide is normal (Brindicci C  et al, 
2005). Exhaled nitric oxide is a promising biomarker for acute exacerbations of COPD. 
In fact, it is increased during exacerbations (Agustí AG et al, 1999; Maziak W et al, 
1998; Bhowmik A et al, 2005). This may reflect increased nitrative stress during 
exacerbations and this hypothesis is supported by the demonstration of increased 
numbers of nitrotyrosine-positive cells, as a result of increased nitrite and 
peroxynitrite formation, in induced sputum during an exacerbation compared to the 
stable state (Tsoumakidou M et al, 2005). Several inflammatory mediators and markers 
of oxidative stress have been measured in exhaled breath condensate. There is a high 
variability in the measurement and dilution results in very low concentrations of many 
mediators, making this a difficult measurement (Horvath I et al, 2005). However, this is 
a non-invasive measurement and is suited to serial measurements during an 
exacerbation of COPD. An increased concentration of hydrogen peroxide in exhaled 
breath condensate has been reported during exacerbations of COPD, suggesting 
increased oxidative stress (Dekhuijzen PNR et al, 1996; Gerritsen WB et al, 2005). Acute 
exacerbations of COPD are associated with an increase in several cytokines in exhaled 
breath condensate, including  tumour necrosis factor α and interleukins 1, 6 and 8 
(Gessner C  et al, 2005; Seemungal T et al, 2001). Kersul et al recently have reported 
that COPD exacerbations are characterised by high levels of nitric oxide in exhaled air, 
plasma CRP and interleukins 6, 8 and 10 in sputum compared with stable COPD and 
controls (Kersul AL et al, 2011). 
Another biomarker, neopterin, has not been proven to be useful in exacerbations of 
COPD. Lacoma et al (Lacoma A et al, 2011) included 318 consecutive COPD patients: 46 
in a stable phase, 217 undergoing an exacerbation, and 55 with pneumonia. A serum 
sample was collected from each patient at the time of being included in the study. A 
second sample was also collected 1 month later from 23 patients in the exacerbation 
group. Procalcitonin and CRP showed significant differences among the three patient 
groups, being higher in patients with pneumonia, followed by patients with 
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exacerbation. For the 23 patients with paired samples, both procalcitonin and CRP 
levels decreased 1 month after the exacerbation episode, while neopterin increased 
(Lacoma A et al, 2011). 
Hence, some of these biomarkers allow prediction of the onset of an exacerbation and 
provide laboratory confirmation supporting the diagnosis of the exacerbation. 
Unfortunately, except for CRP and procalcitonin, their role in patient management is 
far from certain, as intervention studies are not available (Hurst JR et al, 2006a; Stolz D 
et al, 2007a; Stolz D et al, 2007b; Stolz D et al, 2008b).  
Procalcitonin is found in very low levels in healthy individuals. In the presence of 
infection, the circulating concentrations of procalcitonin increase rapidly. The 
ubiquitous release of procalcitonin during bacterial infections is induced either directly 
by microbial toxins or indirectly by humoral factors or the cell-mediated host response 
(Linscheid P et al, 2004). This induction is rather attenuated by cytokines released 
during viral infections, such as interferon-γ (Linscheid P et al, 2004). Therefore, 
circulating levels of procalcitonin are markedly elevated in bacterial infections as 
compared to viral infections or other inflammatory conditions (Becker KL et al, 2004). 
Procalcitonin serum levels > 0.25 ng/ml showed a high specificity (97.7%) for bacterial 
lower respiratory tract infection requiring antibiotic therapy (Stolz D et al, 2006). 
Within this context, the usefulness of procalcitonin for guiding antibiotic therapy in 
208 patients admitted for acute exacerbation of COPD has been analysed (Stolz D et al, 
2007b). At admission, patients were randomized either to a procalcitonin-guided 
strategy or to the standard approach, in which antibiotics were prescribed according to 
the decision of the physician in charge. Patients assigned to the procalcitonin-guided 
group were treated with antibiotics according to serum procalcitonin levels. A 
procalcitonin level < 0.1 µg/l was considered to be nonbacterial and antimicrobial use 
was discouraged. In those with a procalcitonin level > 0.25 µg/l, the exacerbation was 
believed to be bacterial and antimicrobial therapy was encouraged. For patients with 
procalcitonin levels between 0.1 µg/l and 0.25 µg/l, the use of antimicrobial agents 
was based on the stability of the clinical condition. Patients were followed up during 
the hospitalization, at a short-term visit, and through 6 months. Procalcitonin guidance 
reduced antibiotic prescription from 72 to 40% at acute exacerbations, allowing a 
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significant sustained reduction in total antibiotic exposure for up to 6 months (RR: 
0.76, 95% CI: 0.64 – 0.92). Clinical outcome and improvement in FEV1 were not 
compromised. Exacerbation rate and time to next exacerbation did not differ between 
both randomized groups. Given the fact that similar results have been reported in 
lower respiratory tract infection, community-acquired pneumonia, and severe 
bacterial infection (Christ-Crain M et al, 2004; Christ-Crain M et al, 2006; Nobre V et al, 
2008), these findings suggest that procalcitonin guidance offers a sustained advantage 
in reducing antibiotic use for acute exacerbation. The absolute risk reduction of 32% in 
the antibiotic exposure implies that for one in every four patients admitted because of 
acute exacerbation, one antibiotic course can be prevented (number needed to treat: 
3.2, 95% CI: 2.3 – 5.3). Despite the promising results, it still needs to be defined 
whether these results can be replicated in a multicentre trial (Martínez FJ et al, 2007).  
CRP is an acute phase reactant, which is increased in most forms of tissue damage, 
inflammation, and/or infection (Antonescu-Turcu A et al, 2009). CRP is a protein 
produced by the liver in response to stimulation by interleukin 6 (Pepys MB et al, 
2003). A systematic review by Gan et al (Gan W et al, 2004) concluded that patients 
with COPD have elevated CRP levels that were on average 1.86 mg/l higher than those 
of control, a difference that is clinically relevant (Dahl M et al, 2007; Sin D et al, 2003). 
Several studies have shown that high CRP levels have been associated with reduced 
lung function, 6-minute walking distance, pO2 and impaired energy metabolism 
(Broekhuizen R et al, 2006; de Torres JP et al, 2006). 
Numerous prospective studies showed that serum level of CRP is independently 
associated with mortality in whole spectrum of different diseases such as coronary 
heart disease (Lowe GD et al, 2006), high blood pressure, metabolic syndrome, 
obstructive sleep apnoea, diabetes, and renal disease (Linnemann B et al, 2006; Racki S 
et al, 2006). Two large epidemiological studies (Dahl M et al, 2007; Man SF et al, 2006) 
showed that increased CRP values are associated with cardiovascular and general 
mortality in patients with stable mild-to-moderate COPD. Man et al (Man SF et al, 
2006) found that patients in highest CRP quintile (mean CRP: 70 mg/l) had the highest 
risk of all-cause mortality, cancer deaths, and cardiovascular events. Dahl et al (Dahl M 
et al, 2007), using the data from Copenhagen City Heart Study, reported that 
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prospective measurements of CRP levels were predictive of hospitalization and death 
from COPD. This 8-year follow-up study indicated that the absolute 10-year risk for 
COPD hospitalization and death in individuals with CRP levels above 30 mg/l were 54 
and 57%, respectively, among those with a tobacco consumption above 15 g/day and a 
FEV1 less than 50% predicted. These studies concur with previous studies that CRP is a 
strong predictor of future mortality (Ridker P, 2003), but CRP is not associated with an 
independent risk of COPD death. As patients included had mild-to-moderate COPD and 
most of their mortality was due to cardiovascular disease, it is possible that elevated 
CRP is just a marker of increased cardiovascular mortality risk (Donaldson G, 2007). 
Furthermore, de Torres et al (de Torres JP et al, 2008) found that baseline serum CRP 
level was not significantly associated with survival in patients with clinically stable 
moderate-to-severe COPD. In contrast, the body-mass, airflow obstruction, dyspnoea 
and exercise capacity index and its components were strong predictors of survival in 
this group of patients. Of note, the study by de Torres et al was much smaller 
compared with the two large epidemiological studies mentioned above and included 
patients with severe COPD. 
Multiple studies investigated CRP levels during an episode of acute exacerbation of 
COPD (Bircan A et al, 2008; Dev D et al, 1998; Malo O et al, 2002; Spruit MA et al, 
2003; Weis N et al, 2006). In another study, CRP levels were not increased in a large 
proportion of patients with acute exacerbation (Hurst JR et al, 2006b) and initial CRP 
levels seemed not to be correlated with outcome of acute exacerbation (Stolz D et al, 
2007a). CRP levels are highest in bacterial infection. In this context, low levels of CRP 
might just reflect the absence of bacterial infection, thus suggesting that a significant 
proportion of acute exacerbation is caused by triggers other than bacterial infection, 
such as viruses or concomitant heart failure. Accordingly, CRP values are markedly 
increased in COPD patients admitted for acute exacerbation with pneumonia and in 
those with sputum purulence (Weis N et al, 2006). Fluctuation of the CRP levels during 
an exacerbation of COPD and its relationship with treatment has been addressed in 
multiple studies. Spruit et al (Spruit MA et al, 2003) described a significant decrease in 
CRP levels with treatment between days 1 and 3 and between days 3 and 8 in patients 
admitted with acute exacerbations of COPD. More recently, Stolz et al showed that 
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CRP levels, while significantly elevated during an exacerbation of COPD, decreased 
substantially thereafter with comparable levels at day 14 and after 6 months (Stolz D 
et al, 2006; Stolz D et al, 2007a). 
Given the wide range of variation in elevated CRP level between 61 and 88%, some 
authors consider that it is a poor biomarker. It is not entirely clear what is the possible 
explanation for this discrepancy between the studies. There are few possible 
speculations: up to 50% of variation in CRP levels is determined by inherited 
characteristics (Wouter EF, 2006); relatively small number of patients included in the 
studies and inclusion bias; inhaled and systemic corticosteroids may blunt CRP 
response by 50 and 63%, respectively (Sin D et al, 2004); and different causes for acute 
exacerbation have a different impact on CRP levels, in which bacterial infection causes 
a more dramatic increase compared with nonbacterial cause of COPD exacerbation, 
such as a viral infection or heart failure. Supporting this latter hypothesis, Dev et al 
(Dev D et al, 1998) showed that patients with proven bacterial infection had markedly 
elevated CRP levels (mean 103 mg/l). Similarly, Hurst et al (Hurst JR et al, 2006b) 
indicated higher CRP and IL-6 levels in the presence of a bacterial pathogen and levels 
are proportional to the lower airway inflammation. Other investigators indicated that 
CRP levels during an exacerbation correlate with different clinical parameters such as 
sputum characteristics, white blood cell count, presence of an infiltrate on the chest 
radiograph, and type of exacerbation according to Anthonisen criteria (Stockley RA et 
al, 2000, Stolz D et al, 2007a). 
CRP has limitations as well. CRP is increased in response to a number of infectious and 
inflammatory conditions and therefore is not specific to COPD in general and moreover 
to episodes of acute exacerbation. The clinical usefulness of a cut-off value of a 
biomarker depends on the underlying disease and the potential decision for 
treatment. Important limitation in validation of CRP as biomarker for COPD 
exacerbation is lack of agreed method in identification of exacerbations of COPD in 
clinical terms. Based on the available data, CRP is not able to distinguish between 
infection and non-infectious causes of acute exacerbations of COPD.  
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Despite this enormous number of studies published in exacerbations of COPD, no 
studies evaluating the usefulness of CRP on reduction of antibiotic therapy for acute 
exacerbations of COPD have been performed up to now. However, Cals et al have 
shown that those general practitioners (GP) who use the CRP rapid test in the 
consultation as a guidance to prescribe or not antibiotics for lower respiratory tract 
infections; they prescribe antibiotics more prudently (Cals JW et al, 2009; Cals JW et al, 
2010). This fact has been also shown in the Happy Study in Spain; those GPs who 
performed CRP tests prescribed significantly fewer antibiotics for lower respiratory 
tract infections compared to those who did not use this rapid test (Llor C, 2010a). 
 
Antibiotics for exacerbations of non-severe COPD are controversial 
The recommendation for prescribing antibiotics in acute exacerbations of COPD is still 
mainly based on the landmark study by Anthonisen et al (Anthonisen NR et al, 1987; 
Celli BR et al, 2004a; El Moussaoui R et al, 2008; National Institute for Clinical 
Excellence, 2011). In this double-blinded, cross-over trial, 173 patients were randomly 
assigned to either antibiotics or placebo. Outcome was defined as success, no 
resolution, and deterioration and assessed at 21 days. As compared to patients in the 
placebo group, patients receiving antibiotics had a higher success rate in type I 
exacerbations, as defined by increased dyspnoea, increased sputum volume, and 
increased sputum purulence (43 versus 62.9%, p<0.01). Patients with type II and type 
III exacerbations did not statistically benefit from antibiotic therapy. Whereas no 
differences were seen in the number of patients showing ‘no resolution’ in all three 
exacerbation types, patients with type I exacerbation receiving placebo had a higher 
deterioration rate (30.5 versus 14.3%). Hence, antibiotics prevented deterioration in 
9% of all exacerbations treated within the trial. Although this study included moderate-
to-severe COPD patients with a mean FEV1 of 33.1% predicted, 55% of the patients 
were cured without antimicrobial treatment. Interestingly, time to recovery was 
similar in both randomized groups for those classified as ‘no resolution’ or success 
(11.9 versus 12.8 days). On the basis of these results, it is tempting to speculate that 
antibiotics might not influence the clinical course of exacerbation including duration of 
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symptoms but could prevent deterioration in those with underlying bacterial infection. 
Noteworthy, this trial has a few methodological weaknesses: firstly, patients with type 
II and III exacerbations could be reclassified as a type I exacerbation if symptoms 
escalated. Therefore, type I exacerbations were, per definition, more prone to 
represent non-resolving infections. Secondly, only 42% of patients in both treatment 
arms received corticosteroids. Currently, corticosteroids represent a standard 
treatment for acute exacerbations of COPD (Global Initiative for Chronic Obstructive 
Lung Disease, 2010). Finally, the potential benefit of antimicrobial therapy might have 
been underestimated in this trial given the fact that only narrow-spectrum antibiotics 
were available at that time. More recent studies failed to demonstrate an association 
between bacterial infection and Anthonisen type I exacerbations (Stolz D et al, 2007; 
van der Valk P et al, 2004). Nevertheless, a meta-analysis recently included in the 
Cochrane Library suggests that in acute exacerbations with increased cough and 
sputum purulence, the use of antibiotics reduces the risk of short-term mortality by 
77% and decreases the risk of treatment failure by 53% (Ram FS et al, 2006). These 
results should be interpreted with caution, because they might be driven by a single 
study including patients with severe exacerbations treated in the intensive care unit 
and requiring mechanical ventilation (Nouira S et al, 2001). Furthermore, there were 
differences in patient selection, antibiotic choice, small number of included trials, and 
lack of control for interventions that influence outcome, such as use of systemic 
corticosteroids and ventilatory support (Ram FS et al, 2006). Antibiotics influenced 
resolution of sputum purulence but did not influence recovery of peak flow or gas 
exchange (Ram FS et al, 2006). Paradoxically, viral exacerbations are associated with 
more severe exacerbations and prolonged symptom recovery as compared to non-viral 
exacerbations (13 versus 6 days) (Ram FS et al, 2006).  
Current guidelines mainly base their decision about antibiotic prescription on the study 
of Anthonisen (Anthonisen NR et al, 1987) and recommend their use in type I and II 
antibiotics; that is, when two or three of the following criteria are present: increase of 
dyspnoea, increase of sputum production and/or purulence of sputum COPD (Global 
Initiative for Chronic Obstructive Lung Disease, 2010). However, antibiotics can be 
withheld in those type III exacerbations; that is, when only one of the former criteria is 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
39 | P a g e  
 
present. Purulent sputum has been shown to be the most predictive for bacterial 
infection (Stockley RA et al, 2001).  
These recommendations have also been endorsed by many scientific societies in our 
country, and more particularly, by the Spanish Society of Family and Community 
Medicine (Cots JM et al, 2010). Despite the use of these recommendations, the 
evidence for antibiotic prescription for exacerbations of non-severe COPD is weak and 
this fact has been pointed out by three systematic reviews published over the last 
years. 
 
Systematic reviews of placebo-controlled trials 
Three important systematic reviews of placebo-controlled trials about effectiveness of 
antibiotic therapy in acute exacerbations of non-severe COPD have been published 
recently (Puhan MA et al, 2007; Puhan MA et al, 2008; Ram FS et al, 2006). Those 
reviews showed that antibiotics have a significant effect on treatment failure in 
hospitalised patients but not in outpatients. 
There are a large number of randomised trials comparing different antibiotics, without 
placebo control, for the treatment of exacerbations of COPD. Although it may seem 
plausible that antibiotics are beneficial in about 50% of the COPD patients in whom 
bacteria are the cause of the exacerbation (Sethi S, 2004), there is evidence indicating 
that antibiotics have a short-term effect only in COPD patients with severe 
exacerbations but not in mild to moderate exacerbations (Puhan MA et al, 2007). 
Although head-to-head comparisons of different treatment options available in clinical 
practice can be very useful (Tunis SR et al, 2003), an underlying assumption of such 
trials is that the treatments are effective compared with a placebo (Djulbegovic B et al, 
2001; ICH Steering Committee, 2000; Schwartz D et al, 1967). While conducting a series 
of systematic reviews of treatments in COPD, we gained the impression that the 
evaluation of antibiotics for COPD exacerbations had moved to head-to-head 
comparisons of different antibiotics with very little research in placebo-controlled 
trials. Puhan et al (Puhan MA et al, 2008) recently set out to test this hypothesis in a 
more systematic way, counting the number of randomised trials of antibiotic 
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treatment for mild to moderate exacerbations in COPD patients published in the last 
50 years, determining whether they used a placebo control or conducted head-to-head 
comparisons, and contrasting the number of patients studied with the results of a 
cumulative meta-analysis, using data from a recently published systematic review. 
As with any systematic review on this topic, a difficulty is that definitions of COPD have 
varied over time. In particular, spirometric criteria became widespread only after 1995 
and authors generally accept a clinical diagnosis of COPD, chronic bronchitis or 
emphysema. However, in order to include only trials whose patients were very likely to 
have COPD, Puhan et al (Puhan MA et al, 2008) included studies only if patients with 
chronic bronchitis were at least 40 years of age and/or if at least 80% were smokers or 
ex-smokers. The presence of these characteristics (chronic bronchitis, age and smoking 
history) renders a diagnosis of COPD according to spirometric criteria extremely likely 
(Straus SE et al, 2000). However, Puhan et al defined patients to have mild to 
moderate exacerbations if they needed any outpatient treatment. Out of 15 placebo-
controlled trials, seven enrolled outpatients with non-severe exacerbations. A total of 
212 head-to-head trials were identified, of which 101 explicitly enrolled outpatients 
with mild-to-moderate exacerbations and 63 enrolled inpatients. In 48 trials, patients 
with any severity of exacerbations were enrolled or severity of the exacerbation could 
not be determined. From 1957 to 2005, the 101 head-to-head trials enrolled a total of 
34,029 patients with mild to moderate exacerbations. The first head-to-head trial in 
1963 (Christiansen I et al, 1963) included patients with non-severe exacerbations and 
compared sulphonamide with penicillin, with the aim of finding an antibiotic with 
fewer adverse events than oxytetracycline, the drug used in the three earlier placebo-
controlled trials (Berry DG et al, 1960; Elmes PCF et al, 1957; Fear EC et al, 1962). As in 
many of the following head-to-head trials (Wegmuller E, 1979), the role of the 
antibiotic itself was not questioned. A common reason to justify a head-to-head trial 
was that antibiotics are effective against organisms most commonly associated with 
purulent sputum in chronic bronchitis, such as H. influenzae and S. pneumoniae. Thus 
rather than citing evidence from placebo-controlled trials, they referred to the in vitro 
activity of antibiotics, for example (Burrow G et al, 1975; Hamilton BA et al, 1993). Yet 
another group of head-to-head trials referred to placebo-controlled trials to justify 
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their head-to-head trials but selectively cited only those trials with positive results 
(Fogarty C et al, 2005; Willey RF et al, 1978). 
The seven trials included a total of 990 outpatients with mild to moderate 
exacerbations. Figure 1 shows the cumulative meta-analyses for the five trials 
reporting on treatment failure. In one trial, treatment failure was defined as event-
based because of the need for further antibiotics (Elmes PCF et al, 1957), and in four 
trials, a symptom-based definition of treatment failure was used (Anthonisen NR et al, 
1994; Berry DG et al, 1960; Jorgensen AF et al, 1992; Sachs AP et al, 1995). Cumulative 
ORs never reached statistical significance and the most recent, published in 1995, 
cumulative OR was 0.81 (95% CI: 0.52 – 1.28). When the authors also included another 
trial (Allegra LG et al, 1991), the cumulative OR also remained non-significant (0.50, 
95% CI: 0.2 – 1.24). In other words, cumulative evidence from placebo-controlled trials 
did not show any significant effects of antibiotics on treatment failure in COPD patients 
with mild to moderate exacerbations. 
 
FIGURE 1. Cumulative meta-analyses for the five placebo-controlled trials evaluating 
effectiveness of antibiotics in non-severe COPD exacerbations 
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It should be emphasised that the results of Puhan’s meta-analysis apply to antibiotic 
treatment for mild-to-moderate COPD exacerbations. In patients with severe 
exacerbations, antibiotics show a strong effect not only on treatment failure but also 
on mortality (Puhan MA et al, 2008). This analysis of placebo-controlled trials differs to 
some extents to that of the Cochrane review (Ram FS et al, 2006) because Puhan et al 
did not include a study (Elmes PC et al, 1965) that was not a randomised but a 
matched controlled study. However, Puhan et al did include the trial by Sachs et al 
(Sachs AP et al, 1995) missed by the Cochrane review and received the original data 
from the authors. However, the Cochrane review (Ram FS et al, 2006) also showed 
that antibiotics have a significant effect on treatment failure in hospitalised patients 
but not in outpatients. Similarly, a randomized, placebo-controlled trial in 93 
mechanically ventilated patients showed that 10 days of therapy with ofloxacin 
resulted in decreased hospital mortality (4 versus 22%), shorter length of hospital stay, 
and shorter duration of mechanical ventilation (Nouira S et al, 2001). Interestingly, no 
concomitant steroid therapy was offered by study design, a factor that might have 
significantly influenced trial results, given that antibiotic benefits are less prominent if 
steroids are used concomitantly (Wilson R et al, 2004). 
The Cochrane review identified only 11 trials investigating a total of 917 patients (Ram 
FS et al, 2006). This is in striking contrast to the enormous number of patients suffering 
from exacerbations of COPD each year worldwide. This recent analysis showed a 
reduction of the risk of short-term mortality by 77%, a decrease in the risk of 
treatment failure by 53% and the risk of sputum purulence by 44%. However, there is a 
warning that the results have to be interpreted with caution due to the differences in 
patient selection, antibiotic choice, the small number of trials included and the lack of 
control for interventions that influence outcome, such as use of systemic 
corticosteroids and ventilatory support. Most importantly, only three studies (from 
1968, 1972 and 2001) with a total of 298 patients were eligible for assessment of 
mortality. It should be mentioned that, although the combined analysis showed a 
survival benefit, each individual study was relatively small in size and was 
underpowered to answer this critical question (Quon BS et al, 2008). The same was 
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true for studies assessing treatment failure (1968, 1972 and 1992; 263 patients) and 
sputum purulence (1968 and 1972; 205 patients).  
In another recent meta-analysis of 13 trials including 1,557 patients assessing the 
effect of antibiotics on clinically relevant outcomes confirmed that antibiotics do not 
reduce treatment failure in outpatients (pooled OR: 1.09, 95% CI: 0.75 – 1.59) (Puhan 
MA et al, 2007). 
 
Limitations of the systematic reviews 
Definitions used in these trials 
A limitation of systematic reviews in COPD is the evolution of definitions and 
classifications of COPD over the years. This raises uncertainty about the nature of the 
study populations included in trials published before 1995 or even before 2000. Many 
placebo-controlled trials included patients with 'chronic bronchitis' who did not 
present evidence of chronic airflow obstruction or poor reversibility of airflow 
obstruction. 
COPD is a heterogeneous disease 
Outcomes of exacerbations worsen and antibiotic benefit in exacerbations increases 
with worsening underlying airflow obstruction, in frequent exacerbators and with 
comorbid conditions (Miravitlles M et al, 2001; Wilson R et al, 2006). This is likely 
related to a greater proportion of bacterial aetiology and more severe local 
immunocompromise in these patients. In grouping together the trials in theses 
systematic reviews, both Puhan et al and Ram et al (Puhan MA et al, 2007; Ram FS et 
al, 2006) pooled together patients who are very heterogeneous with respect to their 
COPD disease and, therefore, could not discern a beneficial effect of antibiotics. This is 
best illustrated by comparing the patient populations of two trials included in their 
analysis; the trial conducted by Anthonisen et al (Anthonisen NR et al, 1987), which 
showed a significant benefit of antibiotics, and the trial conducted by Sachs et al (Sachs 
APE et al, 1995), which failed to show benefit (Sethi S, 2008). In the Anthonisen study 
(Anthonisen NR et al, 1987), there was significant benefit with antibiotics when all 362 
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exacerbations were considered, but Puhan et al (Puhan MA et al, 2007) consider only 
for their analysis the first exacerbation from the 116 patients in the study, which could 
alter the results. On the other hand, Sachs et al (Sachs APE et al, 1995) included 
patients of younger age, mild underlying disease and asthma. Not surprisingly, only 
11% of their exacerbations were associated with a positive bacterial culture, rather 
than the usual 40% to 50%. Not surprisingly, antibiotics were of no benefit in this study 
and, in their placebo arm, there was a 93% resolution rate compared with 55% in the 
Anthonisen study (Anthonisen NR et al, 1987). 
Severity of exacerbations 
These systematic reviews considered non-severe exacerbations based on the site of 
treatment, that is, outpatient treatment. This classification is clearly very broad as the 
site of care will vary among countries and healthcare systems as well as with patient 
and physician preferences. Furthermore, over time, changes in healthcare delivery and 
results of outcome studies can change the site of care for the same severity of 
exacerbation. As Sethi states (Sethi S, 2008) a 40-year-old smoker without underlying 
airway obstruction, infrequent exacerbations and free of comorbid conditions would 
have been included as a mild-to-moderate exacerbation. On the other hand, a patient 
with severe COPD, frequent exacerbations and comorbid conditions who does not 
require hospitalization would also be classified as a mild-to-moderate exacerbation. In 
the former patient, it is possible that host immunity can adequately deal with the 
infection and the exacerbation will spontaneously resolve. In the latter patient, such 
resolution is less likely and complications are more frequent. Grouping these patients 
together can lead to confusing and contradictory results. 
The severity of an exacerbation is a complicated concept, constituted by at least two 
factors, the severity of the underlying COPD and the acute change induced by the 
exacerbation itself. Therefore, a patient with severe underlying COPD will have 
significant clinical consequences from a relatively small change from the baseline state, 
while a patient with mild COPD will tolerate a much larger change in symptoms and 
lung function. It is evident that we need more objective measures of severity of 
exacerbations.  
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All antibiotics are not the same 
An additional consideration is the spectrum of the different antibiotics used to treat 
COPD. In these meta-analyses, the authors tended to treat all antibiotics as equivalent 
when used to treat exacerbations of COPD. Antibiotics do differ in their antimicrobial 
spectrum, pharmacokinetic/pharmacodynamic profiles and ability to penetrate 
respiratory tissues. Recent studies indeed show differences in clinical outcomes among 
antibiotics used in exacerbations. A recent meta-analysis of antibiotic comparison 
trials, which were quite homogenous, demonstrated that amoxicillin results in 
suboptimal outcomes with increased risk of clinical failures in COPD (Dimopoulos G et 
al, 2007) This has been seen particularly since the early 1990s, when resistance 
emerged to this agent. Interestingly, two trials, published by Sachs et al (Sachs APE et 
al, 1995) and Jorgensen et al (Jorgensen AF et al, 1992) included in these meta-
analyses, both not showing a significant benefit of antibiotics, used amoxicillin and 
were conducted in the 1990s. Two trials comparing fluoroquinolones with non-
fluoroquinolone antibiotics, the GLOBE and MOSAIC trials, showed more complete 
clinical resolution of exacerbations and a prolonged time to the next exacerbation 
(Wilson R et al, 2002; Wilson R et al, 2004). 
End-points in exacerbation trials 
Analysis of any study should critically examine if its end-points were adequate to 
demonstrate the potential benefits of the intervention being tested and were clinically 
relevant. Unfortunately, in the studies evaluated in these systematic reviews, as well 
as in the vast majority of antibiotic comparison trials in exacerbations of COPD, end-
points used favour the demonstration of equivalence rather than differences among 
the arms (Sethi S et al, 2004b). Partly, this is the result of mandates by regulatory 
agencies. These end-points assessed at 2 to 3 weeks after the onset of symptoms and 
the initiation of therapy miss differences in therapeutic effect earlier during the course 
of treatment. In addition, these end-points have minimal relevance to clinical practice. 
In clinical practice, most physicians and patients expect clinical improvement in their 
exacerbation at the first week to ten days after initiation of treatment. In fact, with 
insufficient improvement in that timeframe, therapy is often altered or expanded. 
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Allegra et al (Allegra L et al, 2001) did conduct a placebo-controlled trial where they 
used a 5-day time-point, showing a substantial benefit of antibiotics. 
The adequacy of the traditional goals of treatment of an exacerbation, recovery to 
baseline clinical status and the prevention of complications, are being questioned 
because of several new observations. These include realization of the importance of 
exacerbations in the course of COPD, the role of infection in exacerbations, the high 
rates of relapse with an adequate initial clinical response, and the role played by 
chronic infection in the pathogenesis of COPD. Today, confining our goal in the 
treatment of COPD exacerbations to short-term resolution of symptoms would be 
analogous to treating acute myocardial infarction with the only aim being resolution of 
chest pain. 
Last studies published 
Recently, a placebo-controlled trial investigated the effects of antibiotic treatment 
with doxycycline in addition to corticosteroids in acute exacerbations of COPD (Daniels 
JM et al, 2010). The primary end-point was clinical success on day 30: this was not 
significantly different between groups. However, secondary end-points, such as clinical 
success and clinical cure on day 10, were in favour of antibiotic treatment. This study 
suggests that it is safe to omit antibiotic treatment in a clinical trial of exacerbations of 
COPD but it cannot answer the crucial question of whether antibiotics are efficacious, 
as the results are, again, heterogeneous and the study was underpowered. In addition, 
the antibiotic used, doxycycline, may not be first choice in most European countries. 
The latest publication in the field is a retrospective cohort study of hospitalised 
exacerbations of COPD patients performed at 413 acute care facilities throughout the 
USA (Rothberg MB et al, 2010). The analysis was based on a database developed for 
measuring healthcare quality and utilisation. The primary end-point was a composite 
measure of treatment failure, defined as the initiation of mechanical ventilation after 
hospital day 2, in-hospital mortality and readmission for COPD within 30 days of 
discharge. It was found that the risk for treatment failure was lower in the antibiotic-
treated patients (OR: 0.87; 95% CI: 0.82 – 0.92). However, this analysis has many 
problems. The groups investigated were hardly comparable, as treated patients 
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received more short- and long-acting bronchodilators, steroids, morphine and loop 
diuretics than those not receiving antibiotics. Only administrative data could be used 
for the analysis, such that physiological differences between groups could not be 
directly adjusted for. Identification of patients was performed by administrative data 
review, which implies that classification of patients might have been severely biased. 
To date, there is no single study sufficiently powered to demonstrate the efficacy of 
antibiotic treatment in exacerbations of COPD.  
 
Utilization of antibiotics for COPD exacerbations 
Antibiotics are widely used for acute exacerbations of COPD. It is estimated that more 
than 80% of COPD exacerbations are treated on an outpatient basis, which can be 
regarded as mild-to-moderate exacerbations. Accordingly, antibiotics were prescribed 
in 85% of 69,820 patients admitted for acute exacerbations of COPD to 360 hospitals 
throughout the United States (Lindenauer PK et al, 2006). In a Spanish study carried 
out in the primary care setting, antibiotics were prescribed in 89% of the exacerbations 
(Miravitlles M et al, 1999a). More recently, in the Happy Audit study carried out in 
Spain, antibiotics were prescribed in 81.1% of the cases (Llor C et al, 2010b). 
Antimicrobials are often given either to speed up recovery from a bacterial infection or 
in a defensive manner to avoid the risk of airway infection progressing to pneumonia 
(Wilson R, 2008). 
Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in 
hospitals and the community. The excessive use of antibiotics without clear indication 
contribute significantly to the increase in antibiotic resistance is believed to be the 
main cause of the spread of antibiotic-resistant bacteria (Chen DK et al, 1999; Wenzel 
RP et al, 1999). Antibiotic resistance itself is a major threat to our patients, as it results 
in increased morbidity and mortality. The European Centre for Disease Prevention and 
Control has been campaigning for several years for a more prudent use of antibiotics 
(Earnshow S et al, 2009). The majority of antibiotics are prescribed for respiratory tract 
infections (Bjerrum L et al, 2011). Given COPD's prevalence and the duration of illness, 
reduction of antibiotic prescription for acute exacerbation could have a tremendous 
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impact on the selective pressure for the emergence of bacterial resistance (Gonzales R 
et al, 1999; Guillemot D et al, 2001). In addition, the incidence of antibiotic-related 
adverse effects ranges from 18 to 24% in acute exacerbations (Gotfried M et al, 2007). 
In this context, discriminate use of antibiotics at exacerbation may be pivotal to 
improve outcome in patients with COPD. Despite the debatable efficacy of 
antibiotics in exacerbations of COPD, most GPs will feel compelled to prescribe 
antibiotics, particularly in deteriorating patients and in those admitted to the hospital 
but also in the outpatient setting. 
 
Rationale of this thesis 
Many head-to-head trials of antibiotics for mild to moderate COPD exacerbations have 
been conducted although evidence from randomised placebo-controlled trials never 
showed that antibiotics were effective at all. So, in this case, the evaluation of 
antibiotics did not follow the general principle that placebo-controlled trials must have 
shown that the treatment is better than the placebo, before head-to-head trials are to 
be conducted (ICH Steering Committee, 2000). Probably, this is due to the 
pharmaceutical industry pressure. In general, big pharma tends to favour placebo-
controlled trials in order to show large effects and to avoid direct comparison with 
competitors. Once a treatment, such as antibiotics for COPD exacerbations, is 
established in clinical practice an attractive market is available. If a company wants to 
enter this market it needs to provide a trial showing clinical non-inferiority of a new 
antibiotic and some advantages in terms of adverse effects or costs. This will make it 
relatively easy to get approval from regulatory agencies, as long as the drug is safe. The 
Helsinki Declaration emphasises the great importance of conducting experimental 
studies for medical progress. However, it also states that one should be very careful 
before embarking on randomised trials with placebo controls because research 
participants have a right to the best available treatment (World Medical Association, 
2000). Worries about the 'unethical use of placebo' continue (Fergusson D et al, 2005; 
Michels KB et al, 2003). However, the present thesis tackles the reverse scenario. 
Might there be cases where experimental treatment did not show superiority over 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
49 | P a g e  
 
placebo but where the placebo controls were abandoned nevertheless, thus exposing 
patients to adverse effects and society to healthcare expenditures not offset by any 
beneficial effects. 
The rationale for the first placebo-controlled trials was reported to be the uncertainty 
about the benefits of a short course of intermittent antibiotic therapy for 
exacerbations (Berry DG et al, 1960; Elmes PCF et al, 1957; Fear EC et al, 1962). The 
authors explicitly stated the short duration of antibiotic treatment because 
prophylactic long-term use of antibiotics to prevent exacerbations was quite common 
at that time. However, prophylactic long-term use of antibiotics is not recommended 
nowadays even though some papers have been published very recently (Albert RK et 
al, 2011). Over the following 40 years, authors of placebo-controlled trials argued that 
these trials were required because the role of the antibiotic therapy was not clear 
(Anthonisen NR et al, 1987) or because it was still not sufficiently clarified whether 
acute exacerbations of chronic bronchitis should be treated with antibiotics (Jorgensen 
AF et al, 1992). These statements reflect the ongoing debate about the usefulness of 
antibiotics for COPD exacerbations. The three systematic reviews of placebo-controlled 
trials about effectiveness of antibiotic therapy in non-severe exacerbations of COPD 
failed to conclude that they are effective in mild-to-moderate exacerbations. In spite of 
the high prevalence of COPD and the resulting high number of exacerbations 
worldwide, there are only a very limited number of studies on the efficacy of antibiotic 
treatment in exacerbations of COPD. There is significant heterogeneity in findings 
across these studies, indicating a lack of consistency and robustness in the results 
(Rohde GG, 2010). It is obvious that there is a paucity of reliable data on the use of 
antibiotics for acute exacerbations of non-severe COPD. Most of the studies lack an 
objective definition of COPD and cannot be compared to the standards of current 
guidelines, such as those of the GOLD. Differences in disease definition may have 
severely biased the results obtained. The different study populations showed clinically 
important differences in severity of COPD exacerbations. The small number of studies 
so far does not allow for stratified analysis according to severity of COPD 
exacerbations. There may also be substantial publication bias, as during the time most 
of the studies were performed, mainly the 1970s, negative results might not have been 
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published, and such studies were not centrally captured and published. A very 
important limitation of nearly all studies on the topic is the lack of a standardised 
treatment for exacerbation. So far, only one clinical trial included standardised 
treatment, but the results were not unequivocal (Daniels JM et al, 2010).  
The other reason for conducting this thesis is the overprescription of antibiotics not 
only for acute exacerbations of COPD but also for other lower respiratory tract 
infections. Even though antibiotics are currently recommended for patients with 
severe exacerbations or severe underlying COPD and in those with type I and II 
exacerbations, they are widely prescribed worldwide.  
Most episodes of acute exacerbations of COPD are, however, mild-to-moderate and 
not severe. This fact is even clearer in the primary care setting, with patients with mild 
and moderate airway obstruction as the most frequently attended by GPs. At the 
moment, there is no clear recommendation for antibiotic treatment for these patients. 
These facts underline the need for this thesis, sufficiently powered, randomised, 
placebo-controlled trial of antibiotics for mild-to-moderate acute exacerbations of 
COPD. 
The present thesis is therefore clearly justified. Despite the fact that evidence for 
antibiotic prescription for exacerbations of non-severe COPD is not compelling, 
antibiotics are widely prescribed in this condition. GPs are confirmed in their habit of 
antibiotic prescription because most outpatients with mild-to-moderate exacerbations 
recover within 2 weeks. Yet they do not seem to be aware of the natural recovery rate 
that is, without antibiotics, in these patients, which is 80% or more and equal to that in 
patients receiving placebo (Puhan MA et al, 2007). Furthermore, recent American 
College of Physicians/American College of Chest Physicians guidelines for COPD 
exacerbations alerts about the generalised use of broad-spectrum antibiotics (Bach PB, 
2001). Undoubtedly, as stated in the systematic reviews published so far, we need to 
enlarge our evidence base for the treatment of exacerbations with placebo-controlled 
trials. However, as highlighted in this commentary, these trials should use 
contemporary end-points so that we do not miss important, clinically relevant benefits 
of antibiotics, not assessed by traditional end-points. This thesis tries to answers these 
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questions and clearly overcome the limitations of the placebo-controlled trials 
published so far (Table 3). 
 
TABLE 3. Limitations of published placebo-controlled antibiotic trials in acute 
exacerbations of chronic obstructive pulmonary disease 
Limitation of study design Potential 
consequences 
Proposed goal 
Subjects with no 
underlying COPD 
included (non-smokers, 
chronic bronchitis, no 
spirometric validation) 
Diminished overall 
perceived efficacy of 
antibiotics 
To carry out studies that include 
only patients aged 40 or more, 
who are smoking or have smoked 
at least 10 packs-year, and need of 






perceived efficacy of 
antibiotics 
Include only COPD patients 
Small number of subjects Type 2 error To carry out studies with good 
power  
Inpatients only included External validity 
compromised 
To carry out studies that include all 
stages of COPD 
Antibiotics are more 
controversial in mild-to-
moderate COPD patients 
Increased overall 
perceived efficacy of 
antibiotics 
Include mainly non-severe COPD 
patients, since most of the patients 
are non-severe 




Consider the presence of at least 
one of the Anthonisen criteria 
End-points compared at 3 Spontaneous 
resolution mitigates 
Consider clinical outcome at the 
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weeks after onset differences between 
arms 
first week and at 10 days 





Symptom diaries to be delivered to 
patients 
Lack of long-term follow-
up 
Time to next 
exacerbation not 
assessed 
Needs long-term follow-up after 
treatment, at least one year 
Antibiotic resistance to 




perceived efficacy of 
antibiotics.  









Consider the most important 
biomarkers 
Concurrent therapy not 
controlled 
Undetected bias in 
use of concurrent 
therapy 
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Principal objectives 
• To evaluate the effectiveness of antibiotic therapy compared with placebo at days 
9-11 in acute exacerbations of mild-to-moderate COPD 
• To assess which symptoms, signs, and other variables allow identification of 
patients with acute exacerbations of mild-to-moderate COPD who will recover 
without antibiotic therapy 
 
Secondary objectives 
• To evaluate the rate of clinical success of antibiotic therapy compared with placebo 
at day 20 
• To assess the clinical variables most associated with clinical success in both groups 
• To assess the relationship between CRP concentrations and the resolution of 
symptoms in both groups 
• To assess the relationship between sputum colour and the resolution of symptoms 
in both groups 
• To evaluate if the presence of comorbid conditions is associated with a worse 
resolution of the symptoms in both groups 
• To evaluate the secondary effects and adverse events in both groups 
• To evaluate the speed of resolution of symptoms of antibiotic therapy compared 
with placebo 
• To assess the utility of peak-flow determination and the variation between the 
basal and another determination at day 9-11 for predicting the clinical outcome in 
both groups 
• To assess the symptom-free interval, i.e. number of days till next exacerbation in 
both groups 
 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
























UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
56 | P a g e  
 
Design 
Multicentre, parallel, double-blinded placebo-controlled randomized clinical trial 
carried out from January 2006 to June 2011. 
 
Study setting 
Twenty-three primary care centres in Catalonia, Spain.  
• Main centre: Primary Healthcare Centre Jaume I, Tarragona 
• Secondary centres: Primary Healthcare Centre Les Muralles, Tarragona; Primary 
Healthcare Centre La Marina, Barcelona; Primary Healthcare Centre Breda-
Hostalric, Beda; Primary Healthcare Centre Montilivi, Girona; Primary Healthcare 
Centre Reus-3, Reus; Primary Healthcare Centre Girona-3; Primary Healthcare 
Centre Olot, Primary Healthcare Centre Girona-4; Primary Healthcare Centre Valls 
Urbà, Valls; Primary Healthcare Centre Ponts; Primary Healthcare Centre Jaume 
Soler, Cornellà; Primary Healthcare Centre Martí Julià, Cornellà; Primary Healthcare 
Centre SantIldefons, Cornellà; Primary Healthcare Centre Lluís Millet, Esplugues de 
Llobregat; Primary Healthcare Centre Can Vidalet, Esplugues de Llobregat; Primary 
Healthcare Centre 17 de setembre, Prat de Llobregat; Primary Healthcare Centre 
Rambla, Sant Feliu de Llobregat; Primary Healthcare Centre Vallirana; Primary 
Healthcare Centre Sant Just Desvern; Primary Healthcare Centre Les Planes, Sant 




All the following criteria had to be fulfilled: 
• Patients aged 40 or older 
• Smokers or ex-smokers of ten packs-year or more 
• Spirometrically-based diagnosis of mild-to-moderate COPD: 
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- FEV1 > 50% expected, and 
- FEV1/FVC ratio < 0.7% expected 
From a post-bronchodilator lung function test performed within 24 months prior to 
inclusion, and 
• Presence of an acute exacerbation defined as the presence of at least one of the 
following signs and symptoms: increase of dyspnoea, increase in sputum volume 
and/or increase of sputum purulence 
 
Exclusion criteria  
Any of the following criteria: 
• Patients less than 40 years of age 
• Severe COPD 
• Bronchial asthma 
• Cystic fibrosis 
• Bronchiectasis of origin other than COPD 
• Active neoplasm 
• Tracheotomy 
• Presence of radiological signs of pneumonia 
• Hospital admission criteria, such as presence of confusion, respiratory rate greater 
than 35 breaths/minute, or respiratory failure 
• Antibiotic use in the previous two weeks 
• Immunosuppression or use of immunosuppressive drugs 
• Hypersensitivity to beta-lactams 
• Intolerance to clavulanic acid or lactose 
• History of digestive intolerance to clavulanic acid 
• Institutionalization in a residence 
• Subjects unable to personally provide informed consent 
• Difficulty to attend the programmed visits 
• Non-availability of a spirometry performed over the last two years 
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• Those who refused to participate in the study 
 
Measurements and interventions 
The patients were randomised into two treatment groups: 
• Amoxicillin and clavulanic acid, 500/125 mg three times daily for 8 days; or 
• Placebo, three times daily for 8 days 
Both drugs were requested to be taken after meals. The two medications were kept at 
room temperature and were replaced when the expiry date was reached. Subject 
numbers were assigned sequentially as each subject entered the study. The subjects 
were assigned study drug through a randomization schedule based on the 
randomization plan. Since this was a multicentric study a block procedure was 
undertaken for the assignment of each primary care centre participating in the study. 
The study drug was labelled with the study number and unique identification number. 
Since it was a double-blinded clinical trial, neither the physician nor the patient did not 
know the treatment administered.  
The use of antithermics or analgesics, such as acetaminophen, acetylsalicylic acid or 
ibuprofen was allowed in cases of fever or pain, as were short-acting and long-acting β-
adrenergics, anticholinergics, theophyllines, inhaled or a short course of oral 
corticosteroids in cases of bronchospasm and mucolytics, anti-cough and any 
medication that the patient may been have taken for chronic disease and which had 
been initiated three months prior to inclusion in the study, except for antibiotics.  
Each participant had the right to withdraw study at any time. In addition, the 
investigator might have discontinued a participant from the study at any time if the 
investigator considered it necessary for any reason including ineligibility (either arising 
during the study or retrospective having been overlooked at screening), significant 
protocol deviation, significant non-compliance with treatment regimen or study 
requirements, the presence of an adverse effect which required discontinuation of the 
study medication or resulted in inability to continue to comply with study procedures, 
consent withdrawn, or lost to follow-up. The patient was required to return all the 
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medication samples not taken to the investigator. If the remaining medication was not 
returned, compliance was evaluated as insufficient. Compliance with the prescription 
was assessed on visits 2 and 3. The reason of withdrawal was recorded in the case 
report form [Appendix 1]. If the participant withdrawn was due to an adverse effect, 
the investigator general practitioner was asked to arrange the follow-up visits or 




Efficacy of treatment at day 9-11. Clinical response was defined as follows:  
• Cure: disappearance of the acute signs and symptoms related to the infection, with 
complete return to the previous situation of stability 
• Improvement: non-complete resolution of the symptoms 
• Failure: insufficient reduction in the signs and symptoms of infection 
Clinical success was considered when either cure or improvement was observed. In 
cases of clinical deterioration the medical investigator was asked to open the 
randomization code and evaluate the need for hospitalization or prescribe another 
antibiotic according to his/her clinical judgement. 
The situations in which treatment with antibiotics of exacerbations of mild to 
moderate COPD is not necessary was analysed by means of multivariate logistic 
regression with all the cases not treated with antibiotics. 
 
Secondary endpoints 
The secondary outcome variables considered in this thesis were the following: 
• Efficacy of the treatment at day 20 (visit 4). The same outcomes were considered: 
cure, defined as the disappearance of the acute signs and symptoms related to the 
infection (complete return to the previous situation of stability), improvement, 
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defined as the non-complete resolution of the symptoms and failure, with an 
insufficient reduction in the signs and symptoms of infection. Clinical success was 
considered when either cure or improvement was observed 
• CRP concentration on capillary blood assessed in the first visit, with Orion 
Diagnostica apparatus QuikRead CRP®. All the primary healthcare centres were 
provided with this device. All the participants undertook a workshop about how 
the procedure is performed and they were all given a summary chart [Appendix 2]. 
This apparatus is able to give the CRP result in approximately three minutes after 
the blood has been taken. The patients were invited to undertake this test once 
they were fully informed about the procedure and the interpretation of the results. 
The procedure was carried out following the recommendations of the 
manufacturer 
• Adverse events observed in both groups, assessed in visits 2, 3 and 4 and were 
ranked by intensity (mild, moderate, severe and serious) and relationship to the 
study medication 
• Time of symptom resolution by means of the symptom diaries and reduction in the 
total daily score of the symptom diary (visit 3). This diary was given to the patient 
by the participating physician in visit 1. This diary was developed by the 
investigators of this study based on the description of Woolhouse et al (Woolhouse 
IS et al, 2001) and was aimed at collecting the symptoms by the patient every day 
before bedtime during the following eight days [Appendix 3]. The diary card 
consisted of nine items: general well-being graded from 0 (excellent) to 4 (bad), 
breathing from 0 (excellent) to 4 (bad), cough from 0 (occasionally) to 3 
(persistently), sputum consistence from 0 (watery) to 3 (solid), sputum colour from 
0 (colourless) to 2 (green colour), volume of sputum from 0 (none) to 4 (cupful or 
more), if the patient had taken the pill given or not (0-1), daytime symptoms –
impact of respiratory symptoms on ability to perform normal daily activities– from 
0 (none) to 5 (unable to perform normal daily activities), and return to the basal 
status or not (0-1). The sum of the different items was only taken into account in 
cases in which all had been scored. The score given by the patient to each item for 
the diary card was used in the analysis. In addition, a total diary card score was 
obtained by adding all of the individual scores together and ranged from 0 (best) to 
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27 (worse). In cases of failure the diaries were considered to be completed if the 
patient filled out at least two days, considering the score of day 8 the last one that 
the patient was able to filled in. In case of improvement or cure, the diaries were 
considered to be completed if the patient filled in the eight days. In case of 
partially incomplete diaries the physicians were instructed to help the patients to 
filled them out when they returned them 
• Peak-flow measurements on days 1 and 9-11 and variation between both 
observations. The best measurement out of three determinations was only taken 
into account. All the investigators were requested to proceed to performed these 
determinations uniformly [Appendix 4] 
• Time until next exacerbation in days. Patients were monitored over a period of 365 
days on a three-monthly base. When patients could not attend this scheduled visit, 
they were contacted by telephone. Patients were instructed to contact the 
physician immediately if there was any change in their health status. Diagnosis of a 
new exacerbation was based on the same clinical criteria as the previous. In 
agreement with the studies of Chodosh et al and Lode et al (Chodosh S et al, 1998; 
Lode H et al, 2004) all clinical failures during the study therapy were counted as 
zero exacerbation-free interval days. For patients with no new exacerbation during 
the 1-year observation period, the time till next exacerbation was considered to be 
the number of days that had elapsed between the index exacerbation and the time 
point of the last information available (censored data). In all other cases, the 
number of days that had elapsed between the onset of exacerbation was taken 
into account. For calculation, the onset of an exacerbation was considered the day 
of medical attendance reported by the patient. 
 
Schedule of visits 
The schedule of visits was the following: 
• Visit 1, randomization. On fulfilling the inclusion criteria the nature of the study 
was explained to the patient and informed consent was requested. The study 
scheme and the visit program were also explained to the patient. The patients 
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were randomized to either of the two treatment groups and the medication given. 
On this visit a peak flow measurement and a CRP rapid test were performed. 
Physicians were instructed to request a chest X-ray in case of suspected 
pneumonia; more specifically, they all were instructed to order this procedure in 
case of suspected abnormalities on chest auscultation, temperature > 38ºC, and/or 
CRP > 20 mg/l. In case of a radiological image compatible with pneumonia the 
patient was excluded of the study. In addition, a symptom diary was given as was 
an explanation as to how to fill it in 
• Visit 2, follow up visit at 2-4 days. On this visit worsening of the clinical evolution of 
the symptoms and signs situation of the patient was evaluated and, in the case of 
worsening of the symptoms, hospital referral or the administration of antibiotic 
treatment was considered. Likewise, compliance and possible secondary effects of 
the treatment were evaluated 
• Visit 3, follow up visit at 9-11 days. On this visit the clinical efficacy was assessed 
and in the case of failure, hospital referral or the administration of antibiotic 
treatment was considered. A review of adherence to the study drug and an 
evaluation of the presence of side effects and adverse effects were also evaluated. 
On this visit a peak flow measurement was carried out. The symptom diary was 
collected. In case of a partially incomplete diary the physician was instructed to 
help the patients to filled it out in this visit 
• Visit 4, follow-up visit at day 20.On this visit, efficacy of the treatment was 
reassessed and in case of failure, hospital referral or the administration of 
antibiotic treatment was considered. The patients were instructed to contact again 
in case of a new exacerbation 
• Visit 5, follow-up visit at month 3. The patient was asked to attend a visit at month 
3 after being included. When the patient could not attend a scheduled visit a 
contact by phone was done. Diagnosis of a new exacerbation was based on the 
same clinical criteria as the previous 
• Visit 6, follow-up visit at month 6. The patient was asked to attend a visit at month 
6 after being included. When the patient could not attend a scheduled visit a 
contact by phone was done. Diagnosis of a new exacerbation was based on the 
same clinical criteria as the previous 
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Informed consent form x        
Medical history x x x      
Randomization x        
C-reactive protein x        
Chest X-ray x (1)        
Peak flow  x  x      
Hand-out of the 
symptom diary 
x        
Adverse reactions 
assessment 
 x x x     
Evaluation of clinical 
evolution 
 x x x     
Review of adherence  x x      
Collection of symptom 
diary 
  x      
Time till next 
exacerbation (2) 
    x x x x 
(1) In case of suspected pneumonia on clinical grounds 
(2) These visits could be carried out by phone 
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• Visit 7, follow-up visit at month 9. The patient was asked to attend a visit at month 
9 after being included. When the patient could not attend a scheduled visit a 
contact by phone was done. Diagnosis of a new exacerbation was based on the 
same clinical criteria as the previous 
• Visit 8, follow-up visit ay day 365. The patient was asked to attend a visit at the first 
year after being included. When the patient could not attend a scheduled visit a 
contact by phone was done. Diagnosis of a new exacerbation was based on the 
same clinical criteria as the previous 
A summary of the events performed in this thesis is more clearly described in table 4. 
 
Variables 
• Sociodemographic and toxic habits: date of birth, gender, smoking status, and 
packs-year 
• Comorbidities: diabetes, heart failure, high blood pressure, ischemic heart disease, 
others 
• Chronic treatment: short-acting β-adrenergics, long-acting β-adrenergics, inhaled 
corticosteroids, theophyllines, oral corticosteroids, anticholinergics 
• Colour of the sputum: uncoloured, yellowish or yellowish-green 
• Clinical manifestations of the patient: increase of dyspnoea, increase in sputum 
volume and/or increase of sputum purulence, fever (temperature > 38ºC)  
• Type of exacerbation: I, II or III, depending on the presence or not of the 
Anthonisen criteria (Anthonisen NR et al, 1987) 
• Concentration of CRP in capillary blood 
• Lung function parameters: FEV1 in ml and %, CVF in ml and %, FEV1/FVC ratio in % 
• Chest X-ray: was considered positive if there is any complication such as pulmonary 
consolidation (in which case, the patient is excluded from the study) or negative 
• Symptom diary: nine items were evaluated: general well-being, breathing, cough, 
sputum consistence, sputum colour, volume of sputum, if the patient had taken 
the pill given or not, daytime symptoms, and return to the basal status or not  
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• Treatment administered by the physician: mucolytics or expectorants, 
bronchodilatadors, oral corticosteroids, antitussives, analgesics, antithermics 
• Efficacy outcomes: cure, improvement or failure 
• Adverse events which might have been appeared in both treatment arms 
• Number of days till next exacerbation 
 
Statistical analysis 
The intention-to-treat (ITT) population included all randomized patients receiving at 
least one dose of study drug and the per-protocol (PP) population included patients 
with received no systemic antimicrobial agents other than study drug for at least three 
days in the case of clinical failure or ≥ 80% of study medication in case of cure, with 
adequate documentation of compliance and absence of major protocol violations. 
For the sample size calculation, we accepted a null hypothesis if the cure rate in the 
intervention group was the same or ± 7% as that observed in the placebo arm. Based 
on the literature, the expected rate of cure among patients assigned to antibiotic 
therapy is 90%. For an alpha of 0.05 and a beta of 0.2 and accepting possible losses of 
15%, we calculated that the sample size is 667 patients in total.  
Bivariate analysis was performed with comparison of proportions of the different 
outcomes between both groups of treatment using the chi-square test and the Student 
t was used to assess the relationship between quantitative variables for both 
independent and paired data. Only p values less than 0.05 were considered as 
statistically significant. To further evaluate the prognostic usefulness of the Anthonisen 
criteria based on dichotomous classification for both physicians with CRP and without 
CRP accessibility, we considered receiver operating characteristic (ROC) curve analysis. 
For each ROC curve, we calculated the area under the curve (AUC), which ranges from 
0.5 (for a non-informative marker) to 1 (for a perfect marker). Bootstrap method was 
used to calculate the confidence intervals for AUC. Another ROC curve aimed at 
analysing the trade-off between the false negative and false positive rates across a 
series of cut-off points of CRP concentration was carried out, calculating the Youden 
index. 
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A logistic regression model was constructed to identify the variables independently 
associated with clinical outcome by means the use of ORs.The variables were included 
in the model if they were associated with a high score with a p of less than 0.10 and 
were subsequently eliminated from the model using the stepwise automatic variable 
screening method, the alpha thresholds for inclusion and exclusion being set at 0.20. In 
addition, to analyse the time until the next exacerbation a survival analysis was carried 
out using the Kaplan-Meier method. The Wilcoxon test and log-rank test were applied 
to compare the survival curves for each study drug group.    
 
Ethical considerations 
Approval was previously obtained from the Ethical Committee of Investigation in 
Primary Care (Fundació d’Investigació en Atenció Primària) [Appendix 5]. This study has 
been conducted in accordance with the principles of the Declaration of Helsinki and in 
full conformity with relevant regulations. The study has obtained a grant from the 
Fondo de Investigación Sanitaria of the Ministry of Health [Appendix 6] and has been 
registered in the ClinicalTrials.govdatabase (ID number NCT00495586). 
All the participants were recruited by the physicians in the different health care 
centres and personally signed and dated the latest approved version of the informed 
consent form before any study specific procedures were performed [Appendix 7]. 
Informed consent was requested from all the participants in the study, respecting 
subject autonomy in their decision. To achieve this, the medical investigators read the 
informed consent sheet to the patients and clarified any doubt which might have been 
arising during the reading. Thereafter, patient comprehension of the information was 
always determined and, in the case of acceptation to participate, the patient was 
asked to sign the form. The participants were free to withdraw from the study at any 
time for any reason without prejudice to future care, and with no obligation to give the 
reason for withdrawal. The participants were allowed as much time as wished to 
consider the information, and the opportunity to question their general practitioners 
or other independent parties to decide whether they would have participated in the 
study. The different physicians who obtained the consent were suitably qualified and 
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experienced, and were authorized to do so by principal Investigator. A copy of the 
signed informed consent was given to the participants. The original signed form was 
retained at the study site. 
This study did not require the use of unusual, additional tests: only a chest X-ray was 
undertaken to rule out a pneumonic process and both a peak flow measurement and a 
CRP determination during the visit to know the severity of the infection, being tests 
that were total justified in this project. From an ethical point of view, this is to certify 
that the objective of this study has been important and relevant for primary care, the 
power of the study has been considered as reasonable, this is an original study, the 
risks which the participants might have been incurred justify the investigation being 
carried out with a totally favourable benefit/risk quotient, and the external validity of 
the study to the primary care reality can be ensured, with the inclusion and exclusion 
criteria described. Vulnerable populations were not participating in this study and 
neither was economic compensation being given to patients for their participation. 
The investigators are free to publish the results of this study, regardless of the results 
obtained. The anonymity and confidentiality of the data can be guaranteed and the 
protocol of the study safeguarded that in results of the study all the participants and 
their individual results have been taken into account. Participants were identified only 
by a participant ID number on the case report form. The privacy of the participants has 
been therefore protected and with the randomized design of the study the subjects 
were equally invited to participate and that the possible benefits or adverse effects of 
the investigation were equally shared among all the participants. All documents have 
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Descriptive results 
During the course of 5.5 years, 353 subjects were included in the study. Forty-three 
patients were excluded as they did not fulfil the inclusion criteria. The main reasons for 
exclusion were not having a spirometric diagnosis of mild-to-moderate COPD (32 
cases) and refusing to take part in the study or their follow-up data were incomplete (8 
cases). A chest x-ray was ordered in 64 cases; of which, three were positive for 
consolidation and were therefore excluded from the study (Figure 2). 
Three hundred ten (158 patients in the amoxicillin and clavulanic acid arm and 152 
patients in the placebo arm) fulfilled all the criteria for efficacy analysis and constituted 
the ITT population. Only two patients in the amoxicillin and clavulanic acid arm failed 
to comply with the medication and ere excluded from the PP population (Figure 2). A 
total of 161 patients were included in the main primary healthcare centre (51.9%), 
where seven general practitioners finally recruited at least one patient. Other thirty 
physicians from other twenty-two primary healthcare centres recruited at least one 
patient. 
As is shown in table 5, the mean age was 68.1 ± 10.4 years and 251 were male (81%). 
Despite the fact of observing more male patients among those assigned to the 
intervention group no statistically differences were observed. The mean packs-year 
observed was 38.1 ± 18 and a total of 175 patients were current smokers when they 
were included in the study (56.5%), being former smokers the rest of the sample. The 
comorbid condition more often associated was the high blood pressure since 137 
patients were recorded to have hypertension at the time of recruitment (44.2%), 
followed by diabetes mellitus, with 57 patients (18.4%), No differences were found 
between the two groups regarding these variables. 
Concerning previous therapy for COPD the pharmacological groups more commonly 
taken were the anticholinergics (107 cases, 34.5%) followed by the inhaled 
corticosteroids (88 cases, 28.4%), the short-acting β-adrenergics (71, 22.9%) and the 
long-acting β-adrenergics (69, 22.3%). As is set out in the table 6, few patients were 
previously taken either oral corticosteroids or theophyllines. No differences were 
found between the two groups regarding these variables. 
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FIGURE 2. Flow of patients throughout the study 
 Patients invited to participate in this study 
(n: 353) 
      
      Presented a FEV1/FVC ratio > 70% (n: 14) 
      Presented a FEV1<50% (n: 18) 
 
Patients who fulfilled the inclusion criteria 
(n: 321) 
 
Presented a positive chest X-ray for 
pneumonia (n: 3) 
 
Patients valid for the analysis. ITT population 
  Randomization  (n: 318) 
 
 
Patients assigned to antibiotic        Patients assigned to placebo 
       (n: 162)               (n: 156) 
 
   Withdraw consent            Withdraw consent  
   (n: 4)            (n: 4)    
 
Patients valid for the analysis           Patients valid for the analysis 
       (n: 158)                   (n: 152) 
 
     Medication not taken 
     (n: 2)  
 
     PP population (n: 156)             PP population (n: 152) 
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TABLE 5. Sociodemographic and comorbid conditions of the whole sample and 








Age (years), mean (SD) 68.4  (9.9) 67.8  (11.0) 68.1  (10.4) NS 
Male sex, n (%) 132  (83.5) 119  (78.3) 251  (81.0) NS 
Smoking status: 
- Current, n (%) 
- Former, n (%) 
 
86  (54.4) 
72  (45.6) 
 
89  (58.6) 
63  (41.4) 
 
175  (56.5) 




Packs-year, mean (SD) 38.3  (16.9) 37.9  (19.2) 38.1  (18.0) NS 
High blood pressure, n (%) 64  (40.5) 73  (48.0) 137  (44.2) NS 
Diabetes mellitus, n (%) 29  (18.4) 28  (18.4) 57  (18.4) NS 
Heart failure, n (%)  2  (1.3) 3  (2.0) 5  (1.6) NS 
Coronary heart disease, n (%)  15  (9.5) 19  (12.5) 34  (11.0) NS 
SD: standard deviation; NS: non-significant 
 
TABLE 6. Previous treatment taken by the patients recruited in the study and 








Short-acting β-adrenergics, n (%) 35  (22.2) 36  (23.7) 71 (22.9) NS 
Long-acting β-adrenergics, n (%) 37  (23.4) 32  (21.1) 69 (22.3) NS 
Anticholinergics, n (%) 55  (34.8) 52  (34.2) 107  (34.5) NS 
Theophyllines, n (%) 2  (1.3) 2  (1.3) 4  (1.3) NS 
Oral corticosteroids, n (%) 1  (0.6) 2  (1.3) 3  (1.0) NS 
Inhaled corticosteroids, n (%) 46  (29.1) 42  (27.6) 88  (28.4) NS 
SD: standard deviation; NS: non-significant 
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TABLE 7. Lung function variables, peak flow measurement and classification of COPD 















FVC (%), mean (SD) 70.2  (15.8) 71.5  (18.3) 70.8  (17.1) NS 







FEV1 (%), mean (SD) 64.2  (11.8) 65.9  (12.1) 65.0  (11.9) NS 
FEV1/FVC ratio, mean (SD) 62.3  (6.0) 62.2  (5.8) 62.2  (5.9) NS 
COPD classification: 
- Mild, n (%) 
- Moderate, n (%) 
 
15  (9.5) 
143  (90.5) 
 
20  (13.2) 
132  (86.8) 
 
35  (11.3) 











SD: standard deviation; NS: non-significant; FVC: forced vital capacity; ml: millilitres; 
FEV1: forced expiratory volume in one second; l/min: litres/minute 
 
Table 7 describes the lung function variables observed in the spirometric study 
performed within the previous twenty-four months in all the patients included and 
depending on the treatment group. Both FVC and FEV1, both measured in ml, were 
slightly worse among patients assigned to amoxicillin and clavulanic acid but these 
differences were not clinically relevant. No statistically significant differences were 
observed between both groups in terms of % predicted. The mean FEV1 of the whole 
sample was 65 ± 11.9%. Only 35 patients were classified as mild COPD (11.3%) since 
they had a FEV1 of 80% or more. Conversely, most of the patients had a moderate 
COPD (275 cases; 88.7%). The basal peak-flow was also similar in both groups; with an 
overall mean of 226.4 l/min. 
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TABLE 8. Characteristics of the exacerbations of the patients included in the study 








Increase of the sputum volume, n (%) 125  (79.1) 117 (77.0) 242  (78.1) NS 
Increase of dyspnoea, n (%) 109  (69.0) 98  (64.5) 207  (66.8) NS 
Sputum colour: 
- Uncoloured, n (%) 
- Yellowish, n (%) 
- Yellow-greenish, n (%) 
 
73  (46.2) 
36  (22.8) 
49  (31.0) 
 
53  (34.9) 
46  (30.3) 
53  (34.9) 
 
126  (40.6) 
82  (26.5) 





Sputum purulence, n (%) 85  (53.8) 99  (65.1) 184  (59.4) <0.05 
Fever, n (%) 11  (7.0) 14  (9.2) 25  (8.1) NS 
Type of exacerbation*: 
- Type I, n (%) 
- Type II, n (%) 
- Type III, n (%) 
 
40  (25.3) 
81  (51.3) 
37  (23.4) 
 
45  (29.6) 
72  (47.4) 
35  (23.0) 
 
85  (27.4) 
153  (49.4) 





Drugs administered or adjusted for 
the exacerbation: 
- Short-acting β-adrenergics, n (%) 
- Oral corticosteroids, n (%) 
 
 
54  (34.2) 
26  (16.5) 
 
 
53  (34.9) 
27  (17.8) 
 
 
107  (34.5) 





CRP, median (IQR) 18  (35) 17  (23) 18  (31) NS 
SD: standard deviation; NS: non-significant; CRP: C-reactive protein; IQD: interquartiile 
range 
*Type I: all the Anthonisen criteria present (increased dyspnoea, increased sputum 
volume and purulent sputum); type II: only two criteria present; type III: only one 
criterion present 
 
Table 8 describes the symptoms and signs of the exacerbations, their type and the 
characteristics of the sputum. More patients assigned to placebo had their sputum 
purulent, with differences that were statistically significant (65.1% of the patients 
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assigned to placebo group vs. 53.8% of the patients allocated to the intervention 
group; p<0.05). However, concerning the other Anthonisen criteria, their presence was 
slightly greater among patients assigned to the intervention therapy (79.1% vs. 77% 
had an increase of the sputum volume and 69% vs. 64.5% presented an increase of the 
dyspnoea). When the variable of sputum colour was classified in three categories, this 
difference disappeared. Concerning treatment adjusted or given for the exacerbation, 
β-adrenergics were given or adjusted in 107 patients (34.5%) and oral corticosteroids 
were taken by 53 patients (17.1%), without differences between the two treatment 
groups. In fact, only 26 patients assigned to antibiotic (16.5%) and 27 assigned to 
placebo group (17.8%) were given oral corticosteroid therapy for the acute 
exacerbation. 
A total of 85 patients had type I exacerbations (27.4%) and 153 were type II (49.4%). 
The table also shows the drugs administered or adjusted for the exacerbation and the 
CRP concentrations during the basal visit to the physician. Since CRP was not a 
normally-distributed variable, the median and the interquartile range are presented 
instead. No differences were found between the two groups regarding the variables 
analysed. 
 
Main outcome results 
Primary outcome: clinical outcome at day 9-11 
In the ITT population, a total of 117 patients assigned to the intervention group 
(74.1%) and 91 to control group (59.9%) were considered cured by their general 
practitioners at the end of therapy (p<0.05) (Table 9). Twenty-six patients assigned to 
amoxicillin and clavulanic acid and thirty-two patients assigned to placebo group 
presented an improvement. On the other hand, clinical failure was observed in 15 
patients who received antibiotic therapy (9.5%) and in 29 patients assigned to placebo 
(19.1%). In the PP population we found similar results (75 vs. 59.9%, respectively, 
p<0.01). Clinical success, i.e, those with cure or improvement, was also greater in the 
intervention group compared with placebo (90.5% vs. 80.9%; p<0.05).  
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TABLE 9. Summary of clinical efficacy results at day 9-11 in both study groups 
































ITT: intention to treat, PP: per protocol 
 
Comparison of the results depending of clinical success on day 9-11 
The next tables (10 - 13) show the different results obtained depending on the clinical 
outcome.  
More patients with both high blood pressure and coronary heart disease were 
observed among patients who had a worse outcome. However, the number of diabetic 
patients was similar among patients with good and bad clinical outcome (Table 10). 
Age and gender were not associated with a worse clinical outcome. Neither the 
smoking status nor the number of pack-years was associated as is shown in this table. 
Concerning the basal treatment of the patients included in this study no differences 
were observed between those who had a clinical success and those who failed (Table 
11). Only the use of anticholinergics was greater among those who failed compared 
with the patients who had a positive outcome (p<0.05). Even though all the patients 
who received teophyllines and oral corticosteroids were observed among those with 
clinical success at the end of the treatment, no statistically differences were observed 
between those who had a favourable and those with an unfavourable evolution of the 
exacerbations, since the figures were very low. 
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TABLE 10. Sociodemographic and comorbid conditions depending of the clinical 








Age (years), mean (SD) 68.2  (10.4) 67.2  (10.5) 68.1  (10.4) NS 
Male sex, n (%) 214  (80.5) 37  (84.1) 251  (81.0) NS 
Smoking status: 
- Current, n (%) 
- Former, n (%) 
 
148  (55.6) 
118  (44.4) 
 
27  (61.4) 
17  (38.6) 
 
175  (56.5) 




Packs-year, mean (SD) 37.5  (18.2) 41.3  (16.5) 38.1  (18.0) NS 
High blood pressure, n (%) 112  (42.1) 25  (56.8) 137  (44.2) <0.05 
Diabetes mellitus, n (%) 48  (18.0) 9  (20.5) 57  (18.4) NS 
Heart failure, n (%)  5  (1.9) 0  (-) 5  (1.6) NS 
Coronary heart disease, n (%)  25  (9.4) 9  (20.5) 34  (11.0) <0.05 
SD: standard deviation; NS: non-significant 
 
TABLE 11. Previous treatment taken by the patients recruited in the study depending 








Short-acting β-adrenergics, n (%) 61  (22.9) 10  (22.7) 71  (22.9) NS 
Long-acting β-adrenergics, n (%) 56  (21.1) 13  (29.5) 69  (22.3) NS 
Anticholinergics, n (%) 86  (32.3) 21  (47.7) 107  (34.5) <0.05 
Theophyllines, n (%) 4  (1.5) 0  (-) 4  (1.3) NS 
Oral corticosteroids, n (%) 3  (1.1) 0  (-) 3  (1.0) NS 
Inhaled corticosteroids, n (%) 72  (27.1) 16  (36.4) 88  (28.4) NS 
SD: standard deviation; NS: non-significant 
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Table 12 shows the results of the lung function between these two groups. The FEV1 
was lower among patients who failed (65.3% predicted vs. 63.3% among patients who 
had a clinical success) but the differences were not statistically significant. Curiously, 
the mean basal peak-flow measurement was slightly better among those assigned to 
the control group, since they had a mean of 236.7 l/min (vs. 224.7 l/min observed in 
the intervention group). Similarly, the percentage of patients with mild COPD was 
slightly greater among those with favourable evolution while the percentage of 
moderate COPD was slightly greater among those who had a clinical failure (Table 12). 
 
TABLE 12. Lung function variables, peak flow measurement and classification of 









FVC (ml), mean (SD) 2,763.5  (893.1) 2,727.0  (967.8) 2,758.3  (902.5) NS 
FVC (%), mean (SD) 70.7  (16.7) 71.6  (19.3) 70.8  (17.1) NS 
FEV1 (ml), mean (SD) 1,721.8  (590.2) 1,680.0  (629.6) 1.715.8  (595.0) NS 
FEV1 (%), mean (SD) 65.3  (11.7) 63.3  (12.4) 65.0  (11.9) NS 
FEV1/FVC ratio, mean (SD) 62.3  (6.0) 61.5  (5.5) 62.2  (5.9) NS 
COPD classification: 
- Mild, n (%) 
- Moderate, n (%) 
 
31  (11.7) 
235  (88.3) 
 
4  (9.1) 
40  (90.9) 
 
35  (11.3) 




Basal peak-flow (l/min), 
mean (SD) 
224.7  (80.9) 236.7  (92.9) 226.4  (82.4) NS 
SD: standard deviation; NS: non-significant; FVC: forced vital capacity; ml: millilitres; 
FEV1: forced expiratory volume in one second; l/min: litres/minute 
 
The percentage of patients with increase of dyspnoea was significantly greater among 
those who failed (p<0.05). Similarly, more patients with purulent sputum were found 
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among those who presented a clinical failure at day 9-11 (p<0.05). In fact, among 
patients with clinical failure more than half had green sputum while 43.2% of those 
with good clinical outcome the sputum were uncoloured (p<0.05) (Table 13). More 
patients taking oral corticosteroids were observed among patients with therapeutic 
failure even though the differences were not found to be statistically significant.  
 
TABLE 13. Characteristics of the exacerbations of the patients included in the study 








Increase of the sputum volume, n (%) 204  (76.7) 38  (86.4) 242  (78.1) NS 
Increase of dyspnoea, n (%) 172  (64.7) 35  (79.5) 207  (66.8) <0.05 
Sputum colour: 
- Uncoloured, n (%) 
- Yellowish, n (%) 
- Yellow-greenish, n (%) 
 
115  (43.2) 
72  (27.1) 
79  (29.7) 
 
11  (25.0) 
10  (22.7) 
23  (52.3) 
 
126  (40.6) 
82  (26.5) 





Sputum purulence, n (%) 151  (56.8) 33  (75.9) 184  (59.4) <0.05 
Fever, n (%) 23  (8.6) 2  (4.5) 25  (8.1) NS 
Type of exacerbation: 
- Type I, n (%) 
- Type II, n (%) 
- Type III, n (%) 
 
65  (24.4) 
131  (49.2) 
70  (26.3) 
 
20  (45.5) 
22  (50.0) 
2  (4.5) 
 
85  (27.4) 
153  (49.4) 





Drugs administered or adjusted for 
the exacerbation: 
- Short-acting β-adrenergics, n (%) 
- Oral corticosteroids, n (%) 
 
 
93  (35.9) 
43  (16.2) 
 
 
14  (31.8) 
   10  (22.7) 
 
 
107  (34.5) 





CRP, median (IQR) 16  (23) 50  (49) 18  (31) <0.001 
SD: standard deviation; NS: non-significant; CRP: C-reactive protein; IQR: interquartiile 
range 
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In the following tables a differentiation between those assigned to the different 
treatment groups is presented. In these tables the clinical success is presented (cure + 
improvement). Table 14 shows the demographic and comorbidities presented 
depending on the clinical success on day 9-11 and the treatment group. Curiously, 
patients of intervention group who failed were younger than those who had a clinical 
success and on the contrary, among patients not treated with antibiotics those who 
failed were slightly older. Among those who failed there were more women in the 
intervention group and more men in the control group. The most striking figures 
corresponded to the percentage of patients with comorbidities who failed. In fact, the 
percentage of high blood pressure and coronary heart disease were much greater than 
the observed percentages among both intervention and control groups who had 
favourable evolution.  
 
TABLE 14. Sociodemographic and comorbid conditions depending of the clinical 
success on day 9-11 and the treatment group 









Age (years), mean (SD) 69.0  (9.8) 62.3  (9.7) 67.4  (11.2) 69.7  (10.2) 
Male sex, n (%) 120  (83.9) 12  (80.0) 94  (76.4) 25  (86.2) 
Smoking status: 
- Current, n (%) 
- Former, n (%) 
 
76  (53.1) 
67  (46.9) 
 
10  (66.7) 
5  (33.3) 
 
72  (58.5) 
51  (41.5) 
 
17  (58.6) 
12  (41.4) 
Packs-year, mean (SD) 38.3  (17.0) 37.4  (15.9) 36.6  (19.6) 43.3  (16.7) 
High blood pressure, n (%) 57  (39.9) 7  (46.7) 55  (44.7) 18  (62.1) 
Diabetes mellitus, n (%) 24  (16.8) 5  (33.3) 24  (19.5) 4  (13.8) 
Heart failure, n (%)  2  (1.4) 0  (-) 3  (2.4) 0  (-) 
Coronary heart disease, n (%)  13  (9.1) 2  (13.3) 12  (9.8) 7  (24.1) 
SD: standard deviation 
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TABLE 15. Previous treatment taken by the patients depending of the clinical success 
on day 9-11 and the treatment group 









Short-acting β-adrenergics, n (%) 35  (24.5) 0  (-) 26  (21.1) 10  (34.5) 
Long-acting β-adrenergics, n (%) 32  (22.4) 5  (33.3) 24  (19.5) 8  (27.6) 
Anticholinergics, n (%) 47  (32.9) 8  (53.3) 39  (31.7) 13  (44.8) 
Theophyllines, n (%) 2  (1.4) 0  (-) 2  (1.3) 0  (-) 
Oral corticosteroids, n (%) 1  (0.7) 0  (-) 2  (1.6)  0  (-) 
Inhaled corticosteroids, n (%) 41  (28.7) 5  (33.3) 31  (25.2) 11  (37.9) 
 
TABLE 16. Lung function variables, peak flow measurement and classification of 
COPD depending of the clinical success on day 9-11 and the treatment group 

















FVC (%), mean (SD) 70.0  (15.9) 71.5  (15.1) 71.4  (17.6) 71.6  (21.4) 








FEV1 (%), mean (SD) 64.3  (12.0) 63.7  (9.6) 66.5  (11.6) 63.1  (13.8) 
FEV1/FVC ratio, mean (SD) 62.1  (6.2) 63.6  (4.6) 62.6  (5.8) 60.4  (5.7) 
COPD classification: 
- Mild, n (%) 
- Moderate, n (%) 
 
14  (9.8) 
129  (90.2) 
 
1  (6.7) 
14  (93.3) 
 
17  (13.8) 
106  (86.2) 
 
3  (10.3) 
26  (89.7) 










SD: standard deviation; l/min: litres/minute 
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As is described in table 15, more patients taking long-acting β-adrenergics, 
anticholinergics and inhaled corticosteroids were observed among both therapeutic 
groups who had an unfavorable evaluation on day 9-11. Among patients receiving 
antibiotic all the patients taking short-acting β-adrenergics cured or improved.  
 
TABLE 17. Characteristics of the exacerbations of the patients included in the study 
depending of the clinical success on day 9-11 and the treatment group 









Increase of sputum volume, n 
(%) 
112  (78.3) 13  (86.7) 92  (74.8) 25  (86.2) 
Increase of dyspnoea, n (%) 95  (66.4) 14  (93.3) 77  (62.6) 21  (72.4) 
Sputum colour: 
- Uncoloured, n (%) 
- Yellowish, n (%) 
- Yellow-greenish, n (%) 
 
65  (45.5) 
34  (23.8) 
44  (30.8) 
 
8  (53.3) 
2  (13.3) 
5  (33.3) 
 
50  (40.7) 
38  (30.9) 
35  (28.5) 
 
3  (10.3) 
8  (27.6) 
18  (62.1) 
Sputum purulence, n (%) 78  (54.5) 7  (46.7) 73  (59.3) 26  (89.7) 
Fever, n (%) 11  (7.7) 0  (-) 12  (9.8) 2  (6.9) 
Type of exacerbation: 
- Type I, n (%) 
- Type II, n (%) 
- Type III, n (%) 
 
35  (24.5) 
72  (50.3) 
36  (25.2) 
 
5  (33.3) 
9  (60.0) 
1  (6.7) 
 
30  (24.4) 
59  (48.0) 
34  (27.6) 
 
15  (51.7) 
13  (44.8) 
1  (3.4) 
Drugs administered or 
adjusted for the exacerbation: 
- Short-acting β-adrenergics, 
n (%) 




50  (35.0) 




4  (26.7) 




43  (35.0) 




10  (34.5) 
9  (31.0) 
CRP, median (IQR) 16  (32) 44  (48) 15  (17) 51  (56) 
SD: standard deviation; CRP: C-reactive protein; IQD: interquartiile range 
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Table 16 shows the different spirometric variables for both therapeutic groups 
depending on the clinical outcome. The FEV
who failed. Only seven patients with purulent sputum in the intervention group failed 
and among these patients only one was given an oral corticosteroid (
contrary, 26 out of 29 of patients with purulent sputum assigned to placebo failed. 
Those who failed in the intervention group might not have a bacterial infection. 
 
Best CRP cut-off point for predicting clinical success with placebo
The best CRP serum cut-off point for predicting clinical success with 
calculated. The ROC curve obtained by plot at
 
FIGURE 3. ROC curve of CRP for predicting clinical success among patients not treated 
with antibiotics 
1% figures were lower amon
Table 17). On the 
 
placebo
 different cut-offs is shown in figure 
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TABLE 18. Sensitivity and (1 – specificity) for CRP at different cut-off points for 
predicting clinical success among patients assigned to control group 
CRP 
concentration 
Sensitivity 1- specificity Youden’s index 
3.0 1.000 1.000 0.000 
10.5 0.828 0.678 0.150 
15.5 0.724 0.479 0.245 
20.5 0.724 0.380 0.344 
25.5 0.690 0.231 0.458 
30.5 0.690 0.165 0.524 
35.0 0.655 0.140 0.515 
37.5 0.655 0.132 0.523 
40.0 0.655 0.124 0.531 
42.5 0.621 0.116 0.505 
43.5 0.621 0.107 0.513 
45.0 0.586 0.107 0.479 
50.0 0.517 0.091 0.426 
60.5 0.414 0.074 0.339 
70.0 0.241 0.066 0.175 
80.0 0.172 0.041 0.131 
90.0 0.069 0.033 0.036 
107.5 0.069 0.017 0.052 
116.5 0.034 0.017 0.018 
141.0 0.000 0.017 0.017 
160.0 0.000 0.000 0.000 
CRP: C-reactive protein 
 
The best cut-off was 40 mg/l; at this concentration, the sensitivity and specificity were 
0.655 and 0.876 respectively. The area under the curve was 0.732 (95% CI: 0.614 – 
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0.851), indicating that the CRP concentration is a good indicator to anticipate the 
clinical success of acute exacerbations of mild-to-moderate COPD not treated with 
antibiotics. As shown in table 19, more patients with high levels of CRP failed 
compared with those with concentrations lower than 40 mg/l (p<0.001). As is also 
shown, 77.3% of all determinations presented concentrations lower than forty. 
 
TABLE 19. CRP concentrations depending on clinical success on day 9-11 
CRP concentrations Success Failure Total 
< 40 mg/l 106  (87.6) 10  (34.5) 116  (77.3) 
≥ 40 mg/l 15  (12.4) 19  (65.5) 34  (22.7) 
Total 121  (100.0) 29  (100.0) 150  (100.0) 
CRP: C-reactive protein 
 
FIGURE 4. Probability of clinical success depending of CRP concentrations among 
patients not treated with antibiotics 
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The curve represented in figure 4 clearly indicates that the highest concentrations of 
CRP are associated with the poorer outcomes. Conversely, when the concentrations of 
CRP are lower than 20 mg/l, the likelihood of clinical success exceeds 90% of the cases. 
 
Predictive value of Anthonisen criteria
receiving placebo 
The ROC curve depicted in figure 5 shows the predictive value of the Anthonisen 
criteria (without and with CRP)
 
FIGURE 5. ROC curves showing the 
criteria and b) with the addition of another criterion (CRP 
clinical outcome among mild
treated with antibiotics  
Sensitivity     
1 - specificity
 for predicting clinical outcome in patients 
 for clinical outcome at the end of therapy.
predictive value of a) the classical Anthonisen 
≥ 40 mg/l) for predicting 
-to-moderate COPD patients with exacerbations not 
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When taking the classical criteria reported by Anthonisen (increase of dyspnoea, 
increase of sputum production and increase of purulence of sputum) into account, the 
AUC for predicting clinical outcome at day 9-11 was 0.708 (95% CI: 0.616 - 0.801; p: 
0.001). 
By adding the variable CRP ≥ 40 mg/l, the AUC rose to 0.842 (95% CI: 0.76 – 0.924; 
p<0.001). As is shown in figure 5, it seems from the ROC curves that considering four 
criteria instead of the classical Anthonisen criteria results in a significant improvement 
for anticipating the clinical outcome of acute exacerbations of mild-to-moderate COPD 
not treated with antibiotics. 
 
Predictors for clinical failure among patients not treated with antibiotics  
A multivariate logistic regression analysis was carried out in order to analyse the 
criteria that mostly predicted the clinical success on day 9-11 among patients not 
treated with antibiotics.  
 
TABLE 20. Multivariate logistic regression analysis for predicting clinical success at 
day 9-11 among patients not treated with antibiotics with and without availability of 
CRP rapid test 
Variable Without CRP  With CRP 
OR  (95% CI) p OR  (95% CI) p 
Increase of dyspnoea 0.4  (0.2 – 1.1) NS 0.8  (0.3 – 2.3) NS 
Increase of sputum 
production 
0.5  (0.2 – 1.8) NS 1.6  (0.4 – 6.5) NS 
Increase of purulence 0.2  (0.0 – 0.6) 0.005 0.2  (0.0 – 0.7) 0.012 
CRP ≥ 40 mg/l NA NA 0.1  (0.0 – 0.2) <0.001 
CRP: C-reactive protein; OR: odds ratio; CI: confidence interval; NS: not-significant; NA: 
not available 
 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
87 | P a g e  
 
We carried out all the analyses for both those physicians who have not accessibility to 
CRP rapid test determination and for those with CRP availability. For the former, only 
the increase of purulence of expectoration was statistically associated with clinical 
failure (OR of cure: 0.2; 95% CI: 0 – 0.6). Neither increase of dyspnoea (OR: 0.4; 95% CI: 
0.2 – 1.1) nor increase of sputum production were associated with failure.  
In case of CRP availability, among mild-to-moderate COPD patients with exacerbations 
not treated with antibiotics clinical predictors for failure were CRP ≥ 40 mg/l (OR of 
cure 0.1; 95% CI: 0 – 0.2) and sputum purulence (OR of cure: 0.2; 95% CI: 0 – 0.7). Both 
increase of dyspnoea and increase of sputum production did not achieve statistically 
significant differences (Table 20). 
The next graphs (figures 6 and 7) show the relationship between the number of 
Anthonisen criteria present in the patient and the outcome. Figure 6 describes the 
relationship between the criteria described by Anthonisen (Anthonisen NR et al, 1987) 
and the outcome at day 9-11. This is equivalent to the situation of that physician who 
has no accessibility to a CRP rapid test. However, figure 7 adds the variable ‘CRP 
concentration ≥ 40 mg/l’. This is the situation of the general practitioner that has 
accessibility to the CRP test.  
As is shown in the figure 6, the most frequent outcome in the three cases was the cure 
even though the greater was the number of criteria the lower this percentage was 
observed. Similarly, the percentage of failure was greater with the presence of the 
three criteria compared with patients with two or one criteria (p<0.01). As shown in 
figure 7, among patients with acute exacerbations of mild to moderate COPD not 
treated with antibiotics, most of the patients with only one modified Anthonisen 
criteria were considered cured by the physician at day 9-11, and only 3.2% failed. 
Among patients with two modified Anthonisen criteria, 11.3% of the patients 
presented a failure. This percentage rose to 21.6% among those with three modified 
criteria. As is clearly shown in this graph, most of patients with four criteria actually 
failed and only a bit more of 45% of the patients had a favourable assessment 
(p<0.001). 
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FIGURE 6. Association between the number of Anthonisen criteria (increase of 
dyspnea, increase of sputum volume, and/or increase of sputum purulence) 
presented in patients with acute exacerbations of mild-to-moderate COPD not 
treated with antibiotics and clinical outcome at day 9-11 
 
 
The tables 21 and 22 summarize the most important results of this thesis. Both tables 
describe different clinical scenarios and the associated clinical success rates observed 
when antibiotic therapy is withheld. The first of this table is valid for GPs without CRP 
test and the following table incorporates the possibility of performing a CRP test in the 
consultation. 
Since clinical failure among patients treated with antibiotics was nearly 10%, we 
assume in this study that this percentage should be the maximum risk to be 
considered when antibiotic therapy is not given. Clinical success among patients not 
treated with antibiotics was observed in 65.1% of those with the type I exacerbations, 
ranged from 77.4 to 92.1% in type II exacerbations and ranged from 88.8 to 96.5% for 
those with type III exacerbations. Both in patients with type II and III exacerbations, 
the presence of purulent sputum was associated with a probability of success less than 
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FIGURE 7. Association between the number of modified Anthonisen criteria (increase 
of dyspnea, increase of sputum volume, increase of sputum purulence, and/or CRP ≥ 
40 mg/l) presented in patients with acute exacerbations of mild-to-moderate COPD 
not treated with antibiotics and clinical outcome at day 9-11 
 
 
Table 22 shows the probability of clinical success among patients with exacerbations of 
mild to moderate COPD not treated with antibiotics with availability of CRP.  
In this case we considered four criteria (increase of dyspnoea, increase of sputum 
production, increase of purulence of expectoration and CRP concentrations ≥ 40 mg/l). 
As is shown in this table, the presence of the four criteria was associated with a 
probability of clinical success of 34.7%. Clinical success rates ranged from 24.4 to 
87.7% with the presence of three criteria, from 29.5 to 90.2% with the presence of two 
criteria and from 71.9 to 98.3% with only one criterion. More specifically, the presence 
of either sputum purulence or CRP ≥ 40 mg/l was associated with a probability of 
failure of 10% or greater. Only the association of increase of sputum production and 
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When none of the Anthonisen criteria are present, the percentage of clinical success 
was then greater than 97%. 
 
TABLE 21. Probability of clinical success among patients with exacerbations of mild 
to moderate COPD not treated with antibiotics without availability of CRP 
Criteria % success 
NONE 98.0 
No criteria 98.0 
  
ONE CRITERION 88.8 – 96.5 
Increase of dyspnoea 95.6 
Increase in sputum volume 96.5 
Increase of sputum purulence 88.8 
  
TWO CRITERIA 81.2 – 92.1 
Increase of dyspnoea + increase in sputum volume 92.1 
Increase of dyspnoea + increase of sputum purulence 77.4 
Increase in sputum volume + increase of sputum purulence 81.2 
  
THREE CRITERIA 65.1 
Increase of dyspnoea + increase in sputum volume + increase of sputum 
purulence  
65.1 
Probability of clinical success among patients with acute exacerbations of mild to 
moderate COPD not treated with antibiotics without availability of CRP= Exp(β) / 
(1+Exp(β)) in which β = 3.913 – 0.843 (in case of increase of dyspnoea) – 0.609 (in case 
of increase of sputum volume) – 1.838 (in case of increase of sputum purulence)  
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TABLE 22. Probability of clinical success among patients with exacerbations of mild 
to moderate COPD not treated with antibiotics with availability of CRP 
Criteria % success 
NONE 97.2 
No criteria 97.2 
  
ONE CRITERION 71.8 – 98.3 
Increase of dyspnoea 96.4 
Increase in sputum volume 98.3 
Increase of sputum purulence 84.9 
CRP ≥ 40 mg/l 71.9 
  
TWO CRITERIA 29.5 – 90.2 
Increase of dyspnoea + increase in sputum volume 97.8 
Increase of dyspnoea + increase of sputum purulence 81.2 
Increase of dyspnoea + CRP ≥ 40 mg/l 66.3 
Increase in sputum volume + increase of sputum purulence 90.2 
Increase in sputum volume + CRP ≥ 40 mg/l 80.8 
Increase of sputum purulence + CRP ≥ 40 mg/l 29.5 
  
THREE CRITERIA 24.4 – 87.7 
Increase of dyspnoea + increase in sputum volume + increase of 
sputum purulence  
87.7 
Increase of dyspnoea + increase in sputum volume + CRP ≥ 40 mg/l 76.5 
Increase of dyspnoea + increase of sputum purulence + CRP ≥ 40 mg/l 24.4 




FOUR CRITERIA 34.7 
Increase of dyspnoea + increase in sputum volume + increase of 34.7 
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sputum purulence + CRP ≥ 40 mg/l 
Probability of clinical success among patients with acute exacerbations of mild to 
moderate COPD not treated with antibiotics with availability of CRP= Exp(β) / 
(1+Exp(β)) in which β = 3.535 – 0.261 (in case of increase of dyspnoea) + 0.499 (in case 
of increase of sputum volume) – 1.809 (in case of increase of sputum purulence) – 
2.595 (in case of CRP ≥ 40 mg/l) 
CRP: C-reactive protein 
 
Multivariate analysis of the whole population for evaluating risk factors for failure 
TABLE 23. Bivariate and multivariate logistic regression analysis for predicting clinical 
failure at day 9-11 among patients with exacerbations of mild to moderate COPD 





 OR 95% CI p OR 95% CI p OR 95% CI p 
Treatment with 
placebo 
2.2 1.2–4.4 0.02 2.2 1.1–4.4 0.02 2.9 1.4–6.0 0.01 
High blood 
pressure 
1.8 0.9–3.5 0.07       
Coronary heart 
disease 
2.5 1.1–5.7 0.03    2.6 1.0–6.7 0.05 
Increase of 
dyspnoea 
2.1 1.0–4.6 0.06 2.6 1.2–5.7 0.02    
Sputum 
purulence 
2.3 1.1–4.7 0.03 2.4 1.1–5.0 0.02    
CRP  levels ≥ 40 
mg/l 
6.6 3.3–13 0.00    7.9 3.9–16.3 0.00 
OR: odds ratio; CRP: C-reactive protein 
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Bivariate analyses of logistic regression were carried out for the following variables: 
treatment, age (years), sex, pack-years, high blood pressure, heart failure, coronary 
heart disease, diabetes mellitus, FVC%, FEV1%, CRP ≥ 40 mg/L, sputum colour, increase 
of dyspnea, increase of sputum production, fever, number of Anthonisen criteria, and 
basal peak-flow.  
 
TABLE 24. Probability of clinical failure at day 9-11 among patients with acute 
exacerbations of mild to moderate COPD in case of CRP non-availability 
Criteria % failure 
NONE 2.9 
No criteria 2.9 
  
ONE CRITERION 6.2 – 7.1 
Treatment with placebo 6.2% 
Increase of dyspnoea 7.1% 
Sputum purulence 6.7% 
  
TWO CRITERIA 14.5 – 15.5 
Treatment with placebo + increase of dyspnoea 14.5% 
Treatment with placebo + sputum purulence 13.7% 
Increase of dyspnoea + sputum purulence 15.5% 
  
THREE CRITERIA 29.0 
Treatment with placebo + increase of dyspnoea + increase of sputum 
purulence 
29.0% 
Probability of failure among patients with acute exacerbations of mild to moderate 
COPD without availability of CRP = Exp(β) / (1+Exp(β)) in which β = 3.513 + 0.800 (in 
case of treatment with placebo) + 0.940 (in case of increase of dyspnoea) + 0.876 (in 
case of sputum purulence) 
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The table 23 shows the bivariate analysis and the multivariate analysis. In the 
multivariate analysis we distinguished those physicians with access to CRP and those 
without this point-of-care test. Without access to CRP clinical failure was associated 
with increase of dyspnea (OR: 2.6; 95% CI: 1.2 – 5.7), sputum purulence and treatment 
with placebo. Among physicians with access to CRP test, failure was associated with 
CRP ≥ 40 mg/l (OR: 7.9; 95% CI: 3.9 – 16.3), placebo treatment (OR: 2.9; 95% CI: 1.4 – 
6), and presence of coronary heart disease (OR: 2.6; 95% CI: 1 – 6.7).  
 
TABLE 25. Probability of clinical failure at day 9-11 among patients with acute 
exacerbations of mild to moderate COPD in case of CRP availability 
Criteria % failure 
NONE 3,5 
No criteria 3.5 
  
ONE CRITERION 9.4 – 22.1 
Treatment with placebo 9.4% 
Coronary heart disease 8.5% 
CRP ≥ 40 mg/l  22.1% 
  
TWO CRITERIA 21.2 – 42.4 
Treatment with placebo + coronary heart disease 21.2% 
Treatment with placebo + CRP ≥ 40 mg/l 45.0% 
Coronary heart disease + CRP ≥ 40 mg/l 42.4% 
  
THREE CRITERIA 68.0 
Treatment with placebo + coronary heart disease + CRP ≥ 40 mg/l  68.0% 
Probability of failure among patients with acute exacerbations of mild to moderate 
COPD with CRP availability = Exp(β) / (1+Exp(β)) in which β = 3.329 + 1.061 (in case of 
treatment with placebo) + 0.954 (in case of coronary heart disease) + 2.069 (in case of 
CRP ≥ 40 mg/l) 
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Tables 24 and 25 present combinations of these criteria among those without and with 
access to CRP and the associated clinical failure observed in each case. In the former, 
the presence of three criteria (treatment with placebo + increase of dyspnoea + 
increase of sputum purulence) was associated with a 29% of probability of failure. 
Conversely, when the patient presented neither of these criteria, the risk for failure 
was only 2.9%. In case of CRP availability, the presence of the three criteria (treatment 
with placebo + coronary heart disease + CRP ≥ 40 mg/l) was associated with a risk of 
68% for failure. Conversely, when the patient presented neither of these criteria, the 
risk for failure was only 3.5%.  
 
FIGURE 8. Failure observed in both treatment groups depending on the number of 
modified Anthonisen criteria (increase of dyspnoea, increase in the expectoration 
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Figure 8 clearly shows the importance of considering the four criteria, not only those 
described by Anthonisen et al (Anthonisen NR et al, 1987). The greater the number of 
modified Anthonisen criteria the greater the risk for failure, even though this 
percentage is much higher among patients not treated with antibiotics. 
 
Secondary outcome results 
Clinical cure and success at day 20 
A total of 232 patients were considered cured on day 20, accounting for 74.8 of the 
whole sample. Cure at day 20 was greater among patients assigned to antibiotic (129 
cases, 81.6%) vs. 103 patients observed among the control group (67.8%; p<0.05). On 
the one hand, clinical success at day 20 was found in 143 patients who received 
antibiotic (90.5%), significantly greater than those who did not (122 cases, 80.3%; 
p<0.01). On the other hand, failure was observed in fifteen patients assigned to 
intervention (9.5%) and in thirty patients allocated to placebo (19.7%; p<0.01). One of 
the patients assigned to the placebo group and was considered as improved on day 9-
11 presented a failure on day 20 (Table 26). 
 
TABLE 26. Clinical response of the exacerbations of mild-to-moderate COPD 







Cure 129  (81.6) 103  (67.8) 232  (74.8) 
Improvement 14  (8.9) 19  (12.6) 33  (10.6) 
Failure 15  (9.5) 30  (19.7) 45  (14.5) 
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Adverse events 
A total of 35 adverse events were observed in the whole sample. Thirty-two 
corresponded to gastrointestinal adverse events and two were allergic reactions. 
There is no information of the type of the adverse reaction observed in another 
patient. Among patients assigned to antibiotic therapy, twenty-three presented an 
adverse event (14.5%), being this percentage greater than the percentage of adverse 
reactions found among patients allocated to the control group (12 cases, 7.9%; p<0.05) 
(Figure 9). Curiously, the two skin adverse events were seen among patients assigned 
to placebo. 
Most of the adverse reactions observed in this study were mild, since only two of these 
reactions led to discontinuation of the treatment, both cases among patients who 
were treated with antibiotics. No patients assigned to the placebo group discontinued 
the treatment because of the presence of adverse reactions. No serious adverse 
reactions were reported in this study. 
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Speed of recovery 
Speed of recovery was evaluated through the information contained in the diaries that 
were filled in by the patients who participated in this study. All the patients were 
instructed to deliver the diaries in the third visit (day 9-11), even those who presented 
clinical failure. Information about 298 symptom diaries was available (96.1%). Twelve 
patients did not return the diaries. When the diary was partially incomplete the 
investigator completed it with the aid of the patient. However, diaries were clearly 
incomplete in eight cases. Therefore, complete diaries were obtained in 290 cases 
(93.5%). The mean global symptom score at the first day was 15.14 ± 4, being of 7.24 ± 
4.9 at day 8, with a variation of 7.88 ± 4.7 during this 8-day period. The mean score at 
the beginning was similar in both treatment groups (14.9 ± 3.6 in the intervention 
group and 15.4 ± 4.3 among patients assigned to placebo). However, global score at 
day eight was lower in the intervention group (6.6 ± 4 vs. 7.9 ± 5.7; p<0.05) (Figure 10). 
However, the variation between days 1 and 8 was not significantly different between 
both groups (8.3 ± 4.4 vs. 7.4 ± 5, respectively).  
 
FIGURE 10. Variation of the mean global symptom score between days one and eight 
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FIGURE 11. Variation of the mean global symptom diary score between days one and 
eight depending on the clinical outcome on day 9-11 and the treatment group 
 
   
Out of the 290 cases with completed symptom diaries, 201 corresponded to cases that 
were cured at day 9-11, fifty-four to cases with improvement and thirty-five to failures. 
As commented in the methods section, in cases of failure the diaries were considered 
to be completed if the patient filled out at least two days, considering the score of day 
8 the last one that the patient was able to filled in.  
As is shown in figure 11, the variation of the mean global symptom score was greater 
among patients who were considered as cured by the investigator (10 ± 3.3), followed 
by those who improved (5.9 ± 2.5) while among patients with failure a slight increase 
of the symptom score was even found (- 0.9 ± 2.2; p<0.001). No differences were 
observed between both treatment groups. Table 27 describes the different mean 
scores observed depending on the clinical success on day 9-11. The scores in both 
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TABLE 27. Mean global symptom scores obtained in both treatments groups on days 
1 and 8 and variation between the last and the first days depending on the clinical 
success 
 Antibiotic        Placebo  Total 
Day 1 
Clinical success (n: 257) 14.89  (3.6) 15.06  (3.9) 14.96  (3.8) 
Failure (n: 41) 15.00  (3.7) 16.93  (5.5) 16.27  (5.0) 
Total (n: 298) 14.90  (3.6) 15.41  (4.3) 15.14  (4.0) 
Day 8 
Clinical success (n: 255) 5.75  (2.6) 6.04  (3.6) 5.88  (3.1) 
Failure (n: 35) 16.15  (3.7) 17.68  (4.9) 17.11  (4.5) 
Total (n: 290) 6.64  (4.0) 7.90  (5.7) 7.24  (4.9) 
Variation between days 1 and 8 
Clinical success (n: 255) 9.15  (3.5) 8.99  (3.6) 9.08  (3.6) 
Failure (n: 35) - 0.92 (1.8) - 0.86  (2.4) - 0.89  (2.2) 
Total (n: 290) 8.29  (4.4) 7.42  (5.0) 7.98  (4.7) 
 
 
Change of peak-flow measurements between days 1 and 9-11 
The peak-flow measurement was obtained from 298 patients on day 9-11 (96.1%). The 
mean peak-flow measurement on day 1 was 226.40 l/min (SD: 82.6 l/min). The mean 
peak-flow measurement on day 9-11 was 273.94 l/min (SD: 88.7 l/min). As commented 
in the methods section the best of three repeated measurements were taken into 
account. No differences were observed between treatments groups.  
Patients receiving amoxicillin and clavulanic acid had a peak expiratory flow on day 9-
11 that was 8.55 litres per minute higher than that of patients receiving placebo (95% 
CI: -11.7 to 28.8), with a change from basal data and end of the therapy visit that was 
greater among patients assigned to antibiotic treatment (53 vs. 38.5 l/min; p<0.05) 
(Table 2). The results were exactly the same both for ITT and PP population.  
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TABLE 28. Mean peak-flow measurements obtained in both treatments groups on 
days 1 and 8 and variation between the last and the first days depending on the 
clinical success 
 Antibiotic        Placebo  Total 
Day 1 
Clinical success (n: 266) 223.50  (83.3) 226.08  (78.3) 224.69  (80.9) 
Failure (n: 44) 242.00  (87.0) 233.97  (97.2) 236.70  (92.9) 
Total (n: 310) 225.25  (83.6) 227.59  (81.9) 226.40  (82.6) 
Day 9-11 
Clinical success (n: 262) 283.61  (88.8) 275.53  (83.9) 279.85  (86.5) 
Failure (n: 36) 218.85 (82.8) 237.83  (101.3) 230.97  (94.3) 
Total (n: 298) 278.10  (89.9) 269.55  (87.6) 273.94  (88.7) 
Variation between days 1 and 9-11 
Clinical success (n: 262) 58.86  (59.9) 49.65  (46.0) 54.47  (54.0) 
Failure (n: 36) - 11.15  (45.9) - 20.43  (67.6) - 17.08  (60.1) 
Total (n: 298) 52.75  (61.8) 38.53  (56.0) 45.83  (59.4) 
 
Table 28 describes the mean results of peak-flow meter measurements observed on 
days 1, 9-11 and variation between both days. On day 9-11, the mean measurement 
for those with clinical success was significantly greater (279.85 ± 86.5 l/min) compared 
with those who presented an unfavourable evolution (230.97 ± 94.3 l/min; p<0.01). 
Variations between days 1 and 8 were positive for patients with clinical success while 
they were negative for those who failed (p<0.001).  
 
Time till next exacerbation 
The patients were instructed to communicate when a new exacerbation was present. 
A total of 217 new exacerbations were reported within the following year after the 
inclusion of the patients. This variable was found not to be normally distributed. 
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Because of this, the mean was not taken into account and the non-parametric 
measures were considered instead. 
The days until the next exacerbation are presented in table 29. A total of 173 new 
exacerbations were reported within the following year after the inclusion among those 
patients who had clinical success (83 in the intervention group, 67.5%, vs. 90 in the 
control group, 62.9%).  
 
TABLE 29. Time till next exacerbation in days among patients with clinical success at 
day 9-11 
Population n Antibiotic Placebo p 
ITT 266 160  (66 – 110) 233  (110 – 365) 0.089 
PP 266 160  (66 – 365) 233  (110 – 365) 0.089 
Age 
     < 65 years 





365  (132 – 365) 
198.5  (196 – 365) 
 
170  (66 – 365) 




Severity of airway 
obstruction 
     FEV1 < 65% 







156.5  (91 – 326) 
365  (197 – 365) 
 
 
96  (38.5 – 194) 






     CRP < 40 mg/l 





280  (121 – 365) 
143.5  (92 – 360) 
 
173  (76 – 365) 




ITT: intention to treat, PP: per protocol; FEV1: forced expiratory volume in one second 
CRP: C-reactive protein 
 
Among patients with clinical success – 143 patients in the intervention analysis and 
123 in the control group – the median time to the next exacerbation was slightly lower 
among patients assigned to antibiotic therapy, being of 160 days (IQR: 121.5 – 198.5 
days) compared with 233 days (IQR: 154.9 – 311.1 days) observed among patients 
assigned to placebo (p: 0.089). The number of days till next exacerbation was 
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statistically greater among patients not treated with antibiotics compared with those 
who did receive them when CRP concentrations were greater than 40 mg/l and in 
those cases with FEV1 ≥ 65% (Table 
analysis revealing the time in days until the next exacerbation for both treatment 
groups. 
 
FIGURE 12. Kaplan-Meier survival analysis of exacerbation





29). Figure 12 shows the Kaplan-Meier survival 
-free interval in patients 
-11 
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Summary of main findings 
Treatment of acute exacerbations of mild-to-moderate COPD with amoxicillin and 
clavulanic acid is more effective than placebo, since 74.1% of the former group and 
59.9% of the latter were considered cured at days 9-11 (p<0.05). Among patients not 
treated with antibiotics clinical predictors for failure were CRP ≥ 40 mg/l (OR of cure: 
0.1; 95% CI: 0 – 0.2) and sputum purulence (OR of cure: 0.2; 95% CI: 0 – 0.7). 
Regardless of the number the Anthonisen criteria, the presence of both low levels of 
CRP and uncoloured sputum was associated with a clinical success greater than 90% 
among patients not treated with antibiotics.  
 
Strengths and weaknesses of the study 
The required sample size could not be achieved. The main reason for the recruitment 
problems was that this trial was only partially funded by an independent institution 
(Ministry of Health) and the others fund bodies listed at the end of this thesis gave 
only little money. This trial was carried out only in primary care centres with 
availability of spirometric study and postbronchodilation administration. Some 
patients did not fulfil the criteria for non-severe COPD and others received antibiotic 
treatment before being attended, which were exclusion criteria. The prevalence of 
exacerbations was extremely low in two years. Since this study was scheduled to be 
terminated in three years and no improvement in the inclusion rate was expected, 
recruitment was stopped. The difference of the percentage of clinical success at day 9-
11 between the intervention and control groups was 10.7% in the present clinical trial, 
slightly greater than the predicted minimal difference used for the sample calculation. 
Even though this study was stopped before reaching the sample size initially 
calculated, in the per-protocol population a statistically significant result was observed 
(91.7% with antibiotic and 80.9% with placebo, p<0.01), achieving a power of 80%. 
No microbiological study was performed in this study. This actually constitutes the 
main limitation of this thesis, even though in my opinion, this weakness can be 
considered as minor. This trial was exclusively carried out in the primary health care 
setting in which COPD is usually treated in both the stable phase and for 
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exacerbations. Although it is true that some exacerbations of severe COPD are 
managed in emergency departments or hospitals, most mild-moderate episodes of the 
disease are attended in health care centres. Even though recent data suggest that 
approximately 70% of exacerbations are infectious in origin, only 20 – 30% can be 
related to bacteria detected by sputum culture (Celli BR et al, 2007). It is difficult to 
prove that pathogens detected in sputum are the relevant triggers of exacerbation, as 
detection is not proof of infection. Recent findings have shown that growth of bacteria 
in sputum cultures of COPD patients can also result from colonisation of the airways 
(Sethi S et al, 2002). Moreover, respiratory viruses are detected in > 50% of 
exacerbations and also have to be considered as major infectious triggers (Rohde G et 
al, 2003). On the basis of different studies, mainly carried out with severe patients, 
bacteria can be cultured from the tracheal-bronchial tree in a percentage that ranges 
from 19% to 72% of all episodes of acute exacerbations (Eller J et al, 1998; Ewig S et al, 
2000; Miravitlles M et al, 2002b; van der Valk P et al, 2004). However, bacteria can also 
be isolated from the sputum of stable COPD patients and several studies did not find a 
significant difference in bacterial infection in patients at stable state and exacerbation 
(Papi A et al, 2006). Reported factors associated with positive sputum culture include 
bronchiectasis, long-term oxygen therapy, and low FEV1 (Roche N et al, 2007). We also 
know that the type of sputum bacterial growth at exacerbations changes according to 
the severity of underlying airway obstruction; for example, gramnegative bacteria, 
such as Enterobacteriaceae and Pseudomonas aeruginosa, are particularly common 
among patients with FEV1 < 35% predicted (Eller J et al, 1998; Miravitlles M et al, 
1999b). However, up to one quarter of patients with moderate COPD are colonized by 
potentially pathogenic microorganisms (Rosell A et al, 2005). A combination of a 
negative result of sputum Gram stain, a relevant nonclinical decrease in lung function 
(compared to baseline measurements), and the occurrence of less than two 
exacerbations in the previous year have been proposed to be 100% predictive for a 
non-bacterial origin of the exacerbation (van der Valk P et al, 2004). Therefore, 
microbiological studies with the isolation of potentially pathogenic microorganisms 
with sputum cultures and serologic studies are of little utility in this disease, 
particularly in non-severe COPD. Indeed, the proportion of positive sputum cultures is 
small in the mild form of the disease and serologic studies should be correlated with 
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the isolation of germs. In addition, this study was undertaken in primary care where all 
the exacerbations are generally managed based on clinical criteria without any 
complementary test. Only chest X-ray may be requested on suspicion of pneumonia 
and CRP rapid tests were available. Thus, microbiological studies were not performed. 
Moreover, in the best study to date published by Anthonisen et al (Anthonisen NR et 
al, 1987), microbiological studies were not carried out either.  
Another limitation of this clinical trial is the possibility of heterogeneity. This study was 
performed in twenty-three different health care centres with an investigator-monitor 
figure in each. The methodology used was very simple (as it should be in primary care) 
and the holding of previous meetings with these figures and all the participating 
physicians of the different health care centres allowed the necessary homogeneity to 
undertake the study. However, more than half of the patients recruited came from 
only one centre. Similarly, the marked variability and inconsistency in the use of 
spirometry to diagnose COPD has been published  (Bolton CE et al, 2005; Lee TA et al, 
2006), with a lack of device calibration and quality control (de Miguel Díez J et al, 2003) 
as well as formal and accurate technical training (Hueto J et al, 2006) in primary care. 
All the nurses responsible for performing the spirometry in each of these centres were 
instructed to follow the recommendations and perform the spirometric study after a 
post-bronchodilator administration. We think, as Tumoisto states, that it is possible to 
achieve good quality spirometry in primary care (Tuomisto L et al, 2008) and at levels 
similar to those achieved in the majority of pulmonary function laboratories (Soriano 
JB et al, 2009).  
This study has other limitations, albeit of little importance. Firstly, adjuvant treatment 
other than the treatment of the study was allowed to be prescribed according to the 
criteria of the investigator. We think that this possible bias is eliminated by the sample 
size considered as well as the nature of the methodology used in this study as a 
randomised, double-blind clinical trial. Secondly, no haematologic tests were 
performed. Although these tests may be performed within the primary care setting, 
they are not justified in this study since it was not one of safety but rather was one of 
efficacy. In addition, the antibiotic used has been in the Spanish pharmaceutical 
market for more than 25 years and is currently the most frequently prescribed by 
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Spanish family physicians (Agencia Española de Medicamentos y Productos Sanitarios y 
Dirección General de Farmacia y Productos Sanitarios, 2010). Another limitation of this 
study is the definition of the exacerbation itself. In practice, the diagnosis is clinical 
since there are no complementary tests for its diagnosis. This study took the criteria 
considered in other studies into account and is based on the presence of at least one 
of the classical criteria of Anthonisen (increase in dyspnoea, increase in sputum 
volume and/or an increase in sputum purulence), although the clinical manifestations 
may often be accompanied by an increase in cough and fever or rise in temperature 
(Anthonisen NR et al, 1987). Of interest, patients seek health care for only half the 
episodes that meet the definition of exacerbations of COPD (reported exacerbations) 
(Langsetmo L et al, 2008). The unreported episodes are milder than the reported 
exacerbations but still have significant long term-impact on the course of COPD 
(Langsetmo L et al, 2008). Lastly, some secondary effects of the antibiotic treatment 
used in this clinical study (gastrointestinal effects of the association of amoxicillin and 
clavulanic acid) may break the double-blindness. Nonetheless, the literature reports a 
maximum of 12% of gastrointestinal intolerance with this antibiotic and thus we do not 
consider this a bias (Lode H, 2010).  
In contrast with the study by Anthonisen et al (Anthonisen NR et al, 1987), we believe 
that the approach described presents a series of fundamental strengths. It is of note 
that we have used different criteria of cure such as the time of cure and the time till 
next exacerbation. We used CRP which has not been used in other studies in the 
community setting and performed chest X-rays in all the patients with suspected 
pneumonia thereby ruling out its presence. In fact, a major cause of hospitalisation 
and a common cause of death, community-acquired pneumonia, is most commonly 
seen in individuals who smoke cigarettes and/or have COPD (Ginesu F et al, 1995). The 
impact of underlying COPD on the outcome of pneumonia is at present unclear. Some 
retrospective studies of patients with COPD have reported increased mortality risks 
(Rello J et al, 2006; Restrepo MI et al, 2006) but others have not (García-Vidal C et al, 
2007; Ruiz de Ona JM et al, 2003). Inclusion of patients with pneumonia in a clinical 
trial evaluating the effectiveness of antibiotic therapy versus placebo is also unethical, 
since this infectious disease should be treated always with antibiotics as quickly as 
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possible. In this study, not all the patients undertook a radiographic study but those 
with suspected pneumonia, i.e. high temperature, auscultation abnormalities or CRP 
greater than 20 mg/l were all studied. We believe that the likelihood of having 
recruited a case with pneumonia in our study is negligible.  
Contrary to other studies, we considered the antibiotic of choice in Spain and in many 
other countries, that of amoxicillin and clavulanic acid which is recommended by most 
of the current clinical guidelines since it covers pneumococci and Haemophilus well 
(Cots JM et al, 2010; Llor C et al, 2011). Although the latter is the most frequently 
isolated, in some series carried out strictly in the community pneumococci are also 
frequently presented (Llor C et al, 2006). Neither did we use macrolides – not only 
because these are not considered as first line treatment for exacerbations of COPD but 
rather to avoid the so-called antiinflammatory effect that some studies have 
associated with these antibiotics (Sevilla-Sánchez D et al, 2010). Fluoroquinolones 
were not considered either, because the clinical studies undertaken to date have not 
shown the use of these antibiotics to be superior to the association of amoxicillin and 
clavulanic acid in non-severe COPD, and in this study we did not take the more severe 
patients into account. This is important since patients with COPD with FEV1 > 50% 
rarely have infection by gramnegative microorganisms in contrast with more severe 
patients (Miravitlles M, 2002b).  
Other strengths of note in our study are the use of a larger sample size than used in 
previously published studies since we accepted a difference of 10% among treatments 
as significant, the fact of it having been carried out in a country with one of the highest 
rates of resistance and that only patients with mild-to-moderate COPD diagnosed by 
spirometry were included. The methodology used as a double-blind clinical study 
allowed neither the patient nor the physician to know the treatment administered, 
representing another strength of the study. This is the only way to determine the 
efficacy of antimicrobial treatment in exacerbations of mild-moderate COPD and to 
evaluate what situations are associated with better clinical response to antimicrobial 
treatment and to know the clinical situations which allow identification of the patients 
who recover from an exacerbation without the need for antibiotics.  
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Comparison with other studies 
Fourteen patients diagnosed of COPD in the different primary healthcare centres did 
not fulfil the diagnostic criteria based on an FEV1/FVC ratio < 0.7 after inhaled 
bronchodilatador administration. In addition, eighteen patients had a severe airways 
obstruction. This issue is also observed in other studies mainly carried out in primary 
care. While spirometry is an essential part of the clinical diagnosis of COPD, with 
diagnostic criteria based on an this ratio (Global Initiative for Chronic Obstructive Lung 
Disease, 2010), 21% – 63% of patients registered as having COPD in both primary and 
secondary care do not fulfil the disease criteria largely due to a lack of spirometric data 
(de Miguel Díez J et al, 2003; Naberan K et al, 2006; Pellicer Ciscar C et al, 2010; 
Sichletidis L et al, 2007). 
Another reason of having included so many patients without spirometric criteria for 
non-severe COPD is the fact that in this study some physicians included patients not 
previously diagnosed of COPD but with high suspicion of having a positive spirometry. 
In those cases physicians were instructed to perform the spirometric study one month 
after the inclusion of the patient. In some cases, the patients were correctly diagnosed 
of non-severe COPD but in other cases, the patients were finally excluded due to either 
not fulfil the diagnostic criteria of COPD or have a severe obstruction. Most patients 
with non-severe COPD remain undiagnosed in the community. A Spanish study in 1999 
of adults aged 40–70 years revealed that, from a prevalence of 9.1%, only 22% of 
COPD patients had a previous diagnosis of the disease (Pena VS et al, 2000), which rose 
to just 27% ten years later (Miravitlles M et al, 2009). Overall, 45% – 85% of COPD 
patients are not formally diagnosed, as many accept breathlessness and limited 
exercise tolerance as features of ageing and regard their smoker’s cough as normal 
(Halpin DM et al, 2006). Both patients and physicians play a role in the high rates of 
COPD underdiagnosis. One survey showed that, of 7,000 respondents, 33% said that 
they suffered from chronic respiratory symptoms, but only 56% of those consulted a 
physician (Miravitlles M et al, 2006). Of those individuals who consulted a physician 
with respiratory symptoms, only 42.6% underwent spirometry (Miravitlles M et al, 
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2006). In addition, just 56% of primary care practices were found to have a spirometer 
in a recent nationwide survey of Spain (Miravitlles M et al, 2007). Even though the 
undiagnosed airflow is typically very mild, approximately 5% of the general population 
has an FEV1 < 75% predicted (Coultas DB et al, 2001). The International Primary Care 
Respiratory Group suggests that all smokers aged 35 years and older, individuals who 
have symptoms suggestive of COPD and those who have positive findings on a COPD 
risk evaluation questionnaire should either have initial case-identification spirometry 
or proceed directly to full diagnostic spirometry (Price D et al, 2009). This ‘case-finding’ 
approach of first harnessing symptoms, patient characteristics and lung function 
indicators should improve the recognition of COPD (Soriano JB et al, 2009). The NICE 
guideline recommends the identification of early COPD and that spirometry be 
performed in subjects aged over 35 years, current or ex-smokers and those with a 
chronic cough (National Institute for Clinical Excellence, 2011). It also suggests that 
spirometry be considered in patients with chronic bronchitis; as a significant 
proportion of these will go on to develop airflow limitation (National Institute for 
Clinical Excellence, 2011). In our study, in an attempt of recruiting correct cases we 
narrowed these critera and only patients aged 40 or more with a smoking history of 
greater than ten pack-years were taken into account. 
In this study, use of concomitant therapy showed no influence on the different 
outcomes considered. Other studies performed with mild and moderate COPD 
patients showed similar results. The EUROSCOP study (Pauwels RA et al, 1999) 
investigated the benefits of active treatment in patients with mild-to-moderate COPD. 
For this study, 1,277 individuals with post-bronchodilator FEV1 50% – 100% predicted 
and FEV1/FVC < 70% who continued smoking were randomised to budesonide 400 µg 
or placebo twice daily. After 3 years, there was no difference in the rate of decline in 
FEV1 in patients treated with budesonide compared with those receiving placebo. A 
randomised, double-blind, parallel-group clinical trial nested in the Copenhagen City 
Heart Study indicated that, in 290 patients with an FEV1 86% predicted, budesonide 
400 µg bid, compared with placebo, did not have a significant impact on the rate of 
decline of FEV1 or the number of exacerbations (Vestbo J et al, 1999). In the Lung 
Health Study II, which compared triamcinolone acetonide 600 µg or placebo bid in 
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1,116 patients with mild-to-moderate COPD, active treatment had, again, a non-
significant effect on the rate of decline in FEV1. Nevertheless, there was a significant 
reduction in respiratory symptoms with triamcinolone acetonide and in visits to a 
physician due to respiratory illness (Group LHSR, 2000). A post-hoc analysis of the 
ISOLDE trial of 751 patients treated with fluticasone proprionate 500 µg or placebo bid 
showed that, in 391 patients with an FEV1 ≥ 50% predicted, fluticasone propionate had 
no impact on the number of exacerbations per patient per year, at 1.5 versus 1.8. 
However, the proportion of patients with more than one exacerbations/year treated 
with oral corticosteroids was reduced significantly with active treatment, at 8% versus 
16% for placebo (Jones PW et al, 2003). In the ISOLDE trial as a whole, the annual rate 
of decline in FEV1 was similar in both groups (Burge PS et al, 2000). 
The MISTRAL study, published in 2006, randomised 1,010 COPD patients to tiotropium 
18 µg or placebo once daily for 1 year. Among 426 patients with an FEV1 > 50% 
predicted, tiotropium was associated with a significant reduction in the number of 
exacerbations per patient per year, at 1.2 versus 2, alongside which there was a non-
significant reduction in the number of patients experiencing one or more 
exacerbations in patients with mild COPD (Dusser D et al, 2006). For the BRONCUS 
study, 523 COPD patients were randomly assigned to N-acetylcysteine 600 mg daily or 
placebo and followed-up for 3 years. N-acetylcysteine was found to have, compared 
with placebo, no significant effects on either the decline in FEV1 or the decline in vital 
capacity in 389 participants with GOLD stage II COPD (Decramer M et al, 2005).  
In this thesis, the effect of antibiotic therapy on the main clinical outcome at the end 
of therapy visit was greater than the effect observed among those patients assigned to 
placebo. A similar result has been published in other studies. Taking all the studies 
comparing antibiotic therapy and placebo for acute exacerbations of COPD into 
account, the median treatment failure rate was 0.12 for the antibiotic groups, ranging 
from 0 to 0.47, and 0.34 for the placebo groups, ranging from 0.1 to 0.8 (Puhan et al, 
2007). Thus across all trials, one out of eight patients with antibiotics had a treatment 
failure whereas one out of three patients had a treatment failure with placebo. 
Anyway, the effects of antibiotics were very heterogeneous across all the trials 
published. Antibiotics had a large effect in severe exacerbations in Puhan’s meta-
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analysis (OR 0.25, 95% CI: 0.16–0.39) with a number-needed to treat of 4 (95% CI: 3–5) 
(Puhan MA et al, 2007). 
In this thesis, a bit more of 80% of patients with acute exacerbations of mild-to-
moderate COPD had a favourable course despite not being treated with antibiotics. 
This is an important message since many GPs are reluctant to withhold antibiotic 
therapy among patients diagnosed of COPD. In Anthonisen’s study, roughly 55% of the 
patients not treated with antibiotics presented clinical success (Anthonisen R et al, 
1987). In this study, treatment success with antibiotics compared to placebo was 
especially apparent in patients with severe functional impairment – the mean FEV1 of 
the patients recruited in this landmark paper was 33% predicted –, suggesting that the 
severity of the underlying disease might be an important indicator for antibiotic 
treatment. This sentence is backed up by the observation of the five clinical trials 
included in Puhan’s meta-analysis (Puhan et al, 2008). Clinical success was also 
observed in approximately 80% of the cases not treated with antibiotics, a figure that 
is not different from the one observed in this thesis (Anthonisen NR et al, 1994; Berry 
DG et al, 1960; Elmes PCF et al, 1957; Jorgensen AF et al, 1992; Sachs AP et al, 1995). 
The final decision whether to prescribe antibiotics or not in the setting of exacerbation 
can be based on markers of either disease severity or exacerbation severity. Markers 
of disease severity include the degree of airway obstruction, exacerbation rate, and 
presence of comorbidities. Patients with frequent exacerbations also present a higher 
incidence of viral exacerbations as compared to patients with infrequent exacerbations 
(Seemungal T et al, 2001; Rohde G et al, 2003). Exacerbation severity factors 
commonly considered the presence of clinical symptoms (dyspnea, increase in sputum 
production, and sputum purulence, treatment setting, sputum colour, and sputum 
examination, but also serum biomarkers (Anthonisen NR et al, 1987; Balter MS et al, 
2003; Grossman RF, 1997; Nouria S et al, 2001). According to the updated guideline of 
GOLD, antibiotics should be given to patients with the following three cardinal 
symptoms: increased dyspnoea, increased sputum volume and increased sputum 
purulence or in patients with increased sputum purulence and one other cardinal 
symptom. On the basis of the results of this thesis, this recommendation should be 
changed. Three criteria were associated with clinical failure: placebo assignment, 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
114 | P a g e  
 
coronary heart disease and high CRP levels. Coronary heart disease has been shown to 
increase the rate of treatment failure in other papers (Adams SG et al, 2000; Dewan 
NA et al, 2000). Purulent sputum has been shown to be associated with failure in the 
present study with the bivariate analysis but not in the multivariate logistic regression. 
However, its presence is associated with a clinical success of less than 90% of the cases 
not treated with antibiotics, regardless the number of Anthonisen criteria. Allegra et al 
showed that expectoration of greenish sputum was 94% sensitive and 77% specific for 
the yield of a high bacterial load in exacerbations of COPD. Accordingly, a positive 
bacterial culture was obtained from 84% of patients' sputum if it was purulent as 
compared with 38% if it was mucoid (Allegra L et al, 2005). Another study revealed 
similar figures (sensitivity 89.5%, specificity 76.2%) and suggested that the self-
reporting presence of purulence in the sputum predicted the presence of bacterial 
infection in the distal airways (OR: 27.2, 95% CI: 4.6–60.9) (Soler N et al, 2007). 
However, this finding has not been invariably replicated (van der Valk P et al, 2004). In 
this thesis, CRP levels were much higher among patients with green sputum than those 
with yellow and these more than patients with discoloured sputum. This phenomenon 
has also been reported in other papers (Allegra L et al, 2005).  
The most striking result of this thesis is the usefulness of CRP as a predictor for clinical 
failure. Furthermore, CRP has been shown to be the variable that is more associated 
with failure among patients not treated with antibiotics. This result, however, has also 
been observed in other papers and, in fact, CRP has been extensively evaluated as 
potential confirmatory and predictive parameter in patients with exacerbation of 
COPD. Stolz et al observed among inpatients that those patients admitted with low 
serum CRP levels did not seem to benefit from antimicrobials (Stolz D, 2009). Hurst et 
al (Hurst J et al, 2006a) assessed the value of 36 biomarkers in 90 patients from the 
London COPD study before and during an exacerbation of COPD. CRP was found to be 
the most selective biomarker that differentiates an exacerbation from day-to-day 
symptom variation. Sensitivity and specificity of CRP at 50 mg/l for the confirmation of 
exacerbation was only 74.4 and 57.5%, respectively, resulting in AUC of 0.73. Those 
values do not portray significant clinical relevance, as the assay of any biomarker in 
isolation was no better than the presence of an increase in any one of the major 
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exacerbation symptoms alone on that day (AUC: 0.83). When CRP concentration was 
combined with a major exacerbation symptom, AUC significantly increased to 0.88; 
although value is more attractive, this association has questionable statistical validity 
because of inclusion of a major criterion of exacerbation of COPD. Authors concluded 
that the combination of CRP with any one increased major exacerbation symptom is 
useful in the confirmation of COPD exacerbation (Hurst J et al, 2006a). In our thesis we 
found similar results, with the AUC being of 0.708 (95% CI: 0.616 - 0.801) for the 
Anthonisen criteria and rose to 0.842 (95% CI: 0.76 – 0.924; p<0.001) when high levels 
of CRP were added. This high value of the AUC suggests that we have identified 
important explanatory variables, which could be easily obtained from a mild-to-
moderate COPD exacerbation at the GP’s consultation. 
Different CRP cut-off values can be chosen to optimize sensitivity and specificity, as 
demonstrated by Hurst et al (Hurst J et al, 2006a). In this study, an increase in CRP cut-
off up to 27.6 mg/l resulted in an increase in specificity up to 90%, but was only 40% 
sensitive. More recently, Bircan et al (Bircan A et al, 2008) used a CRP cut-off of 10 
mg/l to predict an exacerbation of COPD; in their study, CRP level had a sensitivity and 
specificity of 72.5 and 100%, respectively. Interestingly, Stolz et al (Stolz D et al, 2006) 
showed that a CRP value of 50 mg/dl had a sensitivity of 93.8% to detect bacterial 
infection, requiring antibiotics in 243 patients who presented with lower respiratory 
tract infection. In this thesis, the best cut-off level among patients treated with 
placebo is 40 mg/l, with an AUC of 0.732. Among these patients, 77.3% of the patients 
presented results lower than 40 mg/l and only 23.7% had concentrations greater than 
this figure. Elevation in the CRP levels is not an uncommon phenomenon in stable 
patients with COPD; using the database from the Third National Health and Nutrition 
Examination Survey, Mannino et al (Mannino DM et al, 2003) revealed that up to 52% 
of patients with moderate-to-severe COPD have CRP levels higher than 30 mg/l and 
levels above 100 mg/l occur in up to 23% of the patients. In a recent study, Dahl et al 
observed that elevated plasma CRP > 30 mg/l compared with < 10 mg/l was associated 
with risk estimates of 1.8 and 2.8 for spirometry-based COPD and of 1.6 and 1.8 for 
hospitalisation due to COPD in the Copenhagen City Heart Study and the Copenhagen 
General Population Study (Dahl M et al, 2011). 
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Clinical parameters are non-specific and unreliable predictors of outcomes in patients 
with exacerbation of COPD. Few investigators assessed the role of CRP as potential 
predictor of outcome in this group of the patients. Perera et al (Perera WR et al, 2007) 
conducted a prospective study in a well characterized cohort of 73 patients with COPD, 
in whom airway (sputum interleukin 6 and interleukin 8) and systemic inflammation 
(CRP and interleukin 6) were assessed in the stable state, at exacerbation onset prior 
to treatment, and throughout recovery period at days 7, 14, and 35. The authors 
concluded that assessment of CRP concentration 14 days after an exacerbation was 
predictive of a failure to completely resolve symptoms and can prognosticate 
recurrence of exacerbation within 50 days. In our study, however, the CRP 
concentrations were not predictive for the presence of a new exacerbation or for a 
shorter exacerbation-free interval. However, we found than among patients with high 
CRP levels, antibiotics were associated with a shorter exacerbation-free interval than 
those not treated with antbiotics. In another study, in patients with end-stage 
respiratory failure due to COPD, Cano et al (Cano NJ et al, 2004) demonstrated that 
survival was independently correlated with systemic inflammation measured by CRP 
levels (cut-off CRP level > 100 mg/l). On the other hand, Stolz et al (Stolz D et al, 2007a) 
studied the prognostic value of three plasma biomarkers (CRP, copeptin, and 
procalcitonin) in 167 patients admitted with COPD exacerbations. Contrary to the 
results of the previous studies, the authors did not find any correlation between CRP 
level and short-term or long-term outcome of exacerbation such as length of hospital 
stay, intensive care unit length of stay, in-hospital, and 6-month mortality.  
The impact of corticosteroids on the attenuation of CRP levels remains unclear. Some 
papers have observed an interaction of CRP levels with the use of systemic 
corticosteroids. We did not observe this interaction, since only two patients assigned 
to control group were previously taking.  Malo et al (Malo O et al, 2002) did not find a 
significant change in CRP levels during recovery in patients with exacerbations of COPD 
treated with intravenous corticosteroids, whereas Sin et al (Sin D et al, 2004) found a 
63% reduction in CRP levels in patients treated with oral corticosteroids. Similar 
controversy exists in patients treated with inhaled corticosteroids. Some investigators 
reported lower CRP levels in COPD patients treated with inhaled corticosteroids (Pinto-
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Plata VM et al, 2006; Sin D et al, 2004) whereas de Torres et al (de Torres JP et al, 
2006) reported no difference in CRP levels in those patients. Most of those studies are 
observational, therefore this controversy demands well designed randomized 
controlled trials, which could clarify whether this biomarker is a useful guide to assess 
efficacy of therapy. Neither did we observe an effect of inhaled corticosteroids on CRP 
levels, probably because of the fact than only one quarter of these patients were 
taking these drugs on a chronic basis. 
The results of this thesis prove the role of CRP as a predictor of the clinical outcome in 
exacerbations of COPD. This suggests that CRP may be used as a marker of significant 
bacterial infection and that it may be used when deciding whether or not to start 
antibiotic treatment. This clinical trial suggests that high CRP values may indicate a 
bacterial exacerbation in COPD patients.  
Another aspect in this thesis is the use of other clinical outcomes such as the time till 
next exacerbation. Among patients with clinical success at day 9-11 those assigned to 
antibiotic therapy had a slightly shorter interval between exacerbations than those 
assigned to placebo. Statistically significant dfferences were only observed in subgroup 
of patients, such as those with CRP levels ≥ 40 mg/l and those with FEV1 ≥ 65%. A post-
hoc analysis of a randomized trial showed that time to next exacerbation might be 
prolonged if patients received moxifloxacin for treatment of the index exacerbation 
(Wilson R et al, 2004). Lode et al studied the exacerbation-free interval comparing 
levofloxacin and clarithromycin. Patients assigned to the quinolone presented a longer 
symptom-free interval than those patients who took the macrolide (Lode H et al, 
2004). However, in a prospective, randomized study, time to next exacerbation was 
similar in the group of patients with low procalcitonin serum levels who did not receive 
antibiotics and in the group of patients receiving antibiotics according to guidelines 
(Stolz D et al, 2007b).  
In the face of the fact that respiratory viruses are detected in 50% of exacerbations, a 
major task is the reduction of unnecessary antibiotic treatment in patients with mild-
to-moderate exacerbation of COPD to stop the threatening increase in antibiotic 
resistance. It has been convincingly shown that prudent reduction of antibiotic use 
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confers low bacterial resistance without increase in complications (Mölstad S et al, 
2008). Daniels et al showed recently that it is safe to treat acute exacerbations of 
COPD patients of all grades of severity (GOLD stages I–IV) with placebo if standardised 
treatment is provided (Daniels JM et al, 2010). In this thesis we have observed that 
antibiotics should be discouraged in most of the acute exacerbations of non-severe 
COPD. Among patients treated with antibiotics nearly 10% of the patients failed. 
Therefore, we can safely consider that antibiotics could and should be withheld when 
the risk of failure exceeds 10% of the cases. It means that we should definitely 
discourage the prescription of antibiotics in exacerbations with CRP levels lower than 
40 mg/l. In this thesis, 77.3% of all CRP determinations presented concentrations lower 
than this cut-off level.   
The presence of adverse events is indeed an important issue. In this thesis, significantly 
more patients assigned to antibiotic therapy compared to those assigned to placebo 
presented adverse effects. It has been shown in several trials that adverse events are 
higher in patients treated with antibiotics than in patients administered a placebo 
(Ram FS et al, 2006). The rate of adverse effects observed in this thesis is very similar 
to the one observed by Puhan’s meta-analysis (Puhan MA et al, 2007). The percentage 
of adverse reactions in this meta-analysis, mostly mild gastrointestinal complaints, was 
0.15 (range 0.05–0.60) for the antibiotic and 0.08 (range 0.04–0.13) for the placebo 
groups (Puhan MA et al, 2007). Hence, the individual patient might benefit from 
reduced adverse events associated with antibiotic treatment if antibiotics are no 
longer prescribed for this indication. In addition, the individual patient might also 
benefit from decreased selection of antibiotic-resistant strains by reduction of 
antibiotic consumption. Society will clearly benefit if unnecessary antibiotic 
prescriptions are reduced. This has been convincingly shown in other settings (Mölstad 
S et al, 2008). In addition, there is the potential economic impact. Antibiotic therapy 
can be costly and it has been shown that reduction in antibiotic use significantly 
reduces costs (Bantar C et al, 2003).  
In conclusion, this thesis has two core take-home messages. On the one hand, the 
present thesis, powered enough to definitively show a benefit of antibiotics, clearly 
show their benefit in acute exacerbations of mild-to-moderate COPD exacerbations. 
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On the other hand, we show that antibiotics can be withheld in patients without 
sputum purulence (if there is no availiabillity of CRP) and in patients with sputum 
purulence or low CRP levels (with CRP availability). We have to assume that antibiotic 
treatment of acute exacerbations of COPD contributes significantly to the misuse of 
antibiotics worldwide and the misuse of antibiotics has been shown to be a major 
cause of the development of antibiotic-resistant bacteria, a fact that has not been 
addressed at all in antibiotic studies in acute exacerbations so far. The present thesis 
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1. Treatment of acute exacerbations of mild-to-moderate COPD with amoxicillin and 
clavulanic acid is more effective than placebo (cure of 74.1% vs. 59.9% on day 9-11; 
p<0.05) 
2. Clinical success on day 9-11 is observed in 90.5% of exacerbations treated with 
antibiotic and in 80.1% of the cases in which antibiotic treatment is not given 
(p<0.05) 
3. The best CRP cut-off point for predicting clinical success with placebo is 40 mg/l. 
The area under the curve is 0.732 (95% CI: 0.614 – 0.851). Concentrations lower 
than 40 mg/l are observed in 77.3% of the exacerbations of mild-to-moderate 
COPD 
4. The predictive value of the Anthonisen criteria for predicting clinical outcome, 
represented by the area under the ROC curve, is 0.708 (95% CI: 0.616 - 0.801) and 
rises to 0.842 (95% CI: 0.76 – 0.924; p<0.001) when CRP ≥ 40 mg/l is added 
5. Only the increase of sputum purulence is statistically associated with clinical failure 
in case of CRP non-availability (OR of cure: 0.2; 95% CI: 0 – 0.6). In case of CRP 
availability, clinical predictors for failure are CRP ≥ 40 mg/l (OR of cure: 0.1; 95% CI: 
0 – 0.2) and sputum purulence (OR of cure: 0.2; 95% CI: 0 – 0.7) 
6. Without CRP utilization, clinical success among patients not treated with antibiotics 
is observed in 65.1% of those with the type I exacerbations, in 77.4 – 92.1% of type 
II exacerbations and in 88.8 – 96.5% of type III exacerbations. In all cases, the 
presence of purulent sputum is associated with a probability of failure of 10% or 
greater 
7. Regardless of the number of Anthonisen criteria, the presence of either sputum 
purulence or CRP ≥ 40 mg/l is associated with a probability of failure of 10% or 
greater among patients not treated with antibiotics 
8. Clinical cure at day 20 is greater among patients assigned to antibiotic (81.6% vs. 
67.8%; p<0.05) 
9. Adverse events are greater among patients treated with amoxicillin and clavulanic 
acid (14.5% vs. 7.9% observed with placebo; p<0.05) 
10. In the multivariate regression analysis, failure in the whole population is associated 
with CRP concentrations ≥ 40 mg/l (OR: 7.9; 95% CI: 3.9 –16.3), placebo treatment 
UNIVERSITAT ROVIRA I VIRGILI 
SITUATIONS IN WHICH TREATMENT OF ACUTE EXACERBATIONS OF NON-SEVERE COPD WITH ANTIBIOTICS IS NOT NECESSARY 
Ana Moragas Moreno 
DL:T. 147-2012 
122 | P a g e  
 
(OR: 2.9; 95% CI: 1.4 – 6), and presence of coronary heart disease (OR: 2.6; 95% CI: 
1 – 6.7) 
11. Speed of recovery is not significantly different between intervention and control 
groups, with variation of global symptom scores between days 1 and 8 of 8.3 and 
7.4, respectively. However, the variation of global symptom scores are significantly 
greater among those patients with clinical success compared to those who failed 
12. Patients receiving antibiotic therapy have a peak expiratory flow on day 9-11 that is 
8.6 litres per minute higher than that of patients receiving placebo (95% CI: -11.7 – 
28.8), with a change from basal data and day 9-11 that was greater among patients 
assigned to antibiotic (53 vs. 38.5 l/min; p<0.05)  
13. Among patients with clinical success the median time to the next exacerbation is 
slightly lower among patients assigned to antibiotic therapy, being of 160 days 
(interquartile range [IQR] 121.5 – 198.5 days) compared to 233 days (IQR 154.9 – 
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APPENDIX 1. Case report form 
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APPENDIX 4. Peak flow measurement instructions  
 
MESURA DEL PEAK FLOW 
El peak-flow meter o mesurador de pic flux és un aparell usat per a la 
mesura ambulatòria del flux espiratori màxim o FEM en L/minut. El 
FEM és la velocitat màxima de l’aire en una espiració forçada 
realitzada després d’una insuflació màxima pulmonar. Reprodueix el 
grau d’obstrucció de les vies aèries de gran calibre i s’ha vist que 
existeix una bona correlació entre FEM i FEV1. 
 
Com es fa? 
• Assegura’t de posar la boquilla correctament (figura) 
• El pacient ha d’estar dret, amb el cos relaxat (figura) 
• S’agafa el mesurador amb una mà, sense obstaculitzar el trànsit de la molla i 
s’ha de posar l’indicador a 0 
• Es treu tot de la boca (p.ex. el xiclet) 
• Se li diu al pacient que faci una inspiració profunda 
• Es comprova que ajusti bé els llavis a la boquilla (figura), vigilant que no hi hagi 
fuites 
• Se li diu al pacient que bufi de forma ràpida i explosiva (espiració forçada) d’1-2 
segons de durada (se li diu que bufi com si volgués apagar una espelma). És 
important que bufi el més fort possible 
                               
Important 
• Si el pacient no ho ha fet mai, se li pot dir que faci proves abans 
• S’ha de fer les mesures sempre amb el mateix aparell. Cal fer-li al pacient dos 
dies (dia 0 i dia 9-11). El que es canvia és la boquilla 
• Cal fer 3 mesures i s’anotarà la més alta de les tres en el full 
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APPENDIX 7. Written informed consent  
 
Título: Situaciones en las que no es necesario tratar con antibióticos las 
agudizaciones de la EPOC leve-moderada (Estudio TRANCE) 
Se está llevando a cabo un estudio que pretende identificar los factores que podrían 
ser más beneficiosos en el tratamiento de los pacientes con enfermedad pulmonar 
obstructiva crónica, que es la enfermedad que usted padece. En ocasiones, esta 
enfermedad mejora sin necesidad de utilizar antibióticos, pero otras veces es 
imprescindible utilizarlos. Los resultados del estudio ayudarán a mejorar el uso de los 
antibióticos y a disminuir el aumento de resistencias que presentan muchos gérmenes.  
Para ello le pedimos su colaboración. Ud.puede hacer todas las preguntas que desee 
sobre el mismo. La participación en el estudio no supone la realización de ninguna 
intervención fuera de lo habitual; únicamente contactaremos más veces con Usted 
para comprobar la evolución de la exacerbación que presenta. La participación en el 
estudio tiene carácter voluntario y si Ud. decide participar tiene la posibilidad de 
retirarse del estudio en cualquier momento sin perjuicio alguno, sin tener que dar 
explicaciones y sin que ello afecte a su relación con los médicos o a futuras terapias. 
Los datos del estudio son confidenciales, y sólo tendrán acceso a ellos los 
investigadores y el personal implicado en la monitorización y análisis de los mismos. 
Las autoridades sanitarias pueden, eventualmente, acceder a los mismos durante una 
inspección. Los nombres de los participantes no aparecerán en ninguna información o 
publicación de los datos del estudio. Este estudio ha sido aprobado por el Comité Ético 
de Investigación Clínica del Instituto de Investigación de Atención Primaria y por las 
autoridades sanitarias españolas. 
 
Yo,.........................................................................................(nombre y apellidos) 
....................................................................(declaro bajo mi responsabilidad que 
...................................................................nombre del participante en el ensayo)   
- Ha podido hacer preguntas sobre el estudio. 
- Ha recibido suficiente información sobre el estudio. 
- Ha sido informado por: .................................. (nombre del investigador)  
Comprende que su participación es voluntaria. 
Comprende que puede retirarse del estudio: 
1-  Cuando quiera. 
2-  Sin tener que dar explicaciones. 
3- Sin que esto repercuta en sus cuidados médicos. 








Firma del paciente 
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